Clinical Development
LAG525
Protocol CLAG525X2101C / [STUDY_ID_REMOVED]
A Phase I/II, open label, multicenter study of the safety and 
efficac y of LA G525 single agent and in combination w ith 
PDR001 administered to patients w ith adv anced 
malignancies
Document type Amended Protocol Version
EUDRACT number 2015 -000449 -21
Version number 10 (Clean )
Development phase I/II
Document status Final
Release date 27 Jun 2019
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Template version 02 -Dec-2013

Novartis Confidential Page 2
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table of contents
Table of contents ................................................................................................................. 2
List of figures ...................................................................................................................... 8
List of tables ........................................................................................................................ 8
List of abbreviations .......................................................................................................... 10
Glossary  of terms ............................................................................................................... 12
Protocol summary :
............................................................................................................. 14
Amendment 10 (27
-Jun-2019) .......................................................................................... 19
Amendment 09 (16
-Aug-2018) ......................................................................................... 21
Amendment 08 (21
-Jun-2017) .......................................................................................... 24
Amendment 07 (09
-Dec-2016).......................................................................................... 27
Amendment 06 (05
-Jul-2016) ........................................................................................... 31
Amendment 05 (12
-Apr-2016).......................................................................................... 33
Amendment 04 (12
-Feb-2016) .......................................................................................... 34
Amendment 03 (04
-Dec-2016).......................................................................................... 38
Amendment 02 (14
-Sep-2015) .......................................................................................... 40
Amendment 01 (27- Apr-2015).......................................................................................... 44
1Background ........................................................................................................................ 45
1.1 Overview of disease pathogenesis, epidemiology
 and current treatment .............. 45
1.2 Introduction to investigational treatment(s) and other study  treatment(s) ............. 46
1.2.1 Overview of LAG525 ........................................................................... 46
1.2.2
Overview of PDR001............................................................................ 47
1.2.3 Overview of the combination of L AG525 and PDR001 ....................... 48
2Rationale ............................................................................................................................ 49
2.1 Study  ration ale and purpose ................................................................................... 49
2.2 Rationale for the stud y design ............................................................................... 51
2.2.1 Phase I ................................................................................................... 51
2.2.2 Japanese single -
agent dose escalation (Arm C) .................................... 52
2.2.3 Phase II .................................................................................................. 52
2.3 Rationale for dose and regimen selection .............................................................. 52
2.4 Rationale for choi ce of combination drugs ............................................................ 53
3
Objectives and end points.................................................................................................. 54
4Study  design ...................................................................................................................... 57
4.1 Description of stud y design ................................ ................................ ................... 57
4.1.1 Phase I dose escalation .......................................................................... 59
4.1.2 Phase II expansion ................................................................................. 60

Novartis Confidential Page 3
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
4.1.3 Study  Periods ........................................................................................ 60
4.2 Timing of interim anal yses and design adaptations ............................................... 61
4.3 Definition of end of the study ................................................................................ 61
4.4 Early study termination .......................................................................................... 61
5Population .......................................................................................................................... 62
5.1 Patient population .................................................................................................. 62
5.2 Inclusion criteria .................................................................................................... 62
5.3 Exclusion criteria ................................................................................................... 63
6Treatment ........................................................................................................................... 66
6.1 Study  treatment ...................................................................................................... 66
6.1.1 Dosing regimen ..................................................................................... 66
6.1.2 Ancillary  treatments .............................................................................. 67
6.1.3 Treatment duration ................................................................................ 68
6.2 Dose escalation guidelines ..................................................................................... 68
6.2.1 Starting dose rationale ........................................................................... 68
6.2.2 Provisional dose levels .......................................................................... 69
6.2.3
Guidelines for dose escalation and determination of MTD/ RP2D ......70
6.2.4 Definitions of dose -limiting toxicities (DL Ts)..................................... 75
6.3 Dose modif ications ................................................................................................ 77
6.3.1 Dose modification and dose delay ........................................................ 77
6.3.2 Follow -up fo r toxicities ......................................................................... 83
6.3.3 Permitted concomitant therap y
............................................................. 83
6.3.4 Permitted concomitant therap y requiring caution and/or action ........... 84
6.3.5
Prohibited concomitant therap y ............................................................ 84
6.4 Patient numbering, treatment assignment or randomization ................................. 85
6.4.1
Patient numbering ................................................................................. 85
6.4.2
Treatment assignment or randomization............................................... 85
6.5 Study  drug preparation and dispensation ............................................................... 85
6.5.1 Study  drug packaging and labeling ....................................................... 86
6.5.2 Drug supply  and storage ........................................................................ 86
6.5.3 Study  drug compliance and accountabilit y
........................................... 86
6.5.4 Disposal and destruction ....................................................................... 86
7
Visit schedule and assessments ......................................................................................... 86
7.1 Study  flow and visit schedule ................................................................................ 86
7.1.1 Screening ............................................................................................... 91
7.1.2 Treatment period ................................................................................... 91

Novartis Confidential Page 4
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
7.1.3 Discontinuation of study  treatment ................................ ....................... 92
7.1.4 Withdrawal of Consent ......................................................................... 93
7.1.5 Follow up period ................................................................................... 94
7.1.6 Lost to follow up ................................................................................... 95
7.2 Assessment ty pes................................................................................................... 95
7.2.1 Efficacy  assessments ............................................................................. 95
7.2.2 Safety  and tolerability  assessments ....................................................... 97
7.2.3 Pharmacokinetics and immunogenicit y assessments .......................... 100
103
8Safety  monitoring and reporting ...................................................................................... 107
8.1 Adverse events ..................................................................................................... 107
8.1.1
Definitions and reporting .................................................................... 107
8.1.2 Laboratory  test abnormalities .............................................................. 108
8.2 Serious adverse events ......................................................................................... 109
8.2.1
Definitions........................................................................................... 109
8.2.2
Reporting............................................................................................. 110
8.3 Pregnancies .......................................................................................................... 111
8.4 Warnings and precautions .................................................................................... 111
8.5 Data Monitoring Committee ................................................................................ 111
9Data collection and management ..................................................................................... 112
9.1 Data confidentiality ............................................................................................. 112
9.2 Site monitoring .................................................................................................... 112
9.3
Data collection..................................................................................................... 113
9.4 Database management and quality  control ................................ .......................... 113
10Statistical methods and data anal ysis.............................................................................. 114
10.1 Analy sis Sets ........................................................................................................ 115
10.1.1 Full Anal ysis Set ................................................................................. 115
10.1.2 Safety  Set
............................................................................................ 115
10.1.3
Per-Protocol Set .................................................................................. 116
10.1.4 Dose -Determining Analy sis Set ......................................................... 116
10.1.5 Pharmacokinetic anal ysis set
............................................................... 117
10.2 Patient demographics / other baseline characteristics ......................................... 117
10.3 Treatments (stud y treatment, concomitant therapies, compliance) ..................... 117
10.4 Primary  Objective ................................................................................................ 118
10.4.1 Variable ............................................................................................... 118
10.4.2 Statistical hy pothe sis, model, and method of analy sis........................ 118

Novartis Confidential Page 5
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
10.4.3 Handling of missing values/censoring/discontinuations ..................... 121
10.4.4 Supportive analy ses............................................................................. 121
10.5 Secondary  Objectives .......................................................................................... 123
10.5.1 Key secondary  objective(s) ................................................................. 123
10.5.2 Other secondary  objectives ................................................................. 123
10.5.3 Safety  Objectives ................................................................................ 124
127
127
128
10.7 Interim Anal ysis................................................................................................... 128
10.8
Sample size calculation........................................................................................ 129
10.9 Power for anal ysis of key secondary  variables
.................................................... 131
11Ethical considerations and administrative procedures .................................................... 131
11.1 Regulatory  and ethica l compliance ...................................................................... 131
11.2
Responsibilities of the investigator and IRB/EC/REB ........................................ 131
11.3 Informed consent procedures
............................................................................... 132
11.4 Discontinuation of the study ................................................................................ 132
11.5 Publication of study  protocol and results ............................................................. 132
11.6 Study  documentation, record keeping and retention of documents
..................... 133
11.7 Confide ntiality  of study  documents and patient records ..................................... 134
11.8
Audits and inspections......................................................................................... 134
11.9 Financial disclosures ............................................................................................ 134
12Protocol adherence .......................................................................................................... 134
12.1 Amendments to the protocol ................................................................................ 134
13References (available upon request) ................................................................................ 135
14Appendices ...................................................................................................................... 137
14.1 Appendix 1: Guidelines for Response, Duration of Overall Response, TTF, 
TTP, Progression -Free Survival  (based on RECIST 1.1) .137
14.1.1 Introduction ......................................................................................... 139
14.1.2 Efficacy  assessments ........................................................................... 139
14.1.3
Definitions........................................................................................... 139
14.1.4 Disease measurability .......................................................................... 139
14.1.5 Eligibility  based on measurable disease .............................................. 140
14.1.6 Methods of tumor measurement -general guidelines ......................... 140
14.1.7 Baseline documentation of target and non
-target lesions ................... 142
14.1.8 Follow -up evaluation of target and non -target lesions ........................ 143

Novartis Confidential Page 6
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.1.9 Follow -up and recording of lesions ..................................................... 143
14.1.10 Non-
nodal lesions................................................................................ 143
14.1.11 Nodal lesions ....................................................................................... 144
14.1.12 Determination of target lesion response .............................................. 144
14.1.13 Determination of non -target lesion response ...................................... 146
14.1.14 New lesions ......................................................................................... 147
14.1.15 Evaluation of overall lesion respons e
................................................. 147
14.1.16 Efficacy  definitions ............................................................................. 148
14.1.17 Best overall response ........................................................................... 148
14.1.18 Time to event variables ....................................................................... 150
14.1.19 Progression
-free survival .................................................................... 150
151
14.1.21 Time to progression ............................................................................. 151
14.1.22 Time to treatment failure ..................................................................... 151
14.1.23 Duration of response ........................................................................... 151
14.1.24 Time to response ................................................................................. 152
14.1.25 Definition of start and end dates for time to event variables .............. 153
14.1.26 Handling of patients with non -measurable disease only  at baseline ...154
14.1.27 Sensitivity  analy ses............................................................................. 155
14.1.28 Data handling and programming rules ................................................ 157
14.1.29 Study /project specific decisions .......................................................... 157
14.1.30 End of treatment phase completion ..................................................... 157
14.1.31 End of post -treatment follow -up (study  phase completion) ................ 158
14.1.32
Medical validation of programmed overall lesion response ............... 158
14.1.33 Programming rules .............................................................................. 159
14.1.34
Calculation of ‘time to event’ variables.............................................. 159
14.1.35 Incomplete ass
essment dates ............................................................... 159
14.1.36 Incomplete dates for last known date patient alive or death ............... 159
14.1.37 Non-target lesion response .................................................................. 159
14.1.38 Study /project specific programming ................................................... 159
14.1.39 Censoring reason ................................................................................. 159
14.1.40 References (available upon request) ................................................... 160
14.2 Appendix 2: Guidelines for immune -related response criteria (IrRC) using 
one
-dimensional measurements (simulating RECIST 1.1) ................................. 161
14.2.1 Introduction ......................................................................................... 161
14.2.2 New Lesions and non -target lesions ................................................... 161

Novartis Confidential Page 7
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.2.3 Follow -up evaluation of target and non -target lesions ........................ 161
14.2.4 Definitions of response categ ories and evaluation of overall lesion 
response ............................................................................................... 162
14.2.5 Only  non- measurable disease at baseline ............................................ 163
14.2.6 Reference (available upon request) ..................................................... 163
14.3 Appendix 3: Statistical details of Phase I Bay esian logistic regression models 
(BLR M) and Phase II hierarchical models .......................................................... 164
14.3.1 Phase I BLRM ..................................................................................... 164
14.3.2 Prior specifications for phase II hierarchical model ........................... 177
14.4 Appendix 4: Statistical details of Phase I Bay esian logistic regression model 
(BLRM) in Japanese patients treated with single agent of LAG525 ................... 180
14.4.1 Statistical model .................................................................................. 180
14.4.2 Prior specifications .............................................................................. 180
14.4.3 BLRM design properties for hy pothetical data scenarios
................... 183

Novartis Confidential Page 8
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
List of figures
Figure 2 -1 Blockade of PD -1/PD -L1 and LAG -3 by PDR001 and LAG525 ......... 51
Figure 4 -1 Study  design .......................................................................................... 58
List of tables
Table 3
-1 Objectives and r elated endpoints .......................................................... 55
Table 6
-1 Dose and treatment schedule................................................................. 66
Table 6
-2 Provisional dose levels (Ph I Arm A and Arm C: single -agent 
LAG525) ............................................................................................... 69
Table 6
-3 Provisional dose levels (Ph I  Arm B: combinations of LAG525 and 
PDR001) ................................................................................................ 70
Table 6
-4 Criteria for defining dose- limiting toxicities......................................... 76
Table 6-5 Recommended Dose Modifications for LAG525 and PDR001 ............ 78
Table 7-1 Visit evaluation schedule ...................................................................... 88
Table 7
-2 Disease assessment collection plan....................................................... 96
Table 7
-3 ECOG performance status ..................................................................... 97
Table 7
-4 Local clinical laboratory  parameters collection plan ............................ 98
Table 7-5 12 Lead ECG collection plan .............................................................. 100
Table 7
-6 Pharmacokinetic blood collection log for LAG525 alone, LAG525 
in combination with PDR001 and PDR001 in combination with 
LAG525 in all patientsb................................ ................................ .......101
104
Table 10-1 Pharmacokinet ic Parameters to be anal yzed....................................... 126
Table 10
-2 Operating characteristics of the design (single agent L AG525) ......... 130
Table 10-3 Operating characteristics of the design (LAG525+PDR001) ............. 131
Table 10-4 Operating character istics of the design (LAG525 + PDR001) ........... 131
Table 14-1 Response criteria for target lesions ..................................................... 144
Table 14
-2 Response criteria for non -target lesions .............................................. 146
Table 14
-3 Overall lesion response at each assessment ........................................ 147
Table 14
-4 Overall lesion response at each assessment: patients with non -
target disease onl y................................ ................................ ............... 154
Table 14-5 Options for event dates used in PFS, TTP, duration of response ........ 155
Table 14-6 Overall response at each assessment ................................ ................... 162
Table 14-7 Prior distribution of model parameters –phase I single agent 
PDR001 ................................ ................................ ............................... 165
Table 14-8 Summary  of prior distribution of DL T rates – phase I single agent 
LAG525 (derived from the mixture prior in Table 14-7) ................... 166

Novartis Confidential Page 9
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 14-9 Summary  of prior distribution of DL T rates – phase I single agent 
LAG525 (derived from the Component 1 prior in Table 14 -7) .......... 166
Table 14-10 Summary  of prior distribution of DL T rates – phase I single agent 
LAG525 (derived from the Component 2 prior in Table 14 -7) .......... 166
Table 14-11 Hypothetical dose escala tion scenarios for on- study  decisions –
phase I single agent LAG525.............................................................. 167
Table 14
-12 Prior distribution of model parameters – phase I LAG525 + 
PDR001 ............................................................................................... 170
Table 14
-13 Summary  of prior distribution of DL T rates – phase I LAG525 + 
PDR001 ............................................................................................... 170
Table 14
-14 Hypothetical dose escalation scenarios for on- study  decisions –
phase I LAG525 + PDR001 ................................ ................................ 171
Table 14
-15 True underl ying probabilities of DL T for Scenari o 1......................... 174
Table 14-16 True underl ying probabilities of DL T for Scenario 2 ......................... 175
Table 14-17 True underl ying probabilities of DL T for Scenario 3 ......................... 175
Table 14-18 True underl ying prob abilities of DL T for Scenario 4 ......................... 175
Table 14-19 True underl ying probabilities of DL T for Scenario 5 ......................... 176
Table 14-20 Results ................................................................................................. 177
Table 14
-21 Prior distribution of hierarchical model parameters ............................ 179
Table 14-22 Data from global patients in study  CLAG525X2101C ....................... 181
Table 14-23 Prior distributions for the parameters of the MAP model used to 
derive the prior ................................ ................................ .................... 182
Table 14-24 Prior distribution of model parameters ............................................... 182
Table 14
-25 Summary  of prior distribution of DL T rates ....................................... 183
Table 14
-26 Hypothetical dose escalation scenarios for on- study  decisions –
phase I single agent LAG525.............................................................. 183
Table 14
-27 dose-DLT scenarios ............................................................................ 185
Table 14
-28 Operating characteristics of BLRM -based dose escalation design ..... 185

Novartis Confidential Page 10
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
List of abbreviations
AE Adverse Event
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
AMI Acute Myocardial Infarction
APC Antigen Presenting Cell
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
AUC Area Under the Curve
BLRM Bayesian Logistic Regression Model
CDP Clinical Development Plan
CMO&PS Chief Medical Office and Patient Safety
CRC Colorectal cancer 
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO Contract Research Organization
CSR Clinical study report
CSR addendum An addendum to Clinical Study Report (CSR) that captures all the additional information 
that is not included in the CSR
CV Cardiovascular
DCR Disease Control Rate
DDP Dose Determining Pharmacokinetic Set
DDS Dose -Determining Safety Set
DLT Dose Limiting Toxicity
DOR Duration of Response
ECG Electrocardiogram
ER Estrogen Receptor
eSAE Electronic Serious Adverse Event
EWOC Escalation W ith Overdose Control
FAS Full Analysis Set
FIH First In Human
FU Follow Up
GDPR General Data Protection Regulation
GEJ Gastro -Esophageal Junction
GLP Good Laboratory Practice
HBV Hepatitis B Virus
HCV Hepatitis C Virus
HED human equivalent dose
HER2 Human Epidermal growth factor Receptor 2
HNSTD highest non -severely toxic dose
i.v. Intravenous(ly)
IEC Independent Ethics Committee
IG Immunogenicity
IL-6 Interleukin -6
IRB Institutional Review Board
irAE Immune R elated Adverse Event
irRC immune related Response Criteria

Novartis Confidential Page 11
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
ITIM Immunoreceptor Tyrosine -based Inhibitory Motif
KO Knockout
LAG-3 Lymphocyte activation gene -3
LLOQ Lower Limit Of Quantitation
LMWH Low Molecular W eight Heparin
mAb(s) monoclonal Antibody(ies)
MHC Major Histocompatibility Complex
MSI-H Microsatellite instability high
MTD Maximum Tolerated Dose
NOAEL No Observed Adverse Effect Level
NPC Nasopharyngeal cancer
NSCLC Non-Small Cell Lung Carcinoma
NYHA New York Heart Association
ORR Overall Response Rate
PAS Pharmacokinetic Analysis Set
PD Pharmacodynamics
PD-1 Programmed Death -1
PD-L1 Programmed Death -Ligand 1
PD-L2 Programmed Death -Ligand 2
PFS Progression Free Survival
PK Pharmacokinetics
PPS Per Protocol Set
PR Progesterone Receptor
Q2W Every 2 weeks dosing schedule
Q3W Every 3 weeks dosing schedule
Q4W Every 4 weeks dosing schedule
RAP Report and Analysis Plan
RCC Renal Cell Cancer
RECIST Response Evaluation Criteria In Solid Tumors
RP2D Recommended phase two dose
SAE Serious Adverse Event
SEC Safety Event Categories
SJS Stevens -Johnson syndrome 
TCR T Cell Receptor
TEN Lyell syndrome/ toxic epidermal necrolysis 
TIL(s) Tumor Infiltrating Lymphocyte(s)
TNBC Triple Negative Breast Cancer
TTR Time To Response
US United States
WT Wild type

Novartis Confidential Page 12
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Glossary  of terms
Assessment A procedure used to generate data required by the study
Biologic Sample A biological specimen including, for example, blood (plasma, serum), 
saliva, tissue, urine, stool, etc. taken from a study subject or study patient
Cohort A group of newly enrolled patients treated at a specific dose and regimen 
(i.e. treatment group) at the same time
Cycles Number and timing or recommended repetitions of therapy are usually 
expressed as number of days (e.g.: q28 days)
Dose level The dose of drug given to the patient (total daily or weekly etc.) 
Enrollment Point/time of patient entry into the study; the point at which informed 
consent must be obtained (i.e. prior to starting any of the procedures 
described in the protocol)
Investigational drug The study treatment whose properties are being tested in the study; this 
definition is consistent with US CFR 21 Section 312.3 and is sy nonymous 
with “investigational new drug.”
Investigational treatment Drug whose properties are being tested in the study as well as their 
associated placebo and active treatment controls (when applicable). This 
also includes approved drugs used outside of their indication/approved 
dosage, or that are tested in a fixed combination. Investigational treatment 
generally does not include other study treatments administered as 
concomitant background therapy required or allowed by the protocol when 
used in within approved indication/dosage
Patient Number (Patient No.) A unique identifying number assigned to each patient/subject/healthy 
volunteer who enrolls in the study
Personal Data Patient information collected by the Investigator that is transferred to 
Novartis for the purpose of the clinical trial. This data includes patient
identifier information, study information, and biological samples.
Premature patient withdrawal Point/time when th e patient exits from the study prior to the planned 
completion of all study treatment administration and/or assessments; at 
this time all study treatment administration is discontinued and no further 
assessments are planned, unless the patient will be foll owed for 
progression 
Stage in cancer The extent of a cancer in the body. Staging is usually based on the size of 
the tumor, whether lymph nodes contain cancer, and whether the cancer 
has spread from the original site to other parts of the body
Stop study participation Point/time at which the patient came in for a final evaluation visit or when 
study treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered 
to the patient (subject) as part of the required study procedures, including 
placebo and active drug run -ins.
In specific examples, it is important to judge investigational treatment 
component relationship relative to a study treatment combination; study 
treatme nt in this case refers to the investigational and non-investigational 
treatments in combination.
Study treatment discontinuation Point/time when patient permanently stops taking study treatment for any 
reason; may or may not also be the point/time of prem ature patient 
withdrawal
Treatment group A treatment group defines the dose and regimen or the combination, and 
may consist of 1 or more cohorts. Cohorts are not expanded, new cohorts 
are enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified timepoints

Novartis Confidential Page 13
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Withdrawal of Study Consent Withdrawal of consent from the study occurs only when a patient does not 
want to participate in the study any longer, and does not allowany further 
collection of personal data. 

Novartis Confidential Page 14
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Protocol summary :
Protocol number CLAG525X2101C
Title A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 
single agent and in combination with PDR001 administered to patients with 
advanced malignancies .
Brief title Phase I/II study of single agent LAG525 or combination of LAG525 and PDR001 
in patients with advanced malignancies.
Sponsor and
Clinical PhaseNovartis
Phase I/II
Investigation ty pe Monoclonal antibody
Study  type Interventional
Purpose and rationale The purpose of this study is to characterize the safety, tolerability including 
determination of maximum tolerated dose (MTD) or recommended Phase 2 dose 
(RP2D), pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity 
of LAG525 as a single agent and in combination with PDR001, an antibody 
directed against PD -1 under investigation in a separate study ([PDR001X2101] ).
In addition, the safety, tolerability, pharmacokinetics and pharmacodynamics of 
single -agent LAG525 in Japanese patients will be evaluated and characterized.
LAG-3 binds its ligand MHC Class II, and regulates T cell signaling. Blockade of 
LAG-3 has been shown to increase T cell proliferation and cytokine secretion, 
most notably IFN -γ. LAG -3 ex pression is also correlated with increased 
suppressive function in both FoxP3 -positive natural regulatory T cells and 
induced FoxP3 -negative regulatory cells.
By blocking the interaction between PD-1 and its ligands, PD -L1 and PD -L2, 
PDR001 inhibits the P D-1 immune checkpoint, resulting in activation of an 
antitumor immune response by activating effector T -cells and inhibiting 
regulatory T -cells.
Preclinical studies in the Sa1N fibrosarcoma and MC38 colon carcinoma models 
demonstrated tumor growth inhibit ion with anti -LAG-3 as a monotherapy with 
enhanced tumor growth inhibition observed with the combination of anti -LAG -3 
and anti -PD-1 immunotherapy. Expression analysis in human tumor infiltrating 
lymphocytes (TILs) from cancer patients supports this conclu sion, with LAG -3 
and PD -1 co -expression identified on tolerized TILs in patients with ovarian 
cancer and microsatellite high colorectal carcinoma (MSI-H CRC).
Primary  Objective(s) Phase I part
●To estimate the RP2D or MTD for single agent LAG525 in all p atients 
(including for Japanese patients)
●To estimate the RP2D or MTD for the combination of LAG525 and PDR001
Phase II part
●To estimate the overall response rate per RECIST V1.1 for single agent 
LAG525 as well as for the combination of LAG525 and PDR001

Novartis Confidential Page 15
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Secondary  Objectives ●To characterize the safety and tolerability of single agent LAG525 given 
alone and in combination with PDR001
●To characterize the pharmacokinetic profile of single agent LAG525 given 
alone and in combination with PDR001
●To assess emergence of anti -LAG525, and anti -PDR001 antibodies following 
one or more intravenous (i.v.) infusions of single -agent LAG525 given alone 
or in combination with PDR001
●To evaluate the preliminary antitumor activity of single agent LAG525 gi ven 
alone or in combination with PDR001
Study  design This study has been designed as a phase I/II, multi-center, open -label study 
starting with a phase I dose escalation part (including a separate Japanese 
single -agent dose escalation arm) followed by a phase II part.
Arm A: single agent LAG525
Arm B: combination of LAG525 and PDR001
Arm C: single agent LAG525 dose escalation in Japanese patients
Data from the dose -escalation arms will be analyzed separately and pooled as 
appropriate. If the recommended dose of single agent LAG525 is the same in 
Arms A and C, patients enrolled in Japan may be recruited into the Phase II 
single agent part of the study. In addition, if the recommended dose of PDR001 
for Japanese patients in the PDR001X1101 study is the sam e as that determined 
in study PDR001X2101, Japanese patients may also enter the combination parts 
of study LAG525X2101 at whichever dose is being tested at that time.
Both PDR001 and LAG525 will be administered i.v. once every two weeks until a 
patient ex periences unacceptable toxicity, progressive disease as per irRC or 
treatment is discontinued at the discretion of the investigator or the patient. In the 
combination cohort, the two antibodies will be administered separately with a 
break of 30 minutes bet ween administrations. Infusions of each antibody can be 
extended to up to 2 hours if clinically indicated and the break between LAG525 
and PDR001 antibody infusions can be up to 4 hours if clinically indicated. A 
cycle is defined as 28 days (21 days for pa tients on Q3W  dosing schedule) for 
both monotherapy LAG525 and the combination of LAG525 and PDR001.
For the combination arm, the first dose for the first two patients treated at each 
untested dose level will be staggered by 24 hours.
Population The phase I part of the study will be conducted in adult patients with advanced 
solid tumors.
The phase II part of the study ,both single agent and combination arms ,will be 
conducted in adult patients with melanoma, NSCLC and renal cancer with or 
without PD -1/PD -L1 treatment experience. The combination arm will also be 
conducted in patients with mesothelioma and TNBC with or without PD -1/PD -L1 
treatment experience .

Novartis Confidential Page 16
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Inclusion criteria 1.Written informed consent must be obtained prior to any procedures. For ‘
Japan only: written consent is necessary both from the patient and his/her 
legal representative if he/she is under the age of 20 years.
2.Age ≥ 18 years
3.Phase I part: Patients with advanced/metastatic solid tumors, with 
measurable or non -measurable disease as determined by RECIST version 
1.1 (refer to Appendix 1 ), who have progressed despite standard therapy or 
are intolerant of standard therapy, or for whom no standard therapy exists.
4.Phase II part: Patients with advanced/metastatic solid tumors, with at least 
one measurable lesion as determined by RECIST version 1.1, who have 
had disease progression. Additionally, the following must apply:
a. NSCLC:
i.Disease recurrence or progression du ring or after no more than one 
prior platinum doublet -based chemotherapy regimen for advanced 
or metastatic disease. Prior maintenance therapy is allowed 
(considered pemetrexed, erlotinib, bevacizumab).
ii.Patients must have been tested for mutations affe cting EGFR 
and/or ALK. (Patients with a known mutation in one gene need not 
be tested for the other). Patients with ALK or EGFR -positive 
NSCLC must have had recurrent or progressive disease after 
treatment with the corresponding inhibitor and no more than one 
platinum doublet -based chemotherapy, in any sequence.
b. Melanoma:
i.Patients with BRAF V600 mutation positive disease must have 
objective evidence of progression of disease after treatment with a 
BRAF inhibitor alone or in combination with other agents.
ii.Patients with BRAF wild -type disease must have objective evidence 
of progression of disease but are not required to have received 
prior therapy .
c. Renal:
i.Patients must have objective evidence of progression of disease 
during or following at least one regimen of treatment for advanced 
renal cancer .
d.Mesothelioma :
i.Patients must have objective evidence of progression of disease 
during or following at least one prior line of systemic chemo therapy 
for advanced disease .
e.TNBC :
i. Patients must have objective evidence of progression of disease 
during or following n o more than 2 prior lines of systemic 
chemo therapy for advanced disease . Patients must have received 
aprior taxane -containing regimen.
5.ECOG Performance Status ≤ 1.
6.Phase IPart: Patie nts enrolled in the Phase I part of the study must provide a 
new tumor biopsy at baseline and during treatment ifmedically feasible.
Phase II part: Patient s enrolled in the Phase II part of the study must provide a 
new tumor biopsy at baseline and during treatment, ifmedically feasible .
Exclusion criteria
(selected)1.Presence of symptomatic central nervous system (CNS) metastases, or CNS 
metastases that require local CNS-directed therapy (such as radiotherapy or 
surgery), or increasing dos es of corticosteroids within the prior 2 weeks. 
Patients with treated brain metastases should be neurologically stable for at 
least 4 weeks prior to study entry and off steroids for at least 2 weeks before 
administration of any study treatment.
2.Histo ry of severe hypersensitivity reactions to study treatment ingredients or 
other mAbs

Novartis Confidential Page 17
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
3.Patient with out -of-range laboratory values defined as:
● Creatinine clearance (calculated using Cockcroft -Gault formula, or 
measured) < 40 mL/min
● Total bilirubin > 1.5 x ULN, except for patients with Gilbert’s syndrome 
who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x 
ULN
● Alanine aminotransferase (ALT) > 3 x ULN
● Aspartate aminotransferase (AST) > 3 x ULN
● Absolute neutrophil count (ANC) < 1.0 x 109/L
● Platelet count < 75 x 109/L
● Hemoglobin (Hgb) < 9g/dL
● Potassium, magnesium, calcium or phosphate abnormality CTCAE > 
grade 2
4.Clinically significant cardiac disease or impaired cardiac function
5.Active, known or suspected autoimmune disease. Patients with vitiligo, type I 
diabetes mellitus, residual hypothyroidism due to an autoimmune condition 
only requiring hormone replacement, psoriasis not requiring systemic 
treatment, or other conditions n ot expected to recur are permitted to enroll. 
Patients previously exposed to anti -PD-1 / PD -L1 treatment who are 
adequately treated for skin rash or who are receiving replacement therapy for 
endocrinopathies should not be excluded.
6.  Patients who required discontinuation of treatment due to treatment -related 
toxicities with prior therapy directed against the same target as th e drug(s)
under study in this protocol .
7.History of drug -induced pneumonitis or current pneumonitis
8.Active infection requiring systemic antibiotic therapy. Patients requiring 
systemic antibiotics for infection must have completed therapy before 
screening is initiated.
9.HIV infection. Testing for HIV status is not necessary unless clinically 
indicate d
10.Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Testing for 
HBV or HCV status is not necessary unless clinically indicated or the patient 
has a history of HBV or HCV infection.
11.Malignant disease, other than that being treated in this study
12.Any medical condition that would, in the investigator’s judgment, prevent the 
patient’s participation in the clinical study due to safety concerns, compliance 
with clinical study procedures or interpretation of study results.
13. a. Systemic anti -cancer therapy within 2 weeks of the first dose of stud y
treatment.
b.For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C, 
nitrosoureas or more recent immunotherapies, 4 weeks is indicated as 
washout period.
c. For patien ts receiving anticancer immunotherapies such as CTLA -4 
antagonists, 8 weeks is indicated as the washout period.
14.Patients receiving chronic treatment with systemic steroid therapy (>10
mg/day prednisone or equivalent) within 7 days of the first dose of study 
treatment , other than replacement- dose steroids in the setting of adrenal 
insufficiency. Topical, inhaled, nasal and ophthalmic steroids are not 
prohibited .
15.Patients receiving systemic treatment with any immunosuppressive 
medication thought to interfere with the mechanism of action of the study 
drugs, other than replacement –dose corticosteroids in the setting of adrenal 
insufficiency.
16.Use of any live vaccines against infectious diseases within 4 weeks of 
initiation of study treatment.
17.Major surgery within 2 weeks of the first dose of study treatment .

Novartis Confidential Page 18
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
18.Radiotherapy within 2 weeks of the first dose of study drug, except for 
palliative radiotherapy to a limited field, such as for the treatment of bone 
pain or a focally painful tumor mass. To allow evaluation of response to 
treatment, patients enrolled in the Phase II part must have remaining 
measurable disease that has not been irradiated.
19.Participation in an interventional, investigational study within 2 weeks prior to 
the first dose of study treatment.
20.Presence of ≥ CTCAE grade 2 toxicity (except alopecia, peripheral 
neuropathy and ototoxicity, which are excluded if ≥ CTCAE grade 3) due to 
prior cancer therapy .
21.Use of hematopoietic col ony-stimulating growth factors (e.g. G-CSF, 
GMCSF, M -CSF) ≤2 weeks prior to the first dose of study treatment
22.Pregnant or lactating women, where pregnancy is defined as the state of a 
female after conception and until the termination of gestation, co nfirmed by a 
positive hCG laboratory test.
23.Women of child -bearing potential, defined as all women physiologically 
capable of becoming pregnant, unless they are using highly effective 
methods of contraception during dosing and for 150 days after the last dose 
of LAG525 or PDR001.
24.Sexually active males unless they use a condom during intercourse while 
taking the drug and for 150 days after stopping study treatment and should 
not father a child in this period. A condom is required to be used also by 
vasectomized men as well as during intercourse with a male partner in order 
to prevent delivery of the drug via seminal fluid.
Investigational and 
reference therapyLAG525 and PDR001
Efficacy  assessments Tumor assessment per RECIST v1.1 and per irRC
Safety  assessments Incidence and severity of AEs and SAEs, including changes in laboratory values, 
vital signs and ECGs
Other assessments Serum PK parameters and immunogenicity.
Data analy sis The study data will be analyzed and reported based on all patients’ data of the 
Phase I and Phase II parts up to the time when all patients have completed at 
least six cycles of treatment or discontinued the treatment. Patient data from 
dose escalation will be analyzed by Arm and from Phase II by Group. Study data 
may be pooled where appropriate.
Key words Phase I/II, LAG525, PDR001, Checkpoint inhibitor, PD -1, PD -L1, LAG -3.

Novartis Confidential Page 19
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Amendment 10 (27- Jun-2019)
Amendment rationale 
The primary  purpose of this amendment is to revise the definition of ‘end of study ’to include 
the option for patients still on study  treatment and who,in the opinion of the investigator ,are 
still deriving clinical benefit at the time of end of study , to transfer to another study  or to an 
alternative treatment option to continue provid ing study  treatment to these patients.
 
 
 
 
 
Changes to th e protocol
 
 
 
 
Section 4.1.3 and Section 4.3 was updated to include the addition of language to account for 
patients who would transfer into another study  or an alternative treatment option to continue 
provision of study  treatment.
Section 7.1.3 was updated to include the addition of language to specify that patients who 
transfer to another study  or an alternative treatment option to continue provision of study 
treatment will complete end of treatment procedures.
Section 7.1.5 was updated to include the addition of language to specify that patients who 
transfer into another study  or an alternative treatment setting to continue provision of study  
treatment will not complete the safet
y, disease progression .
 
Study status
As of 26-Mar- 2019, 450 patients have been enrolled in this trial. Of the 450 patients, 255 
patients have been treated in the dose escalation part, of which 134 received LAG525 single 
agent and 121 received LAG525 in combination with PDR001 and 235 patients that have been 
treated in the combination dose expansion part. As of 26-Mar-2019 there were 39 active patients. 
Ten of these patients were enrolled in the dose escalation part and 29 patients were enrolled in 
the dose expansion part.

Novartis Confidential Page 20
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affec t the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 21
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Amendment 09 (16-Aug-2018 )
Amendment rationale 
The primary  purpose of this amendment is to incorporate health authorit y-requested language 
requiring study  treatment discontinuation in the event of Stevens -Johnson syndrome (SJS)/ 
toxic epidermal necrol ysis (TEN). 
After the occurrence of a case of Stevens Johnson Sy ndrome (SJS) in a study with PDR001 in 
combination with another investigational agent, the dose modification guidelines for protocols 
using PDR001 were updated to mandate permanent discontinuation of study  treatment for 
patients who experience SJS or Lyell syndrome/toxic epidermal necrolysis (TEN). This change 
has alread y been implemented as part of an urgent safet y measure released on 15 June 2018. 
This protocol amendment is now formalizing these changes in the dose modification section 
and corresponding table describing the criteria for dose reduction/interruption and re -initiation 
of treatment for adverse drug reactions. Changes to other sections of the protocol have been 
made to align with the updated dose modification section.
In addition, the protocol has been revised to align with recentl y published guidelines on the 
clinical management of suspected immune -related toxicities.
Other modifications of the protocol are specified below:
Withdrawal of study  consent language has been updated to reflect the European E conomic
Area General Data Protocol Regulation ( GDPR )requirements.
 
 
Clarify  language regarding Progressive Disease in the End of Treatment disposition 
section. The criteria for progressive disease will include evaluation as per RECI ST 1.1 and 
as determined clinically  by the Investigator , in addition to per irRC . 
Languag e within the statistical anal ysis section of protocol was updated to add details and 
clarifications for reporting secondary  safet y and efficacy  objectives.  
 
 
Language within guideline for irRC has been updated to clarify  the selection of new 
measurable lesions, and calculation of follow -up evaluations. 
Study status:
The CLAG525X2101 Cstudy  started enrollment on 17- June- 2015. As of 21-Jun- 2018, 255
patients have been treated in the Phase I study  partand 212 patients have been treated in the 
Phase II study  part which is currently  ongoing. As anti -tumoral activity  was not observed with 
LAG525 single agent but was seen at several dose levels of LAG525 in combination with 
PDR001, it was decided that only the combination portion Phase II expansion would be enrolled. 
This was not a consequence of an y safety concern. 

Novartis Confidential Page 22
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Glossary  of terms wasupdated to include the definition for Personal Data and Withdrawal of 
study  consent. 
Section 5.3 exclusion criteria was changed to align with updated recommended dose limiting 
toxicity  table.
Section 6.2 and Table 6-4 was updated to align with recently  published guidelines on the clinical 
management of suspected immune -related toxicities.
Section 
6.3 and Table 6-5 wasupdated to align with recently  published guidelines on the clinical 
management of suspected immune -related toxicities. 
Section 
6.3.5 wasupdated to include allowed dose of systemic steroid used for the management 
of other concurrent medical conditions. 
Section 7.1.3 wasupdated to have progressive disease include per RECI ST 1.1 or as determined 
clinically  by the Investigator.
Section 7.1.4 was updated to differentiate sample use after a patient withdraws consent based 
on different regulations/laws around the world.
 
Table 7 -6 footers were adjusted to clarify  thatthe 1 -hour post infusion s
ample should be taken 
at all dosing visits from Cy cle 1 through C ycle 6 unless noted otherwise. 
Section 8.3 was updated to note that if the mother consents outcome data will be collected for 
up to 12 months after the birth of the child.
Section 10.5.2 was updated to clarify  data reporting for secondary  efficacy  objectives.   
Section 10.5.3.1 was updated to clarify  what analysis set will be used for safety  anal ysis. 
Section 10.5.3.2 was updated to clarify  which adverse event summaries will be produced.
Section 14.2 was updated to clarify the selection of new measurable lesions and calculation of 
follow -up evaluations. 
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes in this amendment identified above as being related to the USM have alread y been 
implemented by a USM letter issued on 15 June 2018. These changes are required for patient 
safet y (i.e. necessary  to eliminate immediate hazard s to the trial subjects ICH GCP 3.3.8). 
Therefore ,they were required to have been implemented prior to IRB/IEC approval of this 
amendment.

Novartis Confidential Page 23
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
All other changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 24
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Amendment 08 (21- Jun-2017)
Amendment rationale 
The purpose of this amendment is to incorporate the following modifications:
Addition of mesothelioma and triple negative breast cancer (TNBC) indications in the 
combination arm of the phase II part of the study , based on preliminary  evidence of anti-
tumor activity  seen in these indications during the dose-escalation portion of 
CLAG525X2101C (As of 20Mar2017, 2 partial responses in mesothelioma and 2 partial 
responses in TNBC per RECI ST), as well as activity  reported in recent publications (Alley  
2017; Nanda 2016) of othe r checkpoint inhibitors.
To allow single -agent LAG525 patients to continue study  treatment with LAG525 in 
combination with PDR001 upon disease progression after at least 4 cycles of LAG525 
monotherap y treatment and to detail the required tests/samples to be collected. This 
modification to the protocol will: 1.) provide the opportunity  for PDR001 treatment to a 
small number of patients who may not otherwise have access to a PD-
1 inhibitor, and 2.) 
allow potentially  more effective combination treatment with simultaneous LAG525 + 
PDR001 to patients who enrolled onto the LAG525 single- agent arm.
Reduced PK blood sampling timepoints in order to minimize the number of blood samples 
collected for the Phase II patients.  
Inclusion criteria 5: ECOG performance statu s to ≤ 1 (changed from ≤ 2) in order to ensure 
that patients enrolling into phase II indications have a better opportunity to receive and 
tolerate therap y.
Inclusion criteria 6: All phase II patients must provide a new tumor biopsy at baseline and 
during treatment, if medically  feasible. The change from optional to mandatory  biopsies is 
expected to increase the number of paired tumor specimens available for investigation of 
biomarkers relevant to anti-LAG -3 and anti-PD-1 therap y. 
 
 
   
Exclusion criteria 3: Modified potassium, magnesium, calcium or phosphate abnormalit y to 
CTCAE > grade 2 (changed from grade 1) as these lab values tend to fluctuate with frequent 
assessment and may  not reflect the patient's overall clinical status. Low-grade changes can 
be managed with supplementation, and are not intended to be the basis for exclusion from 
the clinical trial if the patient otherwise meets inclusion/exclusion criteria.  Hemoglobin 
must not be < 9 g/dl (changed from < 8 g/dl) in order to potentiall y increase patients’ ability 
to tolerate t herap y.
Exclusion criteria 14: provided washout and corticosteroid dose guidance, since this 
information was not provided previously .
LDH laboratory test has been added for TNBC patients. I n the single -agent pembrolizumab 
trial (Nanda 2016) reported that LDH ≥ 2 times the upper limit of normal was a poor 
prognostic indicator, and was associated with disease progression. 

Novartis Confidential Page 25
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Best overall response per was changed from 30 to 150 days due to delay ed patient response.  
Section 1.2.3.2 was updated with current clin ical experience for LAG525 and PDR001.
Study status:
The CLAG525X2101C study  started enrollment on 17- June- 2015. As of 31-May-2017, 254 
patients have been treated, all in the Phase I dose escalation part. Dose escalation treatment is 
ongoing in all treatme nt arms. The single -agent Phase I dose escalation part enrolled 133 
patients (119 in Arm A and 14 in Arm C)
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Sections 2.1, 2.2.3, 4.1, 5.1, 5.2 and 10 have been updated as described in the above rationale 
section for the addition of mesothelioma and TNBC.
Sections 4.1.3, 7.1.1.2; and Table 7-1 have been update d to collect BRCA status if known for 
TNBC patients.
Sections 5.2 and 5.3 Inclusion/Exclusion criteria have been updated as described in the abov e 
rationale.
Table 7-4 has been updated for LDH to be collected for TNBC patients.
Table 7-6 has been updated related to PK blood samples as described in the above rationale 
section 
Section 7.2.4 has been updated per biops y collection clarification I nclusion criteria 6.
Table 7 -7 has been updated to note total volumes and remove tube t ypes; also changed PBMCs 
to W hole Blood for RNA
Section 
6.2.3.2.1, Table 7-1 and Section 7.2.3 has been updated as described in the above 
rationale section related to single -agent LAG525 patients being allowed to continue study  
treatment with LAG525 in combination with PDR001.
Section 14.1.17 best overall response has been updated as described in the above rationale.
Section 14.2 has been updated to provide additional details for new measurable lesions, 
unknown response and only  non-measurable disease at baseline.
Study status:
The CLAG525X2101 study  started enrollment on 17 -June-2015. As of 31 -May-
2017, 254 
patients had been treated, all in Phase I  the dose escalation study  part. Dose escalation is 
ongoing in all treatment arms.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.

Novartis Confidential Page 26
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 27
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Amendment 07 (09-Dec-2016 )
Amendment rationale 
The purpose of this amendment is to incorporate the following modifications requested by a 
regulatory  authorit y:
Added guidance for patients with hy pergl ycemia or other signs and s ymptoms of diabetes 
and diabetic ketoacidosis.  In patients with severe hypergly cemia ,the recommendation to 
omit the dose of L AG525 and P DR001 and manage as p er Institutional guidelines until 
resolved to ≤ Gr 1 has been added. Additionall y , patients without pre- existing diabetes or 
previously  determined to be normogly cemic , but shown to have an abnormal random 
blood glucose at screening mus t have a fasting blood glucose test performed
. Any 
subsequently  diagnosed hy pergly cemia should be managed appropriatel y as per 
Institutional guidelines.
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, the following eligibility  criteria in sections 5.2 and 5.3 were updated in this 
amendment: Inclusion criteria 4: clarifications on prior therap y requirements for Phase II 
patients to account for current standard o f care. In response to the rapidly  changing 
approach to treatment of patients with melanoma, the eligibility  criterion has been 
change d to no longer require patients with melanoma to have received s ystemic therapy  
prior to being eligible for study  enrolment. All patients with BRAF V600 mutant 
melanoma must have received a BRAF inhibitor.
Inclusion criteria 6: Corrected formatting issue and clarified newl y collected tumor biopsy  
is required at baseline for both Phase I  and II if medically  feasible. 
Exclusio n criteria 1: Added additional guidance regarding patients with brain metastases 
to ensure suitability  of patients to be enrolled.

Novartis Confidential Page 28
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Exclusion criteria 5: Clarified that patients with prior anti -PD-1/PD -L1 treatment who are 
adequatel y treated for skin rash o r replacement therapy  for endocrinopathies should not be 
excluded
Exclusion criteria 6: Added to exclude patients who discontinued prior checkpoint 
inhibitor therapy  due to checkpoint inhibitor -related toxicity  as these patients may  be at 
higher risk of re
-bound toxicity
Exclusion criteria 18: Clarified that patients enrolled in the Phase II part must have 
remaining measurable disease that has not been irradiated.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Section 1.2.2.2 Clinical experience with PDR001: Updated based on CPDR001X2101 trial .
 
 
Section 5.2 and 5.3 Inclusion/Exclusion Criteria has been updated as described in the rationale 
section above.
Section 6.1 Dosing regimen: Clarified guidance regarding resuming study  treatment after dose 
interruptions to accommodate all potential dosing schedules.
Section 6.1.2 Ancillary Treatments: Added that if a patient experiences a Grade ≥3 
anaph ylactic/anaph ylactoid reaction, the patient will be discontinued from the study .
Section 6.2.3 Guidelines for dose escalation: Clarified that the additional cohorts may be opened 
for additional pharmacody namics data. 
Table 6- 4 Criteria for defining DLTs:  C larified DLT window for each Treatment Arm .
Section 6.3 Dose modifications: Adjusted guidance regarding resuming study  treatment after 
dose interruptions.
Table 6-5 Recommended Dose Modifications: Added guidance for Type 1 Diabetes mellitus. 
Also clarified that decreasing the dose level or the dosing frequency is the recommendation for 
certain toxicities. 
Section 6.3.3 Permitted concomitant therap y: Added guidance for certain hormone therapies as 
well as bisphosphonates to allow patients who may benefit from study  treatment to enroll but 
who are dependent upon the therapies described for sy mptomatic disease control. 
Section 6.3.4 Permitted concomitant therap y: Clarified concomitant therapy  requirements apply 
to the DLT observation window (1 cycle for singl e agent, 2 cycles for combination treatment 
arms) .
Table 7 -1 Visit evaluation schedule: added and adjusted biomarker collections and removed 60 
and 120 day  safet y follow up visits.

Novartis Confidential Page 29
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Section 4.1.3 and 7.1.5 Follow up period revised to align with the PDR001 p rogram: removed 
60 and 120 day post-treatment safety  follow up. Also clarified that the follow up can be done 
by telephone or patient visit.
Section 7.2.1 Efficacy  assessments: Clarified the scope of vendor for independent review of 
imaging data for imagin g data in Phase II.
Table 7-2 Disease assessment collection plan: Added guidance on bone scans.
Table 7-4 Local clinical laboratory  parameters collection plan: Added note regarding fasting 
glucose. Also revised collection of LDH to encompass all melanoma patients regardless of when 
they enroll.
Section 
7.2.2.5.2 Clinical Chemistry : Added guidance on when glucose testing should be 
fasting or non- fasting.
 
 
 
 
 
 
 
 
 
Section 8.1.1 Adverse Event defini tions and reporting: Clarified that after initiation of new post-
treatment antineoplastic therap y, only AEs suspected to be related to study  treatment will be 
collected in the safet y follow up period. 
Section 8.2.2 Serious Adverse Event reporting: Clarified that if a patient starts a post treatment 
antineoplastic therapy , only SAEs suspected to be related to study  treatment will be collected 
in the safety follow up period.
Section 8.5 Data Monitoring Committee: Clarified that events through the DLT observation 
window (through Cycle 1 for Arms A and C, through Cy cle 2 for Arm B) will be discussed at 
dose escalation teleconferences.
Section 10.1.4 Dose -Determining Anal ysis Set: The dose-determining set definition has been 
clarified to account for possible different dosing schedules for LAG525 and PDR001.

Novartis Confidential Page 30
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
 
  
Section 11.5 Publication of study  protocol and results: Added details regarding Novartis 
publication process
Study Status
The CLAG525X2101 study  started enrollment on 17- June- 2015. As of 25-Aug-2016, 117 
patients had been treated, all in Phase I the dose escalation study  part. Dose escalation is 
ongoing in all treatment arms. 
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes descr ibed in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 31
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Amendment 06 (05- Jul-2016)
Amendment rationale
The purpose of this amendment is to incorporate changes related to the following: With the 
available PK data obtained from the single agent first-in-human study  CPDR001X2101, an 
exploratory  population PK (PopPK) analy sis showed that the T1/2 of PDR001 in man is 20 [17, 
23] days (mean [90% CI]). Using five times the upper bound of the confidence interval of the 
half-life of 23 days and an added safet y margin, the protocol is amended toincrease the duration 
of contraception and safety  follow -up periods post PDR001 treatment from 90 days to 150 days. 
These changes are related to an Urgent Safety  Measure communicated on 08-June- 2016 to all 
investigators. For logistical simplicity, these changes are applicable for all patients in both the 
single -agent LAG525 and combination L AG525 + PDR001 study  arms.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike thro ugh red font for deletions and red underlined for insertions.
Safety  follow -up period increased from 90 to 150 day s following end of treatment in the 
following sections:
4.1.3 Study  Periods
4.3 Definition of end of the study
6.3.2 Follow -up for toxicities
Table 7- 1 visit evaluation schedule
7.1.5 Follow up periods
8.1.1 Safet y reporting
8.2.2 Reporting (of SAEs)
10.5.3 Safety objectives (definition of on -treatment and post-treatment periods)
Section 7.2.2.5.7 Pregnancy  and assessment of fertility  and Table 7- 1: Pregnancy  testing 
added at 120 and 150 day s following end of treatment.
Exclusion Criteria 23 and 24: Requirement for women of child- bearing potential and 
sexually  active males to use contraception increased from 90 to 150 day s following end of 
treatm ent.
Table 7- 4 Local lab: LDH added for Phase 2 melanoma patients to align with other trials 
in the PDR001 program
Protocol Summary  Table: Population language corrected to align with body  text
Study Status
The CL AG525X2101C study  is currently  ongoing in th e Phase 1 study  part.

Novartis Confidential Page 32
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
IRB/IEC/HA  Approval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 33
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Amendment 05 (12- Apr-2016)
Amendment rationale
The purpose of this amendment is to incorporate the following modifications of the exclusion 
criteria requested b y a regulatory  authority :
Exclusion Criteria 02: Revised to exclude patients with history  of severe h ypersensitivity  
reactions to study  treatment ingredients or other mAbs
Exclusion Criteria 07: Criterion added to exclude patients with a history  of drug- induced 
pneumonitis or current pneumonitis
Exclusion Criteria 23: Clarified the definition of women who are considered post-
menopausal and not of child bearing potential
Additional changes to the protocol:
Exclusion Criteria 13: Washout period requirements for anti- cancer therapies have been 
split for clarification. Four -week washout period requirement for recent immunotherapies 
has been added.
Table 6
-4: Clarified footnote regarding DLT observation window
Section 6.1.2 and Table 6 -5: Clarified wording regarding infusion reactions
Table 7- 1: Formatting corrected to clarify  that capturing AEs and concomitant 
medicat ions continues through the safet y follow -up period
Table 7-2: Clarified that bone scans or other disease assessment methods allowed per 
RECI ST 1.1 may  be used
Section 10.1.4: Clarified minimum exposure for DDS for Q3W and Q4W schedule to 
align with Section 6.3.2
Section 10.4.4, 10.7, 10.8, and 14.3.2: corrected wording to reference 12 Phase 2 groups
IRB/IEC/HA  Approval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authori ties.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.

Novartis Confidential Page 34
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Amendment 04 (12-Feb-2016)
Amendment Rationale
The purpose of this amendment is to include a Japanese dose escalation arm for single -agent 
LAG525 with the goal of informing subsequent clinical development opportunities in Japan.
The single agent dose escalation part of this study  is alread y underway  globally  with the 
exception of Japan. At the time of writing this amendment patients are being treated with single -
agent LAG525 at doses higher than the starting dose (1 mg/kg Q2W). In order to ensure that 
the safet y and pharmacokinetic profiles of single -agent LAG525 are adequately  characterized 
in Japanese patients at more than one LAG525 dose, a Japanese -specific dose escalation of 
single -agent LAG525 has been included in the protocol. The Japanese dose escalation will run 
separately  from the ongoing dose escalation with a starting dose for single -agent LAG525 in 
Japanese patients of 1 mg/kg Q2W. Dose escalati on decisions will be guided by  a BL RM.
If the recommended dose of single agent LAG525 is the same in Arms A* and C**, patients 
enrolled in Japan may  be recruited into the Phase II single agent part of the study . In addition, 
if the recommended dose of PDR0 01 for Japanese patients in the PDR001X1101 study  is the 
same as that determined in study  PDR001X2101, Japanese patients may also enter the 
combination parts of study LAG525X2101 at whichever dose is being tested at that time.
*Arm A: single -agent LAG525
**Arm C: single -agent LAG525 dose escalation in Japanese patients
Additional changes to the protocol:
The landscape of treatment with immunomodulatory therapy  in oncology  is evolving rapidly. 
In response to the growing number of patients with renal cancer receiving anti-PD-1/PD -L1 
therap y, expansion arms have been added for patients with renal 
cancer who are refractory  to 
or have relapsed following prior treatment with PD-1/PD -L1 inhibitors to explore whether 
LAG525 alone or in combination with PDR001 can ov ercome PD -1/PD -L1 resistance.
In order to provide more flexibility  in the palliation of symptoms caused by some tumor lesions 
and allow patients to continue the study  treatment, the prohibited concomitant therap y section 
was updated to allow localized radiotherap y for non -target lesions.
Because the determination of EGFR, ALK, or BRAF V600 status is not performed routinely as 
part of standard assessment of disease in all countries or study  sites, this amendment includes 
the determination of these molecular parameters by a local laborator y, at screening, for patients 
with a tumor of unknown status. However, the test results will not be used for eligibility  of 
enrollment.
List of changes to the protocol
Changes to specific sections of the protocol are shown inthe track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Section 1.2.2.2 Clinical Experience
Added a summary  of PDR001X2101 study .
Section 2.2: Rationale for the study  design:

Novartis Confidential Page 35
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Added a statement to include Japanese dose escalation arm for single -agent LAG525.
A new section (Section 2.2.2) was created to describe Japanese dose escalation.
Statement of recruitment of Japanese patients to the Phase II part was added to section 
2.2.3.
Section 3: Objectives and end points.
Primary  objective was updated to include Japanese patients treated with single -agent 
LAG525.
Section 4.1 Description of Study  Design:
The study  design was updated to include a separate Japanese dose escalation.
Figure 4 -1 was updated to include a separate Japanese dose escalation arm with 
single -agent LAG525 (Arm C).
Updated treatment group after adding renal cell carcinoma pre -treated with PD -1/PD -
L1 in the Phase II expansion part.
Section 4.1.1 Phase I dose escalation.
Added single dose escalation arm (Arm C) for Japanese patients.
Section 4.1.3 Study  period
Added collection of EGFR, AL K, BRAF V600 status
Section 5.2: I nclusion criteria.
Updated for Japan onl y: written consent is necessary  both from the patient and his/her 
legal representative if he/she is under the age of 20 y ears age for Japanese patients.
Section 5.3 Exclusion criteria
Removed one item in the exclusion criteria, which is prior PD
-1 or PD -L1 directed 
therap y for renal cell carcinoma
Changed washout period from 6 weeks to 8 weeks for patients receiving anticancer 
immunotherapies such as CTL A-4 antagonists.
Section 6.2. Dose escalation guidelines
Added Arm C throughout the section
Section 6.2.3: Guidelines for dose escalation and determination of MTD/ RP2D
Added Arm C to include Japan single agent dose escalation.
Section 6.3.4 Permitted concomitant therap y requiring caution and/or action
Updated to allow all t ypes of anti -coagulation be included as permitted concomitant 
therap y, not just warfarin and h eparin
Section 6.3.5 Prohibited concomitant therap y:
Clarified that limited -field palliative radiotherap y to non -target lesion(s) may  be 
allowed after documented discussion with Novartis.
Section 7.1 Study  flow and visit schedule
Added wording to explain category  “D” and “S” in Table 7 -1
Table 7- 1 Visit evaluation schedule
Added collection of EGFR, AL K, BRAF V600 status

Novartis Confidential Page 36
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Pregnancy  test was updated to reflect that during the safet y follow -up period, a 
pregnancy  test can be performed at home if patients are n ot coming to the clinic for 
the safet y follow up visits
Added every  3 week dosing schedule to “stud y drug administration”
Section 7.1.1.2 Patient demographics and other baseline characteristics
Clarified MSI , EGFR, ALK, or BRAF V600 status to be collected at baseline as 
appropriate.
Section 7.1.2 Treatment period
A statement was added that for Japan only, patients enrolled in dose escalation are 
required to be hospitalized during the DLT evaluation period
Section 7.1.5 Follow up period: 90 -day safet y follow up per iod
A statement was added to clarify  that during the safet y follow up period, if patients 
are not coming to the clinic for the safet y follow- up visits, a pregnancy  test may  be 
conducted at home if patients are not coming to the clinic for the safet yfollow up.
Table 7- 2: Disease assessment collection plan
Table 7- 2 was updated with detailed assessment collection plan.
Section 7.2.2.5.7 Pregnancy  and assessment of fertility
A statement was added to clarify  that during the safet y follow up period, if patients 
are not coming to the clinic for the safet y follow- up visits, a pregnancy  test may  be 
conducted at home if patients are not coming to the clinic for the safet y follow up 
visits
Table 7- 6: Pharmacokinetic blood collection log
Updated to provide spe cifications on some of the blood samples for Q2W, Q3W and 
Q4W schedules.
Footnote was updated that the sample collection may  be stopped if sufficient data 
have been collected
Section 8: Safety  monitoring and reporting
Updated section 8 throughout to reflec t eSAE reporting procedure at Novartis
Section 10: Statistical Methods and data anal ysis.
Updated to include data analy sis rules throughout the section; statistical hy pothesis; 
model; and method of analy sis for the Japanese -specific single agent LAG525 dose 
escalation.
Section 14: Appendices.
Added a new Section14.4: “Statistical details of Phase I Bay esian logistic regression 
model (BLRM) in Japanese patients treated with single agent of LAG525”.

Novartis Confidential Page 37
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
IRB/IEC/HA  Approval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 38
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Amendment 03 (04-Dec-2016)
Amendment Rationale
The purpose of this amendment is to incorporate the following revision requested by a 
regulatory  authorit y:
To specify  that if required by  a Regulatory  Authority , recruitment to combination dose 
levels will begin at dose level -1 (0.3 mg/kg LAG525 with 1 mg/kg PDR001) for patients 
from those countries.
To spec ify that for the combination arm, the first dose for the first two patients treated at 
each untested dose level will be staggered b y 24 hours.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Section 2.3 Rationale for dose and regimen selection
Specified that if required by  a Regulatory  Authority , recruitment to combination dose 
levels will begin at dose level -1 (0.3 mg/kg LAG525 with 1 mg/kg PDR001) for 
patients from those countries
Section 4.1 Description of study  design:
Specified that for the combination arm, the first dose for the first two patients treated 
at each untested dose level will be staggere d by 24 hours.
Added that if required b y a Regulatory  Authorit y, recruitment to combination dose 
levels will begin at dose level -1 (0.3 mg/kg LAG525 with 1 mg/kg PDR001) for 
patients from those countries.
Section 6.1.1 Dose regimen
Specified that for the combination arm, the first dose for the first two patients treated 
at each untested dose level will be staggered b y 24 hours.
Section 6.2.1 Starting dose rationale:
Added that if required b y a Regulatory  Authorit y, recruitment to combination dose 
levels wi ll begin at dose level -1 (0.3 mg/kg LAG525 with 1 mg/kg PDR001) for 
patients from those countries
Table 6- 3 Provisional dose levels (Ph I Arm B: combinations of L AG525 and PDR001
Updated the footnote to specify  that if required b y a Regulatory  Authorit y recruitment 
to combination dose levels will begin at dose level - 1 (0.3 mg/kg LAG525 with 1 
mg/kg PDR001) for patients from those countries
Section 6.2.3 Guidelines for dose escalation and determination of MTD/RP2D
Added that if required b y a Regulatory  Authorit y, recruitment to combination dose 
levels will begin at dose level -1 (0.3 mg/kg LAG525 with 1 mg/kg PDR001) for 
patients from those countries
Table 6- 5 Recommended Dose Modifications for LAG525 and PDR001

Novartis Confidential Page 39
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Added a footnote to Pancreatitis to explain: asymptomatic enzy me increases do not 
require delay  of study  treatment or dose reduction
 
Section 7.2.2.5: L aboratory  Evaluations
Clarified that cy tokine release s yndrome testing will be conducted centrall y for sites 
not capable of local testing.
IRB/IEC/HA  Approval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.

Novartis Confidential Page 40
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Amendment 02 (14-Sep-2015)
Amendment Rationale
The goal of this amendment is as follows:
1.To focus the Phase II expansion on three main cancers: NSCLC, melanoma and renal cell 
carcinoma, both single agent and combination Phase II expansion will be conducted in 
cancers which are known to be responsive to single -agent PD -1 inhibition, to determine 
the efficacy  of sing le-agent L AG525 and the combination of L AG525 with PDR001 in 
both the PD -1/PD -L1 pre-treated and naive settings.
a.Expansion arms for patients in the PD -1/PD -L1 naïve setting will explore antitumor 
activity  of single -agent LAG525 and the combination of LAG525 with PDR001.
b.Expansion arms have been added for patients with NSCL C and melanoma who are 
refractory  to or have relapsed following prior treatment with PD -1/PD -L1 inhibitors 
to explore whether LAG525 can overcome PD -1/PD -L1 resistance.
c.  
 
 
 
 
2.Modify  the inclusion criteria in the phase II part of the study  for patients with NSCL C and 
melanoma who are naïve to PD -1/PD -L1 treatment, to align with study  CPDR001X2101 
where PDR001 is being tested as a single- agent in the same patient populations.
3.Allow the option to test alternate dosing (i.e. flat dosing) within single agent dose 
escalation and/or Phase II expansion if flat dosing is supported by  emerging PK data 
generated during the study . Flat dosing may  also be tested in the combination part of the 
study  for both LAG525 and PDR001.
a.Flat dosing decreases operational complexity  with easier study  drug preparation and 
may reduce the possibility  of dosing errors.
4. Allow the option to test two doses of LAG525 during Phase II expansion
5.Allow collection of a blood sample fo r cytokine assessment (IL -6 ) for all 
patients at screening. This baseline sample will serve as a comparator for those patients 
who require follow -up assessment of cy tokines (i.e. in case of an adverse event suspected 
to be cy tokine release s yndro me).
6. Clarification of certain exclusion criteria, and prohibited concomitant medications
7.Align the collection and anal ysis of  with preclinical 
evidence on the timing of immune response in tumor after therap y with PD -1 blocking 
antibodies
 
8.Changed safet y monitoring / reporting and follow up window from 30 days to 90 day s 
throughout the document. During the safety  follow up period, safet y evaluations, 

Novartis Confidential Page 41
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
pregnancy  test need to be performed on 30, 60 and 90 day s after the last dose of the study  
drug.
9. To align this protocol with the latest Novartis guidelines for the prevention of pregnancies 
in participants in clinical trials and their partners, the exclusion criteria were updated to 
exclude sexually  active male subjects who are not willing to use a condom during the 
study .
Additional Changes to the protocol
Section 2.2.2 Phase II:
Updated patient populations to include those treated wi th prior PD -1 or PD -L1 inhibitors.
Section 2.3 Rationale for dose and regimen selection
Introduced alternative dosing (flat dose [mg]) which may  be implemented during the stud y
Section 4.1: Description of study  design:
Modified figure 4- 1 study  design
Modified Arm A to include group 4 and 5 for the single dose expansion part
Modified Arm B to include NSCL C and Melanoma patients who have received prior PD -1 
or PD -L1. Removed patients with gastric, CRC, NPC and renal cell carcinoma with 
previous treatment of PD -1 / PD -L1.
Section 4.1.3 Study  period
Clarified biopsy  requirements, i.e. in dose escalation part, it mandatory , in dose expansion 
part, it is optional.
Section 5.1 Patient population
Updated patient populations in the expansion phase.
Section 5.2: Inclusion criteria
Added detailed patient population criteria for the patients to be enrolled in the Phase II 
part of the stud y.

 
Section 5.3: Exclusion criteria
Added language about certain diseases /conditions that require steroid treatment are 
permitted to be enrolled
RCC patients who have received prior PD -1/PD -L1 ar e now excluded from the Phase II 
expansion. Clarified that the topical use of steroids are not prohibited.
Addition of exclusion criterion 24, which excludes sexually  active male subjects who do 
not use a condom during intercourse
Section 6.1.1 Dosing regimen
Clarified how to handle a dosing delay for PDR001 within the combination arm if 
clinically  indicated (e.g. if an infusion reaction occurs after LAG525 administration). 

Novartis Confidential Page 42
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Emphasized that the break between LAG525 and PDR001 infusions can be up to 4 hours 
if clinically  indicated. If PDR001 cannot be administered safely  within 4 hours after 
LAG525 administration, the dose must be omitted.
Clarified there is a 7 -day window for a dose delay  of either single agent or combination 
treatment.
Alternate dosing (i.e. a flat dose) may  be implemented after at least one cohort has been 
tested using a weight -based dosing paradigm
Introduced an option in the Phase II expansion to test 2 dose levels
Section 6.2.2 Provisional dose levels
Modified Table 6 -2 and Table 6 -3 to a dd flat doses
Section 6.2.3
Added flat dose in “mg” may  be explored for single agent by  opening new cohorts in the 
escalation part
Section 6.2.4
Added DLT window for Q3W dosing schedule. It will 21 day s for patients in Q3W dosing 
schedule.
Clarified the duration of rash and/or photosensitivity  should be 7 day s instead of 14 day s.
Section 6.3.1
Removed the statement about maximum number of dose reductions allowed from Table 6 -
5 and placed the modified statement in the text, which allows more than 2 dose re ductions 
of either drug if a patient is experiencing clinical benefit.
Section 6.3.2 Follow- up for toxicities
Changed the follow -up window from 30 day s up to 90 day s. Safet y evaluations will be 
conducted on 30, 60, and 90 day s after the last doses of LAG52 5 and/or PDR001
Section 7.1 Study  flow and visit schedule
Added assessments for the cy tokines IL -6  at baseline
Modified fresh tumor biopsy  sample collection time, and changed the collection time point 
from cy cle 2 to cy cle 3.
Section 7.2.2.5.6 Cy tokines
Added baseline cy tokines
Added cy tokine sample storage condition
Section 7.2.3 Pharmacokinetics and immunogenicity  assessments
 
Deleted the columns with dose reference ID
Provided a footnote to analytes in Table 7 -6.

Novartis Confidential Page 43
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
 
 
Section 9.3 data collection
Clarified PK and biomarker samples will be analyzed in central labs onl y, not in local 
labs.
Section 10: Statistical methods and data anal ysis
Study  groups were updated to reflect the new study  design.
Added alternative dose (flat dose in mg) and dosing schedule (Q4W) may  be implemented 
during the stud y
Section 10.4.2 Statistical hy pothesis, model, and method of anal ysis
Clarified that DLT data from single agent LAG525 cohorts will be used in the BLRM for 
combo of LAG525 and PDR001
Added BLRM for flat dosing
Updated Phase II analy sis
Section 10.8 sample size calculation
Updated sample size justification for the phase II part
Section 14 Appendices
Updated Appendix 14.3.2 for phase II statistical analy sis

Novartis Confidential Page 44
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Amendment 01 (27-Apr-2015)
Amendment rationale
The purpose of this amendment is to incorporate the following revision requested by a 
regulatory  authorit y:
Revise the DLT criterion for thrombocy topenia to include CTCAE grade 3 
thrombocy topenia with clinically  significant bleeding as a DLT
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Section 6.2.4 Definitions of dose limiting toxicities (DLTs):
Added grade 3 thrombocytopenia with clinically  significant bleeding to hematology  
section of Table 6 -4.
IRB/IEC/HA  Approval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approv al prior to 
implementation.

Novartis Confidential Page 45
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and current 
treatment
Immunotherapies that target immune checkpoints have recently  shown strong efficacy  and are 
emerging as key agents in cancer therap y. Antibodies targeting CTLA -4 (ipilimumab [BMS]) 
and PD-1 (e.g. nivolumab [BMS] and pembrolizumab [Merck]) demonstrate durable anti-tumor 
effects and an acceptable safet y profile. While single agent treatments demonstrate promising 
efficacy , combinations of immunotherapy  approaches suggest that synergistic blockade of co-
inhibitory  proteins demonstrates greater antitumor activity  than the single agent (Wolchok 
2013). Preclinical studies of the combination of PD- 1 and LAG -3 demonstrate that 
simultaneous inhibition of both inhibitory  receptors may have synergistic antitumor activity 
(Drake 2014
; Woo 2012 ).
PD-1 (Pr ogrammed Death -1, CD -279) is a critical co -inhibitory  receptor that is upregulated on 
T cells upon activation (Freeman 2008). It is also expressed by B cells, NK cells, dendritic cells, 
and activated monocy tes. The ligands for PD-1, Programmed Death -Ligand 1 (PD-L1) and 
Programmed Death -Ligand 2 (PD
-L2), are expressed by macrophages and monocytes, and can 
be induced on numerous cell types (T cells, endothelial cells, and tumor cells) during 
inflammation (Keir 2008 ). Engagement of PD -1 by its ligands transduces a signal that inhibits 
T-cell proliferation, cytokine production, and cytolytic function (Riley  2009). During 
tumorigenesis, cancer cells from a wide range of tumor types exploit immune checkpoint 
pathway s, such as PD-1, to avoid detection by the adaptive immune system (Murph y 2011). 
Blockad e of the PD-
1 pathway  has been shown to lead to both accumulation and increased 
activity  of antitumor effector T cells and a reduced numbers of regulatory T cells (Tregs) at the 
tumor site ( Wang 2009
, Mangsbo 2010 , Mkrtich yan 2011 , Rosenblatt 2011 ).
LAG -
3 (Lymphocy te Activation Gene -3, CD223) isa cell surface molecule expressed on 
activated CD4+ and CD8+ T effector cells, multiple populations of regulatory  T cells, NK cells, 
B cells and plasmacy toid dendritic cells (Huard 1994, Triebel 1990, Kisielow 2005). LAG -3 
binds its ligand MHC Class II, and this interaction negatively  regulates T cell signaling 
(Workman 2011). Blockade of LAG - 3 has been shown to increase T cell proliferation and 
cytokine secretion, most notably  IFN-γ (Huard 1997 , Workman 2003). LAG - 3 expression is 
also correlated with increased suppressive function in both FoxP3 -positive natural regulatory  T 
cells and induced FoxP3 -negative regulatory  cells (Huang 2004, Camisaschi 2010, Scurr 2014).
Preclinical studies in the Sa1N fibrosarcoma and MC38 colon carcinoma models demonstrated 
tumor growth inhibition with anti-LAG -
3 as a monotherap y with enhanced tumor growth 
inhibition observed with the combination of anti-LAG -3 and anti-PD-1 immunotherap y (Woo 
2012). Expression analysis in human tumor infiltrating lymphocy tes (TILs) from cancer 
patients supports this conclusion, with LAG
-3 and PD-1 co-expression identified on tolerized 
TILs in patients with ovarian cancer and microsatellite high colorectal carcinoma (MSI -H CRC) 
(Chen 2014).

Novartis Confidential Page 46
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of LA G525
LAG525 is a high -affinity , ligand-blocking, humanized anti- LAG -3 IgG4 antibody  (stabilized 
hinge, S228P) which blocks the binding of the known LAG -3 ligand MHC class II to LAG -3. 
LAG525 is cy nomolgus cross- reactive and shows functional activity .
1.2.1.1 Non
-clinical experience with LA G525
LAG525 binds specifically  and with high affinit y to human LAG -3. In Biacore assay s, the K D
of LAG525 on human LAG-3 is 0.109 nM and in cell binding assay s, LAG525 binds CHO -
hLAG-3 expressing cells with an affinity  of 1.9 nM. LAG525 does not cross- react with rat or 
mouse LAG -3, and therefore cannot be evaluated in murine tumor models. It does cross -react 
with cynomo lgus monkey  LAG -3 (affinity of 2.3 nM on cynomolgus LAG -3-expressing cells), 
making cynomolgus monkey  a relevant species and the only species for toxicology  studies. A 
GLP tissue cross reactivity  study was conducted with 
both human and cynomolgus monkey 
tissue specifically  to assess the potential for off target binding. There was no binding observed 
even for tissues known to express L AG-3. This was likely  due to reagent sensitivity  issues and 
possibly  the lower expression of the target.
Safety  was evaluated in a five week repeat dose GLP toxicology  study as well as in a limited 
panel in a single dose PK study , both in cynomolgus monkey s. In the single dose study , clinical 
observations, clinical chemistry , and hematology  endpoints were evaluated as part of an in-life 
assessment of safet y. There were no findings related to LAG525 administration in this single 
dose study .
In the five week GLP toxicology  study, repeat administration of LAG525 to monkey s 
(3/sex/main and 2/sex/recovery  groups) at doses of 6, 25, an d 100 mg/kg was well tolerated at 
all doses tested. After the fifth dose, the eight week recovery period began for control and high 
dose animals assigned to recovery . Animals assigned to the main phase were sacrificed seven 
days after the last dose was administered. Minimal increases in fibrinogen at 100 mg/kg and 
globulin (relative change from pretest only) in males at 25 and 100 mg/kg were noted. 
Association with LAG525 administration is unclear but cannot be excluded. A female animal 
in the 6 mg/kg group display ed a hypersensitivity reaction soon after the third dose, consisting 
of vomiting and clinical signs of a swollen muzzle and flushed face. The animal was 
subsequently  treated with diphenhydramine and the s ymptoms resolved shortly  after treatment. 
This animal was then pre-treated with diphenh ydramine prior to the last two doses and no 
further intervention was required. It was confirmed that this animal was positive for the 
presence of anti-drug antibodies. A statistically  significant increase in proliferating CD4+ T 
cells was observed in animals given 100 mg/kg/week compared to control animals, a 
pharmacod ynamic effect observed in vitro with LAG-3 blockade (Huard 1997 ; Workman 2003). 
There were no other test article related effects. The highest non -severely  toxic dose (HNSTD) 
and the ‘no observed adverse effect level’ (NOAEL) was 100 mg/kg. LAG525 has a favorable 
safet y profile in monkeys that sup ports the proposed human starting dose of 1 mg/kg.

Novartis Confidential Page 47
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
1.2.1.2 Clinical experience with LA G525
This is the first in human (FIH) study  for L AG525. Please refer to the [L AG525 I nvestigator’s 
Brochure] for more details.
1.2.2 Overview  of PDR001
PDR001 is a high-affinity , ligand-blocking, humanized anti-PD-1 IgG4 antibody  (stabilized 
hinge, S228P) which blocks the binding of PD -L1 and PD -L2 to PD -1. PDR001 is cynomolgus 
cross -reactive and shows functional activity  in vitro and ex vivo. For further details, please 
consult the mos t recent edition of the [PDR001 I nvestigator’s Brochure].
1.2.2.1 Non- clinical experience PDR001
PDR001 binds specifically  and with high affinity  to human PD -1. In Biacore assay s, the K Dof 
PDR001 on human PD-1 is 0.083 nM. In ex vivo lymphocy te stimulation assay susing human 
blood, PDR001 enhances IL -2 production by  approximately  2-fold in response to super antigen 
stimulation with Staphy lococcal enterotoxin B (SEB). PDR001 does not cross -react with rodent 
PD-1, and cannot be evaluated in murine tumor models. It does cross- react with cynomolgus 
monkey  PD-1, and is functionally  active, making cynomolgus monkey  a relevant species for 
toxicology  studies. A GLP tissue cross reactivity  study using frozen human and cynomolgus 
monkey  tissues was also done in support of the safet y of PDR001. There was no unexpected 
binding observed.
The non -clinical toxicology  of PDR001 was evaluated in a five week GL P toxicology  study  in 
cynomolgus monkey s with safet y pharmacology endpoints and an eight week recovery. Repeat 
administration of PDR001 to monkey s was well tolerated at all doses tested in the GLP 
toxicology  study. No test article -related in-life, mortality , organ weight changes, or 
macroscopic findings were noted. There were no PDR001 -related effects seen in any of the 
safet y pharmacology  endpoints assessed (cardiovascular, neurobehavioral, and respiratory ). 
Macrophage infiltrates into the splenic 
white pulp were observed in animals given 100 
mg/kg/week and mononuclear cell infiltrates, often associated with fibrosis, around the
injection site blood vessel (saphenous vein) in a few animals given 25mg/kg/week. These 
PDR001 -related microscopic changes were fully reversible after an eight week recovery .
The following changes were noted in main phase and recovery  treated animals aswell as control 
recovery  animals. Mostly  low grade changes were noted in several tissues in the form of 
mononuclear infiltrates in the vascular and perivascular space. In general, in most organs, 
vascular/perivascular changes were limited to one or a few blood vessels in each organ and 
sometimes involved a segment of a blood vessel with occasional vessel wall degeneration. No 
evidence of parench ymal damage was associated with the vascular/perivascular changes in an y 
of the organs examined and the changes were not associated with any frank tissue injury . While 
these effects were not exclusive to treated animals, because of their nature and close association 
with the expected pharmacology  of PD1 blockade, a potential PDR001 related effect cannot be 
excluded and possibly  explained by mild enhanced pharmacology  of PDR001. There were no 
test article related effects seen in the cardiovascular (CV) assessments. All other microscopic 
findings were considered spontaneous or otherwise unrelated to PDR001 administration.

Novartis Confidential Page 48
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Dose -dependent exposure to PDR001 in each dose group was confirmed. A pharmacod ynamic 
ex vivo superantigen stimulated whole blood assay  measuring IL-2 release was performed. 
Blood from untreated control animals showed augmentation of IL -2 release when PDR001 was 
added ex vivo, whereas blood from treated animals at all doses did not show augmented IL-2 
release, indicating target engagement and inability  to further dis-inhibit the SEB induced 
response with the further addition of PDR001. The HNSTD dose in this study  was 100 mg/kg.
1.2.2.2 Clinical experience
The CPDR001X2101 study  started enrollment on 27 April 2015 and is ongoing. As of 17 
December 2015, a total of 58 patients had been treated in the study  at the dose levels of 1, 3 and 
10 mg/kg Q2W and 3 and 5 mg/kg Q4W. No patients have experienced a DLT. The PK analy sis 
of the dose escalation data using apopulation approach and the expected wide therapeutic index  
of PD- 1 inhibitors support the use of flat dosing for PDR001 of 400 mg Q4W or 300 mg Q3W. 
The expected PDR001 Ctrough concentrations using either dosing regimen exceed the EC50 
for PD-1 blockade by approximately  75-fold in an ex vivo assay  in PBMCs. Based on the 
available PK and safet y data, the RP2D of PDR001 has been declared as 400 mg i.v. Q4W or 
300 mg i.v. Q3W for combination treatment regimens for which this may  be more convenient. 
For furth er details, please 
consult the most recent edition of the [PDR001 Investigator’s 
Brochure].
PDR001 is currently being studied alone or in combination with other agents in ongoing phase 
I/Ib/II clinical trials. The preliminary  toxicity  profile appears to besimilar to that of marketed 
inhibitors of PD-1 including the type, severity and frequency  of occurrence of immune -
mediated adverse events. As observed with other PD -1 inhibitors, immune -mediated toxicities 
observed with PDR001 are reversible in many cas es. In some cases, they may require treatment 
with corticosteroids. Certain toxicities are expected to be lifelong and may  require replacement 
therap y with hormones, for example in the case of hypothy roidism. Based on the preliminary 
data, PDR001 is well tol erated with a safet y profile similar to those of other marketed anti -PD-
1 antibodies. . For further details, please consult the most recent edition of the [PDR001 
Investigator’s Brochure].
1.2.3 Overview  of the combination of LA G525 and PDR001
1.2.3.1 Nonclinical experi ence with the combination of LA G525 and PDR001
Woo (Woo 2012) describe da series of experiments with dual LAG -3/PD - 1 knockout (KO) 
mice evaluating both tumor efficacy  and the KO phenoty pe in these anima ls. Compared to wild-
type (WT), the dual KO mice developed an earl y onset (4 weeks of age) of a lethal autoimmune 
condition that resulted in approximately  80% of the mice moribund by approximately  10 weeks. 
The major histopathologic manifestations included diffuse fibrosing lymphohistiocy tic 
endocarditis, myocarditis, and pancreatitis. In contrast, LAG -3 and PD-1 single KO mice lacked 
any disease manifestations or histopathology  over this period of observation. These results show 
that the PD-1 and LAG-3 pathway s synergistically  regulate immune self-reactivity . These 
results demonstrate a theoretical risk of the simultaneous disinhibition of both the LAG -3 and 
PD-1 receptor pathway s. However, intermittent blocking of both receptors in patients where the 
pathw ays have been biologicall y and physiologically  intact since birth seems unlikely  to 
produce such a severe clinical picture. In addition, in the setting of a clinical trial with intense 

Novartis Confidential Page 49
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
safet y monitoring and clear guidance on drug interruption and withdrawa l, the management of 
immune adverse events should be possible. Any theoretical risk is also balanced by the well-
documented efficacy  of these agents, both alone and in combination, in a host of tumor models 
and for PD -1 inhibition in the clinical setting.
1.2.3.2 Clinical experience with the combination of LA G525 and PDR001
As of a data cut-off date of 15-Nov- 2016, a total of 198patients were treated on the first-in-
human 
clinical study  of LAG525 as a single agent and in combination with PDR001. The Phase 
I part o f the study  is ongoing for both single agent and combination. In the single -agent part of 
the study 106 patients were treated with LAG525 at doses ranging from 1 to 15 mg/kg on Q2W 
and Q4W schedules. Preliminary  PK parameters demonstrated approximately  dose-
proportional increases in exposure observed from 1 to15 mg/kg with low to moderate 
interpatient variability . The observed median half -life forLAG525 ranged from 7.4 to 15.4 days.  
In the combination part of the study , 92 patients were treated with LAG525 in combination with 
PDR001.  PDR001 or LAG525 in combination with showed comparable PK to the single -agent 
data at the same dose levels from the ongoing PDR001 studies. The observed median half -life 
for PDR001 ranged from 7.2 to 23.8 days, which was similar to the results from the ongoing 
CPDR001X2101 study .
2 Rationale
2.1 Stud y rationale and purpose
This is a FIH, phase I/II clinical study  of single agent LAG525 and in combination with PDR001.
The goal of immunotherapy  in cancer is to sustain or rescue an ex isting tumor antigen -specific 
immune response capable of eradicating the disease. Recent advances in cancer immunology 
revealed extensive interaction between the host immune system and the tumor suggesting that 
clinically  evident tumors have evaded potenti ally effective antitumor responses. Tumor antigen -
specific CD8+ and CD4+ T cells isolated from human tumors often display  impaired effector 
function manifested by ineffective cytotoxicity  and impaired cytokine secretion. The 
dysfunction of these tumor specific T cells is thought to result from the immunosuppressive 
tumor microenvironment and comprises T cell intrinsic and extrinsic mechanisms. T cell 
extrinsic mechanisms include suppressor cells (e.g. regulatory  T cells (Treg), myeloid derived 
suppressor cells, MDSC) and soluble cytokines (e.g. IL-10). T cell intrinsic suppression is 
coordinated via a series of membrane receptors on T cells which can be categorized into (1) 
those transducing negative activation signals (co-inhibitory  receptors or “checkpoint s” e.g. 
CTL A-4 or PD -1) and (2) those transducing positive signals for cell activation (co -stimulatory 
receptors, e.g. GITR, 41BB) (Leen 2007). The balance between the signals from co-stimulatory 
and co -inhibitory  receptors controls T cell activation.
Expression patterns of co-inhibitory  and co-stimulatory  receptors on tumor -specific T cells vary 
by both the maturation stage of the T 
cell as well as the location of the T cell (peripheral 
circulation v. intra-tumoral) (Baitsch 2012, Woo 2012 ). These patterns of expression together 
with early studies of the effects of signaling suggest that the netwo rk of co-receptors may 
deliver differential signals (Baitsch 2012 ). Tumor antigen -specific T cells isolated from the 

Novartis Confidential Page 50
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
tumor -draining lymph nodes of melanoma patients have an activation profile, whereas Tcells 
derived from the tumor bed display an exhausted phenotype with strong expression of multiple 
checkpoints, impaired cytokine secretion and activity  (Matsuzaki 2010 ).
Checkpoint inhibitors have been successfully  introduced to clinical practice with the recent 
approval of the antagonists to the CTLA
-4 checkpoint (ipilimumab, BMS) and PD-1 (e.g 
nivolumab [BMS] and pembrolizumab [Merck]). Although the checkpoint inhibitors generall y 
result in similar enhanced anti-tumor T cell activation, their effects are mediated by distinct 
pathway s and they demonstrate enhanced activity  in combination. The combination of 
ipilimumab and nivolumab is more active than either single agent in advanced melanoma 
(Wolchok 2013). LAG -3 is a distinct co- inhibitory  receptor which may cooperate with PD -1 to 
dampen immune responses. I n preclinical studies, the combined inhibition of PD -1 and LAG -3 
checkpoints synergistically  enhances antitumor responses over inhibition of either checkpoint 
alone ( Drake 2014, Woo 2012 ). Taken together, these data suggest that combined inhi bition of 
LAG -3 and PD- 1 in the clinic may  have significant anti -tumor activity .
The purpose of this study  is to characterize the safet y, tolerability , pharmacokinetics (PK), 
pharmacod ynamics (PD) and anti-tumor activity  of LAG525 as a single agent and in 
combination with PDR001, an antibody  directed against PD -1 under investigation in a separate 
study  [PDR001X2101] . PD- 1 blockade has proven clinical efficacy in various disease settings, 
such as melanoma, non-small cell lung cancer (NSCL C), mesothelioma ( Alley  2017), TNBC
(Nanda 2016 ) and renal cell carcinoma.
Following determination of the maximum tolerated dose (MTD) or recommended Phase 2 dose 
(RP2D ) of LAG525 as a single agent, and of LAG525 in combination with PDR001, 
preliminary  anti-tumor activity  of single agent LAG525 and the combination of LAG525 and 
PDR001 will be assessed in melanoma, NSCL C, mesothelioma, TNBC and renal c ancer 
in the 
expansi on part. The RP2D will be determined from the collective experience in the clinic 
considering the safety  data, pharmacokinetic data, pharmacod ynamic data and any early 
antitumor activity  observed along with the statistical inference from the Bayesian Logistic 
Regression Model (BLRM).
Expansion cohorts testing single agent LAG525 will open once the RP2D or MTD of single 
agent LAG525 is identified. Expansion cohorts testing the combination of LAG525 and 
PDR001 will open for enrollment once the RP2D or MTD of the combination is determined.

Novartis Confidential Page 51
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Figure 2-1 Blockade of PD -1/PD- L1 and LA G-3 by PDR001 and LA G525
2.2 Rationale for the study  design
This is an open -label, phase I/II study  of parallel cohorts with single -agent LAG525 or the 
combination of LAG525 and PDR001. The study  consists of two parts: two parallel dose 
escalations with staggered starts in the Phase I part and Phase II cohorts at the maximum 
tolerated dose (MTD), or the recommended phase 2 dose (RP2D), if that is lower than the MTD, 
for the single agent arm and the combination arm in the Phase II part.
This study  includes a Japanese dose escalation for single -agent LAG525 with the goal of 
informing subsequent clinical develo pment opportunities in Japan (see 
Section 2.2.3).
2.2.1 Phase I
In the Phase I part, three dose escalations will be explored in advanced solid tumors : a single -
agent dose escalation of LAG525 (Arm A), a separate single -agen t dose escalation of LAG525 
in Japanese patients (Arm C), and combination dose escalation of LAG525 and PDR001 (Arm 
B).
Dose escalation with combination of LAG525 and PDR001 will begin after the completion of 
at least the first two dose level cohorts of si ngle agent LAG525. Then, the dose escalation arms 
(single agents and combination) may proceed in parallel. The design of the phase I part was 
chosen in order to establish the MTD/RP2D of LAG525 as a single agent and LAG525 in 
combination with PDR001 in patients with solid tumors amenable to immunotherapy . The dose 
escalation decision making will be guided by a Bayesian logistic regression model (BLRM) 
with overdose control (EWOC) principle based on DLT data in the context of available safet y, 
PK and PD info rmation. For details of the dose escalation, please refer to Section 6.2 .

Novartis Confidential Page 52
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
This open -label dose escalation study  design using a BLRM is a well-established method to 
estimate the MTD, or identify a lower RP2D in cancer patients. The adaptive BLRM with 
EWOC principle controls the risk of DLT in future patients on study . The decisions on the 
single dose of LAG525 (during the single agent escalation) or in combination with PDR001 
(during the combination escal ation) are made by the Investigators and Novartis study  personnel 
and will be based upon the dose identified to satisfy  the EWOC criterion under the appropriate 
BLRM, patient tolerability  and safet y, PK and PD data available at the time of the decision 
Section 6.2.3.
2.2.2 Japanese single -agent dose escalation (Arm C)
The purpose of the Japanese dose 
escalation is to ensure that the safety  and pharmacokinetic 
profiles of single -agent LAG525 are adequatel y characterized in Japanese patients at more than 
one LAG525 dose. The Japanese dose escalation for single -agent LAG525 will run separatel y 
from the ongoing dose escalation with a starting dose for single -agent LAG525 in Japanese 
patients of 1 mg/kg Q2W. Dos e escalation decisions will be guided b y a BLRM.
2.2.3 Phase II
Once the RP2D or MTD is determined for either single -agent LAG525 (Arm A) or the 
combination of LAG525 with PDR001 (Arm B), the respective phase II part of the study  will 
begin. The primary  objective of the phase II part is to estimate the preliminary anti-tumor 
activity  of single agent LAG525 and in combination with PDR001.
The Phase II part of the study  will be conducted in five diseases that are known to be potentially 
responsive to single -agent PD-1 inhibition: NSCLC, melanoma , mesothelioma, TNBC and 
renal cancer . The efficacy  of single -agent LAG525 and the combination of LAG525 with 
PDR001 in these diseases will be assessed in both the PD-1/PD -L1 pre-treated and naive 
settings.
A Bayesian design will be used in order to estimate the overall response rate (ORR) in each 
disease area with single agent LAG525 or in combination with PDR001, evaluated at the RP2D 
of both single -agent LAG525 and the combination of L AG525 with PDR001 identified du ring 
phase I. The Phase II arms are designed to detect efficac y signals indicating a population where 
further study  of either single -agent LAG525 or the combination of LAG525 with PDR001 is 
warranted. If the recommended dose of single -agent LAG525 is the same in Arms A and C, 
patients enrolled in Japan may be recruited to the Phase II single -agent part of the study . In 
addition if the recommended dose of PDR001 for Japanese patients in the PDR001X1101 study  
is the same as that determined in study  PDR001X2101, Japanese patients may also enter the 
combination parts of study LAG525X2101 at which ever dose is being tested at that time.
2.3 Rationale for dose and regimen selection
The starting dose of LAG525 in the clinical setting was determined from toxicology  stud ies as 
well as observed toxicity and efficacy  from agents in the clinic with the similar mechanism of 
action of checkpoint inhibition (e.g. CTLA -4 and PD -1 inhibitors). The HNSTD dose from the 
cynomolgus monkey  for LAG525 was 100 mg/kg. As LAG525 will be a dministered i.v., and it 
is generall y accepted that antibody  therapeutics allometrically  scale according to body  weight, 
the human equivalent dose (HED) of the HNSTD is 100 mg/kg. Based on the ICH S9 guidance, 

Novartis Confidential Page 53
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
a factor of six can be used to determine the maximum allowable starting dose, with an estimated 
maximum starting dose of 17 mg/kg administered weekl y. LAG525 will be administered via 
i.v. infusion every 2 weeks, consistent with a schedule commonly  used for humanized 
monoclonal antibodies with an expec ted half -life of approximately  10-20 days. Based on the 
pharmacologically  active doses of 2-10 mg/kg in the clinic with agents having a similar 
mechanism of action (checkpoint inhibitors, CTLA -
4 and PD-1 inhibitors, Topalian 2014, 
Wolchok 2013, Robert 2014) and with the intent to fully  characterize the safet y, 
pharmacokinetics, pharmacody namics andpreliminary  efficacy  at multiple dose levels, the 
starting dose of LAG525 is 1 mg/kg every  2
 weeks. For the combination of LAG525 with 
PDR001 in dose escalation, the starting dose of PDR001 is 1 mg/kg and of LAG525 is 1 mg/kg 
administered intravenously  once every  2  w eeks and is based on the preclinical safet y, 
tolerability , and PK data observed in the cynomolgus monkey with both PDR001 and LAG525 
as described in Section 6.2.1 . If required by a Regulator y Authority , recruitment to combination 
dose levels will begin at dose level -1 (0.3 mg/kg LAG525 with 1 mg/kg PDR001) for patients 
from those countries
For both LAG525 single agent and the combination of LAG525 with PDR001, alternative 
dosing (e.g. flat dose [mg]) and dosing schedules (e.g. less frequent dosing) may be 
implemented during the study  based on emerging clinical toxicity  and preliminary  PK, PD and 
efficacy  data.
2.4 Rationale for choice of combination drugs
In vivo studies have demonstrated a syner gistic effect in antitumor activity of the dual blockade 
of the LAG -
3 and PD-1 co-inhibitory  receptors when compared to the inhibition of either 
checkpoint alone. CD4+ and CD8+ TIL from Sa1N fibrosarcoma, MC38 colon carcinoma and 
B16 melanoma have previously  been shown to co-express PD-1 and LAG -3; Woo and 
colleagues demonstrated some single agent activity  of anti-LAG -3 treatment in both Sa1N 
fibrosarcoma and MC38 colon carcinoma. Importantly , combined LAG -3 and PD-1 blockade 
led to rapid and complete regre ssion of established tumors in 70% of Sa1N fibrosarcoma and 
80% of MC38 colon carcinoma within 50 days of the initiation of therapy. Using the maximum 
likelihood model, this demonstrated synergy  of co-blockade over single agent activit y. Both 
TIL and lymphocytes from draining lymph nodes harvested from treated mice had increased 
numbers of CD8+IFN -gamma+ TIL, further supporting the anti-tumor role of co-blockade 
(Woo 2012 ).
The growth of syngeneic tumors was also studied in LAG -
3 and PD-1 double deficient mice 
(Lag3-/-Pdcd1-/-). While combination blockade (using murine antibody  reagents) did not show 
efficacy  in B16 melanoma, both Pdcd1-/-and doubly  deficient mice showed inhibited tumor 
growth. Depletion of CD4+ and CD8+ T cells led to restoration of normal tumor growth, 
demonstrating the dependency  of the phenot ype on T cell alteration. MC38 colon carcinoma 
implanted in doubly  deficient mice showed 80% reduction (compared to 40% in Pdcd1-/-mice), 
confir ming the synergistic action of PD-1 and LAG -3 seen in the co-blockade experiments 
(Woo 2012 ).
Taken together, these preclinical data demonstrate that co-blockade of the PD-1 and LAG -3 
pathway s leads to anti-tumor activity  superior to blockade of either inhibitory  protein alone. 
(Woo 2012 ).

Novartis Confidential Page 54
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
3 Objectives and end points
Objectives and related endpoints are described in Table 3-1below and apply  to all patients 
enrolled and treated unless otherwise stated.

Novartis Confidential Page 55
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary Section 10.4.1
Phase I part :
To estimate the RP2D or MTD for:
●Single -agent LAG525 (including Japanese patients)
● Combination of LAG525 and PDR001.The incidence of dose limiting toxicities (DLTs) during the first 
cycle of treatment with single agent LAG525. For the 
combination treatment of LAG525 and PDR001, the DLT 
window will be 2 cycles of the treatment.
Phase II part :
To estimate the overall response rate per RECIST V1.1
●Single -agent LAG525
● Combination of LAG525 and PDR001Overall response rate per “Response Evaluation Criteria in 
Solid Tumors (RECIST) V 1.1”
Secondary Section 10.5
Phase I and Phase II parts:
To characterize the safety and tolerability of single -agent 
LAG525 given alone and in combination with PDR001● Safety incidence and severity of adverse events (AEs) and 
serious adverse events (SAEs) including changes in laboratory 
parameters, vital signs and ECGs
● Tolerability: Dose interruptions, reductions and dose intensity.
To characterize the pharmacokinetic profile of single -agent 
LAG525 given alone and in combination with PDR001●Serum PK parameters (e.g. AUC, Cmax, Tmax, t 1/2half-life)
To assess emergence of anti -LAG525, and anti -PDR001 
antibodies following one or more intravenous (i.v.) infusions of 
single -agent LAG525 given alone or in combination with 
PDR001●Presence and/ or concentration of anti -LAG525 and anti -
PDR001 antibodies

Novartis Confidential Page 56
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Objective Endpoint Anal ysis
Phase I part:
●To evaluate the preliminary antitumor activity of single -agent 
LAG525 given alone or in combination with PDR001●ORR, progression free survival (PFS), duration of response 
(DOR) and disease control rate (DCR)Section 10.5
Phase II part:
●To evaluate the preliminary antitumor activity of single-agent 
LAG525 given alone or in combination with PDR001●ORR per immune related Response Criteria (irRC), PFS, 
DOR, DCR per RECIST V1.1 and per irRC

Novartis Confidential Page 57
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
4 Study  design
4.1 Description of study  design
This study  is a phase I/II, multi- center, open -label study  which consists of 2 dose escalation 
parts (Arms A and B) with a staggered start, each followed by an expansion part. The first 
escalation will be conducted with single -agent LAG525 in advanced solid tumors. Once the 
MTD/RP2D of single -agent LAG525 is determined, the study  will continue with a Phase II 
expansion part with single -agent LAG525 in defined patient populations. The second dose 
escalation part will be performed with the combination of LAG525 and PDR001 in advanced 
solid tumors followed by a Phase II expansion part with the combination in defined patient 
populations. The dose escalation of the combination of LAG525 and PDR001 will not begin 
until a cohort of 3 mg/kg single -agent LAG525 has been completed. If the single -agent LAG525 
dose of 3 mg/kg satisfies the EWOC criterion, the combination dose will begin with the planned 
starting dose as specified in Section 6.2.2. For the combination treatment arm, the first dose for 
the first two 
patients treated at each untested dose level will be staggered by 24 hours. If 3 
mg/kg with single agent does not satisfy  the EWOC criterion, or if required by a Regulatory 
authori ty, then the combination dose will begin with a lower dose level (please refer to Section 
6.2.3 for details of the dose escalation process).
A separate Japanese dose escalation (Arm C) will be performed in order to ensure that the safet y 
and pharmacokinetic profiles of single -agent LAG525 are adequatel y characterized in Japanese 
patients at more than one LAG525 dose. The Japanese dose escalation will run separately from 
the ongoing dose escalation with a starting dose for single -agent LAG525 in Japanese patients 
of 1 mg/kg Q2W. Dose escalation decisions will be 
guided by a BLRM. If the recommended 
dose of single agent LAG525 is the same in Arms A and C, patients enrolled in Japan may  be 
recruited into the Phase II single -agent part of the study . In addition, if the recommended dose 
of PDR001 for Japanese patients on the PDR001X1101 study is the same as that determined in 
study  PDR001X2101, patients in Japan may also enter the combination parts of the study at 
whichever dose is being tested at that time. After Japanese patients have enrolled in the 
combination dose escalation arm, and if during review of safet y data (either in a Dose Escalation 
Meeting or during a regular safety  review) Novartis and the enrolling Investigators consider the 
safet y profile of Japanese patients treated in the combination arm to be potentially  worse than 
that of patients treated in the rest of the world, an additional 3 to 6 Japanese patients may be 
recruited to a lower dose combination (previously  studied in dose escalation) to further 
characterize the safet y and tolerability of the combination in patients enrolled in Japan. If after 
review of safety  data at the lower dose level, Novartis and the enrolling Investigators feel that
re-escalation to a higher combination dose level is acceptable, Japanese patients may be treated 
at the same dose as patients in the rest of the world. If re-escalation is not acceptable, any 
additional Japanese patients recruited to the combination dose escalation will be treated at the 
lower dose. The combination dose escalation in the rest of the world may  continue as planned.
Both PDR001 and LAG525 will be administered i.v. once every  two weeks until a patient 
experiences unacceptable toxicity , progres sive disease as per immune related Response Criteria 
(irRC) or treatment is discontinued at the discretion of the investigator or the patient. In the 
combination cohorts, the two antibodies will be administered separatel y with a break of 30 

Novartis Confidential Page 58
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
minutes between administrations. The study  design is summarized in Figure 4-1. Alternative 
dosing schedules (e.g. less frequent dosing) may be implemented during the study  based on 
clinical toxicity  and preliminary  PK,  and efficacy  findings, including data from study 
PDR001X2101.
Figure 4
-1 Study  design
Note: In the single -agent LAG525 dose escalation (Arm A) at least 21 patients are required to define the 
RP2D; in the combination dose escalation (Arm B) at least 15 patients are required to define the RP2D 
and in the Japanese single -agent LAG525 dose escalation (Arm C) at least 12 patients are required to 
define the RP2D.
The primary  clinical study  report (CSR) will be based on all patients’ data from both phase I 
and phase II parts, up to the time when all patients have completed at least six cycles of 
treatment or discontinued the treatment. Patients who are on study  beyond cy cle 6 may  remain 
on treatment as per the protocol. Any  additional data (after the data cut- off date for the primary 
CSR) will be further summarized at completion of the study , as defined in Section 4.3.

Novartis Confidential Page 59
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Study treatment group to be analy zed in Phase II expansion cohorts
Arm A: Single -agent LA G525 cohorts
Group 1: single -agent LAG525, NSCLC (naïve to PD -1/PD -L1 )
Group 2: single -agent LAG525, Melanoma (naïve to PD1/PD -L1)
Group 3: single -agent LAG525, Renal cancer (naïve to PD -1/PD -L1)
Group 4: single -agent LAG525, NSCL C (pre -treated with PD -1/PD -L1)
Group 5: single -agent LAG525, Melanoma (pre -treated with PD -1/PD -L1)
Group 11: single -agent LAG525, Renal cancer (pre- treated with PD -1/PD -L1)
Arm B: Combination LAG525 + PDR001 cohorts
Group 6: combination LAG525+PDR001, NSCLC (naïve to PD- 1/PD -L1)
Group 7: combination LAG525+PDR001, Melanoma (naïve to PD -1/PD -L1)
Group 8: combination LAG525+PDR001, Renal cancer (naïve to PD- 1/PD -L1)
Group 9: combination LAG525+ PDR001, NSCLC (pre -treated with PD -1/PD -L1)
Group 10: combination LAG525+PDR001, Melanoma (pre -treated with PD -1/PD -L1)
Group 12: combination LAG525+PDR001, Renal cancer (pre- treated with PD -1/PD -L1)
Group 13:  combination LAG525+PDR001, Mesothelioma (naïv e to PD -1/PD -L1)
Group 14:  combination LAG525+PDR001, TNBC (naïve to PD- 1/PD -L1)
Group 15:  combination LAG525+PDR001, M esothelioma (pre -treated with PD -1/PD -L1)
Group 16:  combination LAG525+PDR001, TNBC (pre-treated with PD -1/PD -L1)
4.1.1 Phase I dose escalat ion
Single -agent LA G525 (A rm A)
During the phase I single -agent dose escalation, patients with an y adv anced solid tumor will be 
treated with single -agent LAG525 until the MTD is reached or a lower RP2D is established. At 
least 21 patients are required during dose escalation to define the MTD/RP2D.
Combination of LA G525 with PDR001 (A rm B)
During the phase I combination dose escalation, patients with any  advanced solid tumor will be 
treated with LAG525 in combination with PDR001 until the MTD is reached or a lower RP2D 
is established. It is expected that an RP2D will be established before the MTD is reached. At 
least 15 patients are required during dose escalation to define the MTD/RP2D.
For all dose escalation arms, to assure that the RP2D does not exceed the MTD, the dose 
escalation will be guided by an adaptive Ba yesian logistic regression model (BLRM) following 
the EWOC principle. For further details, please refer to Section 6.2.3.

Novartis Confidential Page 60
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Single -agent LAG525 in Japanese Patients (A rm C)
The Japanese dose escalation Arm C will be run separately  from Arm A. At least 12 patients 
are required during dose escalation to define the MTD/RP2D. Dose escalation decisions will be 
guided by a separate BLRM to estima te the MTD /RP2D in Japanese patients (see Appendix 
14.4).
4.1.2 Phase II expansion
Once the MTD and/or RP2D have been determined in the escalation parts, additional patients 
will be enrolled in the respective phase II expansion parts in order toassess the preliminary 
anti-tumor activity  of single -agent LAG525 and LAG525 in combination with PDR001. Phase 
II Expansion cohorts testing single -agent LAG525 will open once the RP2D or MTD of single -
agent LAG525 is identified. Phase II Expansion cohorts testing the combination of LAG525 
and PDR001 will open for enrollment once the RP2D or MTD of the combination is determined.
Novartis may elect not to initiate any given treatment arm based on emerging data (including 
but not limited to preliminary  anti-tumor activity ).
In the phase II part, patients will be assigned to different groups depending on the tumor type 
as shown in Figure 4-1. Please refer to Section 5.1and Section 7.1.1 for further details. Each 
group will enroll approximately 20 patients, unless enrolling 20 patients to any of these groups 
is not logistically  feasible, in which case enrollment may be stopped before 20 patients are 
treated in that group. Details of the sample size calculations leading to the patient numbers are 
provided in Section 10.8 . The sample size in any  group may  be expanded to approximate ly 40 
patients, if at least 3 patients (or if at least 2 patients for TNBC) have an objective response (PR 
or CR) per RECI ST 1.1 or irRC in that group. A Bayesian design will be used in order to 
estimate ORR within each disease group (see Section 10.8 for details of sample size).
4.1.3 Study Periods
Screening period
The screening period begins once the patient has signed the study  informed consent. Patients 
will be evaluated against study  inclusion and exclusi on criteria 
Section 5.2 and Section 5.3.
Status of MSI (high or low) for patients with CRC will be collected during 
screening. In addition, 
EGFR, ALK or BRA F V600 status is to be collected at baseline as appropriate. If known, BRCA 
status will be collected at baseline
 
 
 
 
Treatment period
The treatment period will begin on Cycle 1 Day 1. For the purpose of scheduling and 
evaluations, a treatment cycle will consist of 28 days (21 days for patients on Q3W dosing 
schedule).

Novartis Confidential Page 61
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Further details are provided in Table 7-1 and Section 7.1.2 .
150-day follow -up (FU) period
Patients will be followed up for safety evaluations on 30, 90, and 150 days after the last dose of 
study  treatment . Please refer to Table 7 - 1andSection 7.1.5 for further details.
Disease progression FU
Patients who discontinue the study  for any reasons other than disease progression as per irRC 
will be followed for progr ession of disease . Please refer to Section 7.1.5 for further details.
 
4.2 Timing of interim analy ses and design adaptations
No formal interim analyses are planned. However, inthe phase I part, the dose-escalation design 
foresees that decisions based on the current data will be taken before the end of the study . In 
the phase II part, the number of tumor responses will be monitored to determine if the 
enrollment in any group sho uld be expanded from 20 to approximately  40 patients . Please refer 
toSection 10.7 for further details.
4.3 Definition of end of the study
The end of stud y will be when:
80% of the patients per disease group inthe phase II part have completed the follow -
up for disease progression or discontinued the study  for any reason, and all patients 
have completed treatment and the 150 day  safet y follow -up period
or
If the study  is terminated earl y
or
Another clinical study  becomes available that can continue to provide study  treatment 
in this patient population, and all patients ongoing are transferred to that clinical study.
At the end of the study , every  effort will be made to continue provision of study  treatment 
outside this study  through an alternative treatment option to patients who,in the opinion of the 
investigator ,are still deriving clinical benefit.
See Section 
10Statistical Methods and Data Analy sis for details of timing of the primary 
analysis and final reporting of data.
4.4 Early study  termination
The study or any  treatment group of the study  can be terminated at any  time for any  reason by 
Novartis. Should this be necessary , the patient should be seen assoon as possible for End of 

Novartis Confidential Page 62
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Treatment (EoT) visit and the assessments for EoT should be performed as described in 
Section
7.1.3 for a discontinued or withdrawn patient. The investigator may be informed of 
additional procedures to be followed in order to ensure that adequate consideration is given to 
the protection of the patient’s interests. The investigator will be responsible for informing IRBs 
and/or ECs of the earl y termination of the trial.
5 Populat ion
5.1 Patient population
In the phase I part of the study, both single and combination escalation will be conducted in all 
types of advanced solid tumors regardless of PD -1/PD -L1 treatment history .
In the phase II part of the study , both single agent and combination expansion arms will be 
conducted in patients with NSCLC, melanoma, and renal cancer as outlined in Figure 4 -1.  The 
combination arm will also be conducted in patients with mesothelioma and TNBC as outlined 
in Figure 4 -
1, 
The investigator or designee must ensure that only patients who meet all the following inclusion 
and none of the exclusion criteria are offered treatment in the study .
5.2 Inclusion criteria
Patients eligible for inclusion in this study  have to meet all of the following criteria:
1.Written informed consent must be obtained prior to any  procedures
For Japan only : written consent is necessary  both from the patient and his/her le gal 
representative if he/she is under the age of 20 years.
2.Age ≥ 18 y ears
3.Phase I part: Patients with advanced/metastatic solid tumors, with measurable or non -
measurable disease as determined by  RECIST version 1.1 (refer to Appendix 1), who have 
progressed despite standard therapy  or are intolerant of standard therapy , or for whom no 
standard therap y exists.
4.
Phase II part: Patients with advanced/metastatic solid tumors, with at least one measurable 
lesion as determined b y RECI ST version 1.1, who have had disease progression. 
Additionally , the following must appl y:
a.NSCL C:
i.Disease recurrence or progression during or after no more than one prior platinum 
doublet -based chemotherapy  regimen for advanced or metastatic disease. Prior 
maintenance therap y is allowed (considered pemetrexed, erlotinib, bevacizumab).
ii.Patients must have been tested for mutations affecting EGFR and ALK. (Patients 
with a known mutation in one gene need not be tested for the other. )Patients with 
ALK or EGFR -positive NSCL C must have had rec
urrent or progressive disease 
after treatment with the corresponding inhibitor and no more than one platinum 
doublet -based chemotherapy , in any  sequence.
b.Melanoma:

Novartis Confidential Page 63
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
i.Patients with BRAF V600 mutation- positive disease must have objective evidence 
of progressio n of disease after treatment with a BRAF inhibitor alone or in 
combination with other agents.
ii.Patients with BRAF wild -type disease must have objective evidence of progression 
of disease but are not required to have received prior therap y.
c.Renal:
i.Patients m ust have objective evidence of progression of disease during or 
following at least one regimen of treatment for advanced renal cancer .
d. Mesothelioma
i.Patients must have objective eviden ce of progression of disease during or 
following at least one prior line of systemic chemo therap y for advanced disease.
e. TNBC
i.Patients must have objective evidence of progression of disease during or
following no more than 2 prior lines of s ystemic chemotherapy  for advanced
disease . Patients must have received a prior taxane
-containing regimen.
5.ECOG Performance Status ≤ 1
6.Phase IPart: Patients enrolled in the Phase I part of the study  must provide a new tumor 
biopsy  at baseline and during treatment if medically  feasible.
Phase II part: Patients enrolled in the phase II part of the study  must provide a new tumor 
biopsy  at baseline and during treatment, if medically  feasible.
5.3 Exclusion criteria
Patients eligible for this study  must not meet anyof the following criteria:
1.Presence of s ymptomatic central nervous s ystem (CNS) metast ases, or CNS metastases 
that require local CNS -directed therapy (such as radiotherap y or surgery), or increasing 
doses of corticosteroids within the prior 2 weeks. Patients with treated brain metastases 
should be neurologicall y stable for at least 4 weeks prior to study  entry  and off steroids for 
at least 2 weeks before administration of any  study  treatment.
2.History  of severe hy persensitivity  reactions to study  treatment ingredients or other mAbs
3.Patient with out -of-range laboratory  values defined as:
Creat inine clearance (calculated using Cockcroft- Gault formula, or measured) < 40 
mL/min
Total bilirubin > 1.5 x ULN, except for patients with Gilbert’s sy ndrome who are 
excluded if total bilirubin > 3.0 x UL N or direct bilirubin > 1.5 x ULN
Alanine aminotransf erase (ALT) > 3 x UL N 
Aspartate aminotransferase (AST) > 3 x ULN
Absolute neutrophil count (ANC) < 1.0 x 109/L
Platelet count < 75 x 109/L
Hemoglobin (Hgb) < 9g/dL
Potassium, magnesium, calcium or phosphate abnormality  CTCAE > grade 2

Novartis Confidential Page 64
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
4.Clinically  signific ant cardiac disease or impaired cardiac function, including an y of the 
following:
Clinically  significant and/or uncontrolled heart disease such as congestive heart 
failure requiring treatment (NYHA grade ≥ 2), uncontrolled hy pertension or clinically  
signif icant arrh ythmia
QTcF >470 msec on screening ECG or congenital long QT s yndrome
Acute m yocardial infarction or unstable angina pectoris < 3 months prior to study 
entry
5.Active, known or suspected autoimmune disease.  Patients with vitiligo, ty pe I diabetes 
mellitus, residual hy pothy roidism due to an autoimmune condition only  requiring 
hormone replacement, psoriasis not requiring s ystemic treatment, or other conditions not 
expected to recur, are permitted to enroll. Patients previously  exposed to anti -PD-1 / PD-
L1 treatment who are adequately treated for skin rash or who are receiving replacement 
therap y for endocrinopathies should not be excluded. 
6.Patients who required discontinuation of treatment due to treatment -related toxicities with 
prior therap y directed against the same target as the drug(s) under study  in this protocol.
7.History  of drug -induced pneumonitis or current pneumonitis.
8.Active infection requiring s ystemic antibiotic therapy . Patients requiring s ystemic 
antibiotics for infection must have completed therap y before screening is initiated.
9.HIV infection. Testing for HIV status is not necessary  unless clinicall y indicated.
10.Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Testing for HBV or 
HCV status is not necessary  unless clinicall y indicated or the patient has a history of HBV 
or HCV infection.
11.Malignant disease, other than that being treated in this study . Exceptions to this exclusion 
include the following: malignancies that were treated curativel y and have not recur red
within 2 y ears prior to study
 treatment; completely  resected basal cell and squamous cell 
skin cancers; an y malignancy considered to be indolent and that has never required 
therap y; and completely  resected carcinoma in situ of any  type.
12.Any medical con dition that would, in the investigator’s judgment, prevent the patient’s 
participation in the clinical study  due to safet y concerns, compliance with clinical study 
procedures or interpretation of study  results.
13.a. Sy stemic anti -cancer therap y within 2 weeks of the first dose of study  treatment.
b. For cy totoxic agents that have major delay ed toxicity , e.g. mitomy cin C, nitrosoureas or 
more recent immunotherapies, 4 weeks is indicated as washout period.
c. For patients receiving a CTL A-4 antagonist or vaccin e as anticancer therapy , 8 weeks is 
indicated as the washout period.
14.Patients receiving chronic treatment with s ystemic steroid therap y (> 10 mg/day 
prednisone or equivalent) within 7 day s of the first dose of study  treatment , other than 
replacement -dose s teroids in the setting of adrenal insufficiency . Topical, inhaled, nasal
and ophthalmic steroids are not prohibited.
15.Patients receiving s ystemic treatment with any  immunosuppressive medication that would 
interfere with the action of the study drugs, other than replacement- dose corticosteroids in 
the setting of adrenal insufficiency .

Novartis Confidential Page 65
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
16.Use of an y live vaccines against infectious diseases within 4 weeks of initiation of study 
treatment.
17.Major surgery within 2 weeks of the first dose of study  treatment (mediasti noscopy , 
insertion of a central venous access device, and insertion of a feeding tube are not 
considered major surgery).
18.Radiotherap y within 2 weeks of the first dose of study  drug, except for palliative 
radiotherap y to a limited field, such as for the tre atment of bone pain or a focally  painful 
tumor mass. To allow evaluation of response to treatment, patients enrolled in the Phase II 
part must have remaining measurable disease that has not been irradiated.
19.Participation in an interventional, investigation al study  within 2 weeks prior to the first 
dose of study  treatment.
20.Presence of CTCAE ≥ grade 2 toxicity  (except alopecia, peripheral neuropathy  and 
ototoxicity , which are excluded if ≥ CTCAE grade 3) due to prior cancer therap y.
21.Use of hematopoietic colon y-stimulating growth factors (e.g. G -CSF, GMCSF, M -CSF) ≤ 
2 weeks prior to the first dose of study  treatment . Patients must have completed therap y at 
least 2 weeks prior to the first dose of study  treatment with any  hematopoietic colony -
stimulating growth factors. An ery throid stimulating agent is allowed as long as it was 
initiated at least 2 weeks prior to the first dose of study  treatment.
22.Pregnant or lactating women, where pregnancy  is defined as the state of a female after 
conception and until the term ination of gestation, confirmed by  a positive hCG laboratory  
test.
23.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they  are using highly  effective methods of contraception 
during dosing and for 15 0 day s after the last dose of LAG525 and/or PDR001. Highl y 
effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
patient. Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y or tubal ligation at least six weeks before taking 
study  treatment. In case of oophorectom y alone, only  when the reproductive status of 
the woman has been confirmed by  follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female patients on the 
study  the vasectomized male partner should be the sole partner for that patient .
Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS), or other forms of hormonal 
contraception that have com parable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception.
In case of use of oral contraception women should have been stable on the same pill for a 
minimum of 3 months before taking stud y treatment.
Women are considered post-menopausal and not of child bearing potential if they have had over 
12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (age 
appropriate (e.g. generally 40-59 years), history  of vasomotor symptoms (e.g. hotflushes) in 

Novartis Confidential Page 66
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
the absence of other medical justification or have had surgical bilateral oophorectom y (with or 
without hysterectomy ), total hysterectom y or tubal ligation at least six weeks ago. In the case 
of oophorectom y alone, only when the reproductive status of the woman has been confirmed 
by follow up hormone level assessment is she considered not of child bearing potential.
24.Sexually  active males unless they use a condom during intercourse while taking the drug 
and for 150 day s after stopping study  treatment and should not father a child in this period. 
A condom is required to be used also by vasectomized men as well as during intercourse 
with a male partner in order to prevent delivery  of the drug via seminal fluid
6 Treatment
6.1 Stud y treatment
For this study, the investigational drugs refer to LAG525 and PDR001. Both study  drugs will 
be provided by Novartis. PDR001 will be supplied in lyophilized powder formulation. LAG525 
will be supplied as a liquid formulation.
All dosages prescribed and dispensed to pat ients and all dose changes during the stud y must be 
recorded on the Dosage Administration Record eCRF.
6.1.1 Dosing regimen
Table 6-1 Dose and treatment schedule
Study
treatmentsPharmaceutical form and route 
of administration Dose*Frequency  and/or 
Regimen**
LAG525 Liquid in vial for i.v. infusion 1 mg/kg (starting dose) Every 2 weeks
PDR001 Powder for solution for infusion 1 mg/kg (starting dose) Every 2 weeks
*Flat dosing may be tested based on the review of emerging PK data generated during the study
**Alternate dosing regimens may be implemented to assess a less frequent dosing regimen
For the combination arm of the study , the first dose for the first two patients treated a t each 
untested dose level will be staggered by 24 hours. LAG525 and PDR001 will be administered 
via i.v. infusion over 30 minutes once every  2 weeks. They  will be administered separatel y in 
the same fashion with at least a 30 -min break between the two ant ibody  infusions. I nfusions of 
each antibody  can be extended to up to 2 hours if clinically  indicated and the break between 
LAG525 and PDR001 antibody  infusions can be up to 4 hours if clinically  indicated.
Both study  drugs may be infused using the same i.v. access site. LAG525 will be given first 
followed b y PDR001. The same administration sequence must be followed for all participants, 
i.e. LAG525 is infused first. If an infusion reaction occurs after administration of LAG525, the 
subsequent PDR001 infusio n must be delay ed until it is safe for the patient to receive PDR001 
based on the clinical discretion of the investigator. The delay  between LAG525 and PDR001 
infusions can be up to 4 hours if clinically  indicated. If PDR001 cannot be administered safel y 
within 4 hours after LAG525 administration, the dose must be omitted.
A scheduled dose (of either single -agent LAG525 or the combination of LAG525 and PDR001) 
may be delayed to recover from an unresolved AE. If a patient requires a dose interruption of > 
21days from the intended day  of the scheduled dose due to an unresolved AE related to study  

Novartis Confidential Page 67
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
drug(s), then the patient must be discontinued from the study , unless the patient is receiving 
clinical benefit and in the opinion of the investigator it is in the p atient’s best interest to remain 
on study . The patient may  restart treatment after discussion with Novartis. Dose modifications 
should be followed described in Section 6.3.1 and Section 6.3.2.
If a significant number of patients require dose delays due to drug -related toxicities, the dosing 
regimen for the study  may  be changed to once every  21 or 28 day s. This will be discussed i
n a 
dose escalation teleconference at the time of the proposed change and documented in the 
minutes of this meeting accordingl y Section 6.2.3.1 . Alternative dosing regimens (flat dose, mg) 
or a less frequent dosing regimen (e.g. Q3W or Q4W) may also be considered based on 
emerging clinical toxicity  and preliminary  PK  and efficacy  data generated during the 
study . A treatment cycle 
is defined as 28 days (21 days for patients on Q3W dosing regimen) 
with the potential to extend the cycle an additional 7 days if necessary  for recovery  of toxicities, 
as described above. Missed doses will not be made up. The first dose of LAG525 or combination 
of LAG525 and PDR001 is Cy cle 1 Day  1 which defines the patient’s treatment cy cles for the 
study .
Flat dosing may also be investigated in the combination part of the study  for both L AG525 and 
PDR001.
Optional testing of two dose levels during phase II expansion
After a preliminary  assessment of safety  data in dose escalation, a decision may be made to 
investigate a second dose of LAG525 alone during the phase II expansion to further assess 
safet y and efficacy . This would be performed in one disease setting. The two dose levels will 
be assigned in an alternating fash ion to patients of the same disease group across all the sites in 
this global stud y.The number of patients required to be tested at this second dose level will be 
equivalent to the number of patients to be enrolled in this disease setting at the RP2D.
6.1.2 Ancillary  treatments
Patients should not receive any pre-medications before the first infusion of the investigational 
drug LAG525 and/or PDR001. If a patient experienced an infusion reaction, he/she may receive 
pre-medications on subsequent dosing days after consultation with the Novartis Medical 
Monitor. Pre-medications should include but are not limited to paracetamol/acetaminophen and 
an antihistamine. The use of corticosteroid pre-medication will be at the discretion of the 
principal investigator in consul tation with the Novartis Medical Monitor.
If ≥ 2 patients experience moderate to severe acute infusion reactions in a dose escalation cohort 
on C1D1 or if >25% of patients experience mild infusion reactions in the dose escalation, then 
mandatory  primary  prophy laxis regimens (i.e. before dosing on C1D1) will be instituted after 
discussion and agreement among principal investigators and Novartis. Prophy laxis regimens 
will include both paracetamol/acetaminophen and an antihistamine.
Acute allergic reactions should be treated as needed per institutional standard of care. In the 
event of anaphy lactic/anaphy lactoid reactions, this includes any therapy  necessary  to restore 
normal cardiopulmonary  status. If a patient experiences a Grade ≥3 anaph ylactic/anaph ylactoid
reaction, the patient will be discontinued from the study . Such acute allergic reactions will be 
reported to the Sponsor in an expedited manner. These should be designated as reportable as a 

Novartis Confidential Page 68
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
SAE regardless of hospitalization as medicall y important events. Please refer to SAE reporting 
section for details.
Patients should be treated in a facility  equipped for cardiopulmonary resuscitation. Appropriate 
resuscitation equipment should be available at the bedside and a ph ysician readily  available.
Guidelines onmanagement of LAG525 or PDR001 infusion reactions are provided in
Section 6.3.1 and Table 6 -5.
The CTCAE category  of “Infusion related reaction” should be used to describe LAG525 and/or 
PDR001 infusion reactions, unless the investigator considers another category , such as 
“Allergic reaction,” “Anaphy laxis,” or “Cytokine release syndrome” more appropriate in a 
specific situation.
6.1.3 Treatment duration
A patient may continue treatment with LAG525 until the patient experiences unacceptable 
toxicity , confirmed disease progression per irRC and/or treatment is discontinued at the 
discretion of the investigator or the patient. Refer to Section 7.1.3 and Section 7.1.5.
If more than 2 consecutive doses of LAG525 or combination of LAG525 and PDR001 have to 
be skipped due to drug -related toxicities, then the dr ugs should be permanently  discontinued. If 
a patient who misses more than 2 consecutive doses due to a drug-related toxicity  is 
experiencing clinical benefit, and in the opinion of the investigator it is in the patient’s best 
interest to remain on study, t hen the patient may continue the treatment(s) after discussion with 
Novartis.
6.2 Dose escalation guidelines
6.2.1 Starting dose rationale
Starting dose of LA
G525 as a single agent (A rm A and Arm C)
The starting dose of LAG525 selected for this study is based on 4-w eek GLP toxicology  studies 
performed in cynomolgus monkeys as LAG525 cross reacts with monkey  LAG -3 but not rat or 
murine LAG -3. LAG525 is a monoclonal antibody that does not have agonist activity , and will 
be administered to patients with advanced maligna ncies; therefore the starting dose is based on 
the ICH S9 guidance. In the cynomolgus monkey study, the HNSTD dose was 100 mg/kg. The 
human equivalent dose (HED) of the HNSTD is 100 mg/kg. Based on the ICH S9 guidance, a 
factor of six can be used to determ ine the maximum allowable starting dose, with an estimated 
maximum starting dose of 17 mg/kg administered weekl y. Based on the pharmacologicall y 
active doses of 2-10 mg/kg in the clinic with agents having a similar mechanism of action 
(checkpoint inhibitor s, CTL A
-4 and PD-1 inhibitors, Topalian 2014 , Wolchok 2013 , Robert 
2014) and with the intent to fully characterize the safet y, pharmacokinetics (PK), 
 and preliminary  efficacy at multiple dose levels, the starting dose of 
LAG525 is 1 mg/kg every  2 weeks.

Novartis Confidential Page 69
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Starting dose of LA G525 and PDR001 combination (A rmB)
PDR001 cross reacts with monkey  PD-1 and thus, the starting dose of PDR001 selected for this 
study  is based on 4-week GL P toxicology  studies performed in cynomolgus monkey s and prior 
clinical experience with nivolumab and pembrolizumab (Topalian 2014, Robert 2014). It is 
anticipated that PDR001 will have similar PK/PD properties to these comparators; PDR001 is 
expected to demonstrate antitumor activity at doses of 2-3 mg/kg dosed every  2- 3 weeks. The 
HNSTD of PDR001 was 100 mg/kg, administered i.v., once weekl y. The human equivalent 
dose (HED) of the HNSTD is 100 mg/kg. The maximum permitted starting dose in patients is 
1/6 x 100 mg/kg, or 17 mg/kg administered weekly .
In order to evaluate the safet y, PK , and antitumor activity  of PDR001 in combination 
with L AG525 across a range of doses, the starting dose in the combination study  is 1 mg/kg of 
PDR001 and 1 mg/kg of LAG525 i.v. administered every 2 w eeks (Q2W). If required by a 
Regulatory  Authority , recruitment to combination dose levels will begin at dose level -1 (0.3 
mg/kg LAG525 with 1 mg/kg PDR001) for patients from those countries.
For details of dose escalation please refer to Section 6.2.3 .
6.2.2 Provisional dose levels
There will be three dose escalation arms in this study ; Table 6-2and Table 6-3describe the 
starting doses and the provisional dose levels of single -agent LAG525 and the combinations of 
LAG525 and PDR001 ,respectively , that may be evaluated during this trial. With the exception 
of starting dose level 1, actual dose levels will be determined based on available toxicity , 
pharmacokinetic  data, guided by the BLRM, following a discussion with 
participating Investigators during dose escalation teleconferences Section 6.2.3. Dose 
escalation will continue until one or more MTDs or/RP2Ds are de
termined.
Table 6-2 Provisional dose levels (Ph I A rm A  and Arm C: single -agent LA G525)
Dose levelProposed dose LAG525*
Weight adjusted dose (Flat dose)**** Increment from previous dose
-1** 0.3 mg/kg (20 mg)*** -70%
1 (starting dose) 1 mg/kg (80 mg)*** 0
2 3 mg/kg (240 mg)*** <300%
3 10 mg/kg (800 mg)*** < 333%
*It is possible for additional and/or intermediate dose levels to be added during the course of the study Cohorts 
may be added at any dose level below the MTD in order to better understand safety, PK  Multiple dose 
levels below the MTD may be evaluated simultaneously i n order to obtain PK  data across a range of 
doses.
**Dose level -1 represents treatment doses for patients requiring a dose reduction from the starting dose level.
***Alternate dosing may be explored (i.e. flat dose , mg). If an alternate dosing regi men is used the dose may 
need to be adjusted to achieve an equivalent exposure per cycle.
****1 mg/kg corresponds to a flat dose of 80 mg

Novartis Confidential Page 70
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 6-3 Provisional dose levels (Ph I A rm B: combinations of LA G525 and 
PDR001)
Dose levelProposed dose LAG525*
Weight adjusted dose(flat dose)****Proposed dose PDR001*
Weight adjusted dose (Flat dose****)
-2** 0.3 mg/kg ( 20 mg) 0.3 mg/kg ( 20 mg )
-1** 0.3 mg/kg (20 mg) 1 mg/kg (80 mg)
1 (starting dose) 1 mg/kg (80 mg ) 1 mg/kg ( 80 mg)
2 1 mg/kg (80 mg) 3 mg/kg (240mg)
3 3 mg/kg (240mg) 3 mg/kg (240mg)
4 3 mg/kg (240mg) 10 mg/kg ( 800 mg)
5 10 mg/kg (800 mg) 10 mg/kg ( 800 mg)
*It is possible for additional and/or intermediate dose levels to be added during the course of the study Cohorts 
may be added at any dose level below the MTD in order to better understand safety, PK . Multiple dose 
levels below the MTD may be evaluated simultaneously in order to obtain P K  data across a range of 
doses.
**Dose level -2 and -1 represent treatment doses for patients requiring a dose reduction from starting dose 
level. If required by a Regulatory Authority, recruitment to combination dose levels will begin at dose level -1 
(0.3 mg/kg LAG525 with 1 mg/kg PDR001) for patients from those countries.
***Alternate dosing may be explored (i.e. flat dose , mg). If an alternate dosing regimen is used the dose may 
need to be adjusted to achieve an equivalent exposure per cycle.
****1 mg/kg corresponds to a flat dose of 80 mg
6.2.3 Guidelines for dose escalation and determination of MTD/ RP2D
The maximum tolerated dose (MTD) is defined as:
Arm A and Arm C (single -agent LAG525): for patients enrolled in the single agent arm 
with administra tion of single agent LAG525, the highest drug dosage that is unlikely  (< 25% 
posterior probabilit y) to cause DLT in 33% or more of the treated patients in the first cy cle 
of study  treatment under that schedule. The DLT window forArm A and C isone cycle 
(28 days, 21 days for patients on Q3W dosing schedule) . Patients enrolled in this arm 
must receive at least two doses (Q2W schedule) of L AG525 to be considered evaluable for 
toxicity . For the Q3W and Q4W schedule, one dose must be received.
Arm B (combinat ion of LAG525 and PDR001): for patients enrolled in the combination 
treatment arm in the dose escalation part with administration of both LAG525 and PDR001, 
the highest combination drug doses that is unlikely  (< 25% posterior probability ) to cause 
DLT in 3 3% or more of the treated patients in the first two cy cles of study  treatment under 
that schedule. The DLT window for Arm B is two cycles (56 days, 42 days for patients 
on Q3W dosing schedule). Patients must receive at least three doses (Q2W schedule) of 
both study  drugs during the first two cycles (DLT observation window) to be considered 
evaluable for toxicity . For the Q3W and Q4W 
schedule, patients must receive 2 doses of 
both study  drugs during the first two cy cles.
During the dose escalation of combina tion agents, only  1 of the 2 study  drugs can be escalated 
at a time.
Adverse events and laboratory  abnormalities considered to be DLTs are defined in Table 6 -4.
For Arm B, since several combinations may correspond to this definition, more than one MTD 
may be identified with different doses of the study  drugs. One (or more) of these MTDs or a 
suitable lower dose combination will then be selected as the RP2D(s).

Novartis Confidential Page 71
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
The applied adaptive Bay esian methodology  provides an estimate of the single -agent LAG525 
and the combinations of LAG525 and PDR001 not exceeding the MTD. Typically  the MTD is 
a tested dose (or combination) with maximum probability  of targeted toxicity  (DLT rate 
between 16% and <33%). The use of theEWOC principle limits the risk that a potential next 
dose will exceed the MTD Section 10.4.2.
For the purposes of dose escalation decisions, each cohort will consist of 3 to 6 newly enrolled 
patients 
who will be treated at the specified dose level in the arm of treatment (Arm Aand C
refers to single agent and Arm B refers to combination treatment). Multiple cohorts may be 
sequentially  enrolled to the same dose level. Additional cohorts of 1 to 6 patients may be 
enrolled at any dose level below the estimated MTD(s)/ RP2D(s) for further elaboration of 
safet y, pharmacokinetic  parameters as required.
The dose escalation will proceed as follows:
Arm A (Single -agent LAG525): The first c ohort enrolled in the study will be treated with 
the starting dose of 1 mg/kg LAG525 as a single agent in Arm A. Once this cohort is 
complete and the dose escalation decision has been determined collectively  between the 
Sponsor and the participating invest igators to escalate, the second cohort in Arm A will 
open with 3 mg/kg. Once a cohort of 3 mg/kg is complete and demonstrated to satisfy  the 
EWOC criterion (< 25% posterior probability  to cause DLT in 33% or more of the treated 
patients in the first cycle of study treatment), combination dosing will begin (Arm B) at the 
planned starting dose. In the event that the single -agent LAG525 dose of 3 mg/kg does not 
satisfy  the EWOC criterion, then combination dose escalation may only proceed at a dose 
level one level below the LAG525 dose deemed safe (i.e. combination dose level -1, 0.3 
mg/kg LAG525 with 1 mg/kg PDR001).
Arm B (LAG525 and PDR001 combination): The combination dose escalation ( Arm B) 
will proceed provided that the single -agent LAG525 dose of 1 mg/kg did not exceed the 
MTD. The starting dose for the combination will be 1 mg/kg of LAG525 combined with 1 
mg/kg of PDR001, unless the second dose level of single -agent LAG525 at 3 mg/kg is not 
tolerated or if required by a Regulatory  Authority , in which case combination dose 
escalation will proceed at dose level -1 (0.3 mg/kg LAG525 with 1 mg/kg PDR001). The 
dose escalation of the combination Arm B will then proceed in parallel with the remaining 
dose escalation of Arm A.
Arm C (Japan single -agent LAG525): The same guidelines will be applied to dose 
escalation of single -agent LAG525 in Japanese patients. The first cohort of patients enrolled 
in the Japanese sub-population will be treated with a starting dose of 1 mg/kg LAG525 Q2W 
as a single agent. Once this cohort is complete and the dose 
escalation decision has been 
determined collectively  between the Sponsor and the participating investigators to escalate 
the dose, the second cohort will open at a dose of up to 3 mg/kg Q2W (or flat dose equivalent) 
that satisfies EWOC criterion. The dose escalation will then proceed until the RP2D or MTD 
is determined. The Japanese dose escalation Arm C will be run separately  from Arm A. 
Dose escalation decisions will be guided by the BLRM to estimate the MTD / RP2D in 
Japane se patients in the context of available safet y and PK information.
Arm A and Arm B in dose escalation may enroll patients in an alternating fashion if two cohorts 
in the arms are open in parallel. If only one cohort is open at a given time, patients will enroll 
only into the open cohort and enrollment will pause until an additional cohort in either arm is 

Novartis Confidential Page 72
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
opened for enrollment. Patients identified for enrollment in dose escalation will be assigned to 
the appropriate cohort b y Novartis.
For the purposes of dose escalation decisions, patients can be considered evaluable in each arm 
after having met the following criteria:
Arm A and Arm C: Patients must complete a minimum of 1 cycle of treatment with the 
minimum safety  evaluation and drug exposure (at least tw o doses of LAG525) or have had 
a DLT within the first cycle of treatment to be considered evaluable for dose escalation 
decisions.
Arm B: Patients must complete a minimum of two cycles of treatment with the minimum 
safet y evaluation and drug exposure (at least three doses of both stud y drugs) or have had a 
DLT within the first two cy cles of treatment to be considered evaluable for dose escalation 
decisions.
Dose escalation decisions will be made by investigators and Novartis study  personnel. For each 
arm, decisions will be based on a synthesis of all relevant data available from all dose levels 
evaluated in the ongoing study  including safet y information, DLTs, all CTCAE Grade ≥ 2 
toxicity  data during C ycle 1 (arm A and Arm C), and cy cles 1 and 2 (arm B), PK ,  data 
from evaluable patients. The recommended dose for the next cohort of subjects will be guided 
by the BLRM with EWOC principle (Section 2.2) and determined by a synthesis of all available 
data from the cohort.
The adaptive Bayesian methodology  provides an estimate of all dose levels of LAG525 and 
PDR001 that do not exceed the MTD and incorporates all DLT information at all dose levels 
for this estimation. In general, the next dose will have t he highest chance that the DLT rate will 
fall in the target interval [16-33%) and will alway s satisfy  the EWOC principle. In all cases, the 
dose for the next cohort will not exceed a 333% (1/2 Log10) increase from the previous dose. 
Smaller increases in dose may be recommended by the Investigators and Sponsor upon 
consideration of all of the available clinical data.
If the first 2 
patients in a previously  untested dose level experience a DLT, further enrollment 
to that cohort will stop and the BLRM will be updated with this new information. Re-evaluation 
of the available safet y, PK,  data will occur. By incorporating information gained at the 
preceding dose levels, additional patients may be enrolled at this dose level or a lower dose 
level as agreed b y Investigators and Novartis personnel and if the BLRM predicts that the risk 
that this dose exceeds the MTD remains below 25% (EWOC).
Dose escalation for each arm (Arm A and Arm C, single -agent LAG525 or Arm B, combination 
of LAG525 and PDR001) will conti nue until identification of the RP2D or the MTD of the 
single -agent or combination.

Novartis Confidential Page 73
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
The MTD/RP2D will be determined if the following conditions are met:
1.at least 6 patients have been treated at this dose
2. this dose satisfies one of the following conditions:
a.the posterior probabilit y of targeted toxicity  at this dose exceeds 50%, or
b.minimum of 21 patients for the single agent Arm A or 15 patients for the combination 
Arm B, or 12 patients for the Japanese dose escalation Arm C have alread y been 
treated on the trial for this arm.
3. it is the dose recommended for patients, either per the model or by  review of all clinical 
data b y Novartis and Investigators in a dose -escalation teleconference, see
Section 6.2.3.1.
To better understand the safet y, tolerability , PK 
 of single -agent LAG525 or 
combinations of LAG525 and PDR001, additional cohorts of patients may be enrolled at 
preceding dose levels, or to intermediate dose levels before or while proceeding with further 
dose escalation.
If a decision is made to escalate to a higher dose level but one or more additional patient(s) 
treated at the preceding dose level experiences a DLT during the DLT window, then the BLRM 
will be updated with this new information before any additional patients are enrolled at that 
higher dose level. Subjects ongoing will continue treatment at their assigned dose levels.
If the circumstance arises that a MTD is not reached in either single agent LAG525 escalation 
or that of the combination, then the RP2D of that arm will be determined from a synthesis of 
all data available, including safety  and tolerability , pharmacokinetic  
assessments and an y preliminary  antitumor activity  observations.
Change of schedule:
In theevent of a change in dosing schedule, then a new BLRM will be used to evaluate this new 
schedule. This new BLRM will incorporate down -weighted existing dose escalation data in the 
prior distribution.
The starting dose for the new regimen will be determine d based on the available data, including 
safet y, and will be subject to the EWOC criterion under the newl y constructed model. The new 
regimen will be less frequent than the Q2W schedule.
Change to flat dose:
Flat dosing (in mg) may be explored for single -agent LAG525 by opening a new cohort(s) in 
the escalation part of this study. The combination of LAG525 and PDR001 utilizing flat dosing 
may also be explored from the start of the combination dose escalation. Please refer to Table 6-
2and Table 6
-3.
Additional BL RMs will be developed to evaluate the flat dosing for single -agent LAG525 and 
its combination with PDR001. Those BLRMs will incorporate down -weighted dose escalation 
data from the weight -based dosing cohorts in an informative prior distribution.
The starting dose for the flat dose will be determined based on the available data, including 
safet y, and will be subject to the EWOC criterion under the newl y constructed model. The 
equivalent weight based dose should have been tested and shown to satisfy  the EWOC criterion.

Novartis Confidential Page 74
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
6.2.3.1 Implementation of Dose Escalation Decisions
To implement dose escalation decisions, the available toxicity  information (including a ll safet y 
data, AEs Grade ≥ 2 and laboratory  abnormalities that are not DLTs), the assessment of those 
doses satisfy ing the EWOC criterion from the BLRM, and the available PK  information 
will all be evaluated by the Investigators and Novartis study  personnel (including the study 
physician and statistician) during a dose decision meeting by teleconference. All occurrences 
of DLT will be discussed and agreed at the dose decision teleconference among participating 
investigators and Novartis study  person nel.
Cohort enrollment and drug administration at the next higher dose level may  not proceed until 
the investigator receives written confirmation from Novartis indicating that the results of the 
previous dose level were evaluated and that it is permissible to proceed to a higher dose level 
with written confirmation of the next higher dose level to be tested.
6.2.3.2 Intra -Patient dose escalation
Intra -patient dose escalation is not permitted at any  time within the first 4 cycles of treatment. 
After the 4thcycle iscompleted, individual patients may be considered for treatment at a dose 
of single agent LAG525 or in combination with PDR001, higher than the dose to which they 
were initially  assigned. Only  one of the study  drugs will be escalated at any one time. Study
drugs will be escalated as detailed in Section 6.2.2. In order for a patient to be treated at a higher 
dose of either single agent LAG525 or in combination with PDR001, he or she must have 
tolerated the lower dose combination for at least 4 cycles of therapy  (e.g., he or she must not 
have experienced at the lower dose level originally  assigned a toxicity  of CTCAE grade ≥ 2 
considered related to study
 drug). Moreover, the new, higher dose combination w ith which the 
patient is to be treated must be a dose combination that has completed evaluation in a dose-
escalation meeting and satisfies the EWOC criterion under the Bayesian model given all 
available data.
There is no limit to the number of times a patient may have his or her dose of LAG525 increased 
as a single agent or in combination with PDR001. Any further increases after the initial intra-
patient dose escalation are subject to the same rules as for the initial intra-patient escalation. 
Consultation with Novartis must occur prior to any intra-patient dose escalation occurring. 
These changes must be recorded on the Dosage Administration Record CRF.
6.2.3.2.1 Switch to LAG525 in combination with PDR001 for patients treated 
with LA G525 single -agent
Upon disease progression, patients assigned to LAG525 monotherap y during dose escalation 
may switch to LAG525 + PDR001 at a combination dose level that uses the patient’s same 
LAG525 dose and has been determined safe and tolerable in previous dose escalation patients.  
If there is no combination dose level that includes the patient’s LAG525 monotherapy  dose, the 
patient may receive a lower dose level of LAG525 when switching to LAG525 in combination 
with PDR001 ; alternatively , the patient may switch to the LAG525 + PDR001 recommended 
Phase II dose, once the RP2D has been established. Patients switching to combination therapy 
must have completed at least 4 cycles of LAG525 monotherap y with no toxicity  of CTCAE 
grade ≥ 2 considered related to study  treatment .

Novartis Confidential Page 75
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
PDR001 may  be a dded to L AG525 treatment only after documented discussion and agreement 
between Novartis and the Investigator, based on each patient’s condition and review of the 
planned dose and schedule.
Patients will start LAG525 in combination with PDR001 on Day 1 of the cycleduring which 
the switch is made and patients will resume their standard scheduled visits per Table 7-1. For 
patients who switch from single -agent LAG525 to LAG525 in combination with PDR001, 
patients will resume the standard visit schedule; hematology/chemistry labs and vital signs will 
be collected on Days 8 and 15 as unscheduled assessments for the first cycle upon switch to the 
LAG525 in combination with PDR001. Cycle 1 will start based on 
the patient’s first dose of the 
original LAG525 monotherap y.After switching to combination therap y, patients will continue 
to have efficacy  assessments as per protocol; however, the response data from these patients 
will not be incorporated into the ORR. No additional biopsies will be required. For patients who 
switch from single -agent LAG525 to LAG525 in combination with PDR001, immunogenicit y 
samples will be collected as unscheduled assessments (instead of their standard PK collection 
schedule) on Day 1 pre-dose for the first 6 cycles upon switch to the LAG525 in combination 
with PDR001, and PK blood samples will be collected on Days 1 (pre-infusion) and 8 as 
unscheduled assessments (instead of their standard PK collection schedule) for the first cycle 
upon switch to the LAG525 in combination with PDR001.   Patients who switch from single 
agent LAG525 to LAG525 in combination with PDR001 will need to complete an additional 
End of Treatment Phase Disposition CRF, but the EOT tests/procedures are not required until 
discontinuation of L AG525 in combination with PDR001.
6.2.4 Definitions of dose -limiting toxicities (DLTs)
A dose-limiting toxicity  (DLT) is defined as an adverse event or abnormal laboratory  value of 
CTCAE grade ≥ 3 assessed as having a suspected relationship to study  drug, and unrelated to 
disease, disease progression, inter-current illness, or concomitant medications that occurs 
within the first cycle of treatment with single agent LAG525 or within the first two cycles of 
treatment with the combination of LAG525 and PDR001, and meets any of the criteria included 
in Table 6-4.
DLT w indow:
Arm A and Arm C with single agent LAG525: 28 day s (one cy cle) (21 day s for patients 
on Q3W dosing schedule).
Arm B with combination of LAG525 and PDR001: 56 day s (two cy cles) (42 day s for 
patients on Q3W dosing schedule).
Emerging data from the new field of immune -immune combination studies suggest that some 
immune -related adverse events have a prolonged latency  (Wolchok 2013 ). As such, the DLT 
window for the combination arm in this trial is extended to the length of two cycles or 56 days.
National Cancer Institute Common Terminology Criteria for Adverse events (NCI  CTCAE) 
version 4.03 will be used for all grading unless otherwise specified. For the purpose of dose-
escalation decisions, DLTs will be considered and included in the BLRM.

Novartis Confidential Page 76
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
The investigator must notify  the Sponsor immediately  of any unexpected CTCAE grade ≥ 3 
adverse events or laboratory  abnormalities. Prior to enrolling patients into a higher dose level, 
CTCAE grade ≥ 2 adverse events will be reviewed for all patients at the current dose level.
Table 6-4 Criteria for defining dose -limiting toxicities
During dose escalation, any Grade 3 or Grade 4 A Es related to study treatment occurring in 
cycle 1 (applies to dose escalation A rm A  and A rm C) , and in cycles 1 and 2 (applies to dose 
escalation A rm B) are DLTs, EXCEPT:  
Fatigue Grade 3 fatigue that resolves to ≤ Grade 1 within 7 days.
Fever, Infection Grade 3 infection or fever, in the absence of neutropenia ,that resolves within 
7 days.  
Hypertension Grade 3 hypertension that resolves within 7 days after starting anti-
hypertensive therapy .
Gastrointestinal Grade 3 nausea and vomiting that resolves to ≤ Grade 1 within 48 hours of 
starting optimal anti -emetic therapy . 
Grade 3 diarrhea that resolves within 7 days after st arting optimal anti -
diarrhea treatment, where colitis is not suspected.
Hepatic Grade 3 ALT or AST in the absence of significantly increased bilirubin that 
resolves to ≤ Grade 1 within 7 days.
Amylase and lipase Asymptomatic Grade ≥ 3amylase or lipase.
Dermatologic Grade 3 non bullous rash without epidermal detachment that resolves to ≤ 
Grade 1 within 7 days of starting treatment.
Hematologic Grade 3 neutropenia without fever or other clinical symptoms that resolves 
to ≤ Grade 1 within 7 days .
Grade 3 thrombocytopenia without clinically significant bleeding. 
Grade 3 anemia that resolves within 7 days in the absence of transfusion.
Lymphopenia of any grade is not a DLT.
Electrolytes Grade 3 electrolyte abnormalities that resolve to ≤ Grade 1 within 7 days 
after starting supplementation.
Musculoskeletal Grade 3 asymptomatic increase in creatine kinase that resolves within 14 
days in the absence of evidence of cardiac involvement.
Immune -related toxicities * In general, a Grade 3 immune- related AE that resolves to ≤ Grade 1 within 7 
days of starting appropriate treatment is not a DLT.  

Novartis Confidential Page 77
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
The follo wing Grade 2 A Es related to study  treatment are considered DLTs:
Ocular disorders Grade 2 eye pain or reduction of visual acuity are DLTsif they do not 
respond to topical therapy and do not improve to Grade 1 severity within 2 
weeks of the initiation of topical therapy ,ORif they require systemic 
treatment.
Pneumonitis Grade 2 pneumonitis is a DLT if it does not resolve to ≤ Grade 1 wit hin 7 
days of starting corticosteroids. 
Myocarditis Grade 2 myocarditis is a DLT.
Colitis Grade 2 colitis is a DLT if it persists > 7 days despite treatment with 
corticosteroids.
HepaticGrade 2 ALT or AST accompanied by bilirubin >1.5 x ULN is a DLT.
Dermatologic Grade 2 bullous disease that does not resolve to ≤ Grade 1 within 7 days of 
starting corticosteroids is a DLT .
Other adverse events Other clinically significant toxicities, including a single event or multiple 
occurrences of the same event that lead to a dosing delay of > 7 days within 
the DLT window, may be considered to be DLTs by the Investigators and 
Novartis, even if not CTCAE grade 3 or higher. Infusion reactions will not be 
considered as dose limiting because they are idiosyncratic an d not related 
to dose.
*Depending on the nature of the AE, there may be cases where immune -related Grade 2 -3 AEs of any 
duration warrant declaration of a DLT and permanent study discontinuation (e.g. Stevens -Johnson Syndrome 
(SJS)) .  DLT determination no t already outlined in this table will be made on a case -by-case basis after 
Investigator discussion with the Novartis Medical Monitor.
6.3 Dose modifications
6.3.1 Dose modification and dose delay
For patients who do not tolerate the protocol -specified dosing schedule, dose or schedule 
adjustments are permitted in order to allow the patient to continue the study  treatment. The 
following guidelines need to be applied:
If a patient experiences an AE m eeting the criteria for DLT as outlined in Section 6.2.4
(including events occurring after cycle 1 for Arm A and C or including events occurring 
after cycle 2 for Arm B), treatment should be withheld at the onset of the AE. Following 
resolution of the toxicity  to grade 1 or to the patient’s baseline value, the patient may 
resume study treatment after discussion with Novartis. I f the investigator considers it to 
be in the patient’s best interest to resume therapy  before the toxicity  has resolved to 
grade 1 or to the patient’s baseline value ,this may  be permitted on a case by  case basis 
after discussion with Novartis.
For clinical management of suspected immune -related events, reference to consensus 
management guidelines is recommended such as those provided in the National 
Comprehensive Cancer Network (NCCN) Guidelines for the Management of 
Immunotherap y
-Related Toxicities (available at : 
https://www.nccn.org/professionals/phy sician_gls/default.aspx#immunotherapy ), the 
American Societ y for Clinical Oncology  clinical practice guideline for Management of 
Immune -Related Adverse Events in Patients Treated With I mmune Checkp oint 

Novartis Confidential Page 78
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Inhibitor Therap y (Brahmer 2018) or the European Society  for Medical Oncology  
(ESMO) Clinical Practice Guidelines for Management of Toxicities from 
Immunotherap y (Haanen 2017).  Note that in general, study  treatment should be 
interrupted for grade 3 and 4 toxicities and for a subset of lower grade toxicities.
Consider earl y referral to specialists with expertise in the diagnosis and management 
ofimmune -related AEs to thoroughl y investigate events of uncertain etiology.
Events not included in the study  protocol or the reference guidance documents should 
be managed per institutional preference.
A scheduled dose (of either single -agent LAG525 or thecombination of LAG525 and PDR001) 
may be delayed to recover from an unresolved AE. If a patient requires a dose interruption of > 
21 days from the intended day  of the scheduled dose due to an AE related to study  drug(s), then 
the patient must be discontin ued from the study , unless the patient is receiving clinical benefit 
and in the opinion of the investigator it is in the patient’s best interest to remain on study . The 
patient may  restart treatment after discussion with Novartis.
Patients who discontinue the study  for a study  related AE or a study -related abnormal laboratory 
value must be followed as described in Section 6.3.2 .
Table 6-5 outlines the recommended dose modifications for selected toxicities. 
All interruptions or change to study  drug administration must be recorded on the Dose 
Administration Record eCRF.
Table 6-5 Recommended Dose Modifications for LAG525 and PDR001
Worst toxicity  CTCAEa grade Recommended Dose Modification
Infusion reaction or hy persensitivity  reaction
Grade 1 Decrease infusion rate until recovery from the symptoms.
Grade 2 Stop infusion immediately, and keep line open. 
Follow institutional guidelines for the management and follow -up of 
infusion reaction.
Restart infusion at 50% of previous rate under continuous observation. 
Ensure that there is a minimum observation period of 1 hour prior to 
restarting the infusion.
If the AE recurs at the reinitiated slow rate of infusion, and despite oral 
pre-medication, then permanently discontinue study treatment.
Grade 3 and Grade 4 Discontinue infusion immediately, and discontinue stu dy treatment.
Provide supplemental oxygen, fluids, and other resuscitative measures 
as needed. Monitor vital signs (e.g. blood pressure, pulse, respiration, 
and temperature) every 15 ± 5 minutes until resolution.
Cytokine Release Sy ndrome (CRS)
Grade 2 See instructions for Grade 2 Infusion Reaction above.
Grade 3 or Grade 4 Discontinue study treatment.
Follow -up CRS as per institutional guidelines.
Take blood for cytokine measurements as specified in Section 8.4.1 –
Laboratory evaluations.

Novartis Confidential Page 79
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Worst toxicity  CTCAEa grade Recommended Dose Modification
Ocular (uveitis, ey e pain, blurred vision)
Grade 1 Continue study treatment without dose modification.
Ophthalmology consultation.
Grade 2 Hold study treatment.
Urgent ophthalmology consultation.
Upon resolution to ≤ Grade 1 may consider resuming study treatment 
without dose reduction after discussion with the Novartis Medical 
Monitor and in consultation with ophthalmology.
Grade 3 or Grade 4 Discontinue study treatment.
Urgent ophthalmology consultation.
Pulmonary  (pneumonitis)
Grade 1 Consider study treatment hold.
Manage per institutional practice.
Consider resuming study treatment upon radiographic evidence of 
improvement.
Grade 2 Hold study treatment.
Pulmonary and infection workup.
Upon resolution to ≤ Grade 1, may resume study treatment without
dose modification.
Grade 3 or Grade 4 Discontinue study treatment.
Cardiovascular
ECG QTc -Interval prolonged; h ypertension
Grade 3 Hold study treatment. 
Upon resolution to Grade ≤ 1 or baseline (hypertension, QTc) or < 30 
msec difference from baseline (QTc) within ≤ 7 days , may resume 
study treatment without dose modification after discussion with the 
Novartis Medical Monitor. Baseline ECG refers to the EC G(s) collected 
at screening.
Grade 4 Discontinue study treatment.
Other cardiovascular disorders
Grade 2 (except myocarditis) Hold study treatment.
Upon resolution to Grade ≤ 1 or baseline, may resume study treatment 
without dose modification after discussion with the Novartis Medical 
Monitor.
Grade 2 myocarditis, or 
Grade ≥ 3 other cardiac disorders 
related to study treatmentDiscontinue study treatment.
Gastrointestinal
Diarrhea/colitis*
Grade 1 May continue study treatment without dose modification .  Manage per 
institutional standard guidelines which should include anti-diarrheal 
treatment, consideration of corticosteroid therapy, and hydration.
Grade 2 Hold study treatment.
GI consultation.
Upon resolution to ≤ Grade 1 and tapering of steroid requirement to ≤ 
10 mg prednisone per day, resume study treatment without dose 
modification after discussion with the Novartis Medical Monitor.

Novartis Confidential Page 80
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Worst toxicity  CTCAEa grade Recommended Dose Modification
Grade 3 Hold study treatment.
GI consultation.
Upon resolution to ≤ Grade 1 and tapering of steroid req uirement to ≤ 
10 mg prednisone per day, consider resuming study treatment after 
discussion with the Novartis Medical Monitor.
Grade 4 Discontinue study treatment.
AST and/or ALT elevation
Grade 2 AST and/or ALT Hold study treatment.
Manage per institutional practice.
Upon resolution to ≤ Grade 1 or baseline, consider resuming study 
treatment without dose modification.
Grade 2 transaminitis with 
bilirubin >1.5 x ULN (unless Gilbert’s 
syndrome)Discontinue study treatment.
Grade 3 AST and/or ALT Hold study treatment.
Manage per institutional practices.
Upon resolution to ≤ Grade 1 or baseline within 7 days, consider 
resuming study treatment without dose modification after discussion 
with the Novartis Medical Monitor.
Otherwise, discontinue study treatment.
Grade 4 AST and/or ALT Discontinue study treatment.
Isolated total bilirubin elevation**
Grade 2 Hold study treatment. 
Upon resolution to ≤ Grade 1 or baseline, may continue study treatment 
without dose modification.
Grade 3 Hold study treatment.
Upon resolution to ≤ Grade 1 or baseline, may consider resuming study 
treatment after discussion with the Novartis Medical Monitor.  
Grade 4 See footnote**.  Otherwise, discontinue study treatment.
Asymptomatic amy lase and/or lipase elevation***
Grade 3 or Grade 4, not associated 
with symptoms or clinical 
manifestations of pancreatitis***Continue study treatment. 
If levels do not resolve to ≤ Grade 2 within ≤ 14 days after the initial 
report, hold study treatment.
Upon resolution to ≤ Grade 2, may resume study treatment without 
dose modification , after discussion with the Novartis Medical Monitor.
Pancreatitis
Grade 2/radiologic evidence Hold study treatment.
Manage per institutional practice.
Upon resolution to ≤ Grade 1 , may resume study treatment without 
dose modification, if no clinical evidence of pancreatitis and after 
discussion with the Novartis Medical Monitor.
Grade 3 or Grade 4 Discontinue study treatment.
Renal
Serum creatinine
Grade 2 Hold study treatment.
Manage per institutional practice.
Upon resolution to ≤ Grade 1 , may resume study treatment without 
dose modification after discussion with the Novartis Medical Monitor.
Grade 3 or 4 Discontinue study treatment.

Novartis Confidential Page 81
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Worst toxicity  CTCAEa grade Recommended Dose Modification
Musculoskeletal
Grade 2 or Grade 3 Hold study treatment.
Consider resuming study treatment without dose modification upon 
resolution to ≤ Grade 1 with appropriate management.
Grade 4 Discontinue study treatment.
In some cases, resuming study treatment may be considered after 
discussion with the Novartis Medical Monitor and consultation with a 
rheumatologist.
Endocrine
Hypoth yroidism or hy perth yroidism
Grade 2 May continue study treatment without dose modification.
Management according to institutional practice.
Grade 3 Hold study treatment. 
Upon resolution to Grade ≤ 1 with appropriate management, may 
resume study treatment without dose modification.
Grade 4 May resume therapy following resolution or control with physiologic 
hormone replacement.
Other endocrine disorders
Grade 2 and Grade 3 Hold study treatment. 
Upon resolution to Grade ≤ 1 with appropriate management, may 
resume study treatment without dose modification.
Grade 4 Hold study treatment.
Grade 4 treatment -related endocrinopathies , such as 
adrenal insufficiency, adrenocorticotropic hormone 
(ACTH) deficiency, hyper -or hypothyroidism, or glucose intolerance, 
which resolve or are adequately controlled with physiologic hormone 
replacement (corticosteroids, thyroid hormones) or glucose -controll ing 
agents, respectively, may not require discontinuation after discussion 
with and approval from the Novartis Medical Monitor.
Neurology
Grade 1 Consider study treatment hold, particularly for clinical 
suspicion of Guillain -Barre syndrome, encephalitis, aseptic meningitis, 
transverse myelitis, or peripheral neuropathy.
Grade 2 Hold study treatment.  
In some cases, resuming study treatment may be 
considered after discussion with the Novartis Medical 
Monitor.
Grade 3 or Grade 4 Discontinue study treatment.
Dermatology (rash)
Grade 1 Continue study treatment without dose modification . Topical steroids, 
antihistamines, topical emollients
Grade 2 Consider holding study treatment.
Topical or oral steroids, antihistamines.
If study treatment is held and resolution to ≤ Grade 1, resume study 
treatment without dose modification.
Grade 3 or Grade 4 Hold study treatment.
Manage per institutional practice.
After resolution to ≤ Grade 1, consider resuming study treatment after 
discussion with the Novartis Medical Monitor.

Novartis Confidential Page 82
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Worst toxicity  CTCAEa grade Recommended Dose Modification
Bullous dermatitis Hold study treatment.
Grade 1 -2 bullous dermatitis: discussion with the Novartis Medical 
Monitor is required before considering resuming study treatment.  
Grade 3 bullous dermatitis: consider resuming therapy after expert 
consultation and documented discussion with the Novartis medical 
monitor.
Grade 4 bullous dermatitis: discontinue study treatment
Stevens -Johnson syndrome (SJS), or 
Lyell syndrome/toxic epidermal 
necrolysis (TEN)Permanently discontinue study treatment
Hematology
Neutropenia (ANC)
Grade 3 or Grade 4 Hold study treatment. 
Upon resolution to ≤ Grade 2 or baseline within ≤ 7 days, resume study 
treatment without dose modification, after discussion with the Novartis 
Medical Monitor.
Febrile neutropenia
Grade 3 or Grade 4 Hold study treatment.
Upon resolution of fever and improvement of neutropenia to ≤ Grade 2 
or baseline, resume study treatment without dose modification, after 
discussion with the Novartis Medical Monitor.
Thrombocy topenia
Grade 3 Hold study treatment.
Upon resolution to ≤ Grade 2 or baseline, resume study treatment 
without dose modification.
For Grade 3 associated with major bleeding, discontinue study 
treatment.
Grade 4 Discontinue study treatment.
Anemia
Grade 3 or Grade 4 Hold study treatment. 
Upon resolution to ≤ Grade 2 or baseline within ≤ 7 days, resume study 
treatment without dose modification.
Lymphopenia
Any grade Treatment -related lymphopenia does not require study treatment hold 
or discontinuation.
Other laboratory  adverse events, not specified elsewhere in table and not included in the consensus 
guidelines
Grade 3 Hold study treatment. 
Upon resolution to ≤ Grade 1, resume study treatment without dose 
modification.
Grade 4 Isolated Grade 4 electrolyte abnormalities not associated with clinical 
sequelae and corrected after appropriate management within 72 hours 
of their onset do not require discontinuation.
In the case of Grade 4 electrolyte imbalances associated with clinical 
sequelae, or not resolved to ≤ Grade 1 within 72 hours despite 
appropriate management, discontinue study treatment.

Novartis Confidential Page 83
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Worst toxicity  CTCAEa grade Recommended Dose Modification
Other non -laboratory  adverse events, not specified elsewhere in table and not included in the consensus 
guidelines
Grade 2 Consider study treatment hold, at Investigator discretion.
Upon resolution to ≤ Grade 1, resume study treatment without dose 
modification.
Grade 3 Hold study treatment.
Upon resolution to ≤ Grade 1, resuming study treatment must be 
discussed with the Novartis Medical Monitor.
Grade 4 Discontinue study treatment.
All dose modifications should be based on the worst preceding toxicity.
aCommon Toxicity Criteria for Adverse Events (CTCAE)
*Note: anti -diarrheal medication is recommended at the first sign of abdominal cramping, loose stools or overt 
diarrhea.
**Note: If Grade 3 or 4 hyper -bilirubinemia is due to the indirect (non-conjugated) component only, and hemolysis 
as the etiology has been ruled out as per i nstitutional guidelines (e.g., review of peripheral blood smear and 
haptoglobin determination), then delay study treatment until resolved ≤ Grade 1, and resume study treatment at 
the discretion of the investigator.
***Note: A CT scan or other imaging study to assess the pancreas, liver, and gallbladder must be performed 
within one week of the first occurrence of any ≥ Grade 3 of amylase and/or lipase. 
6.3.2 Follow -up for toxicities
Patients whose treatment is interrupted or permanently  discontinued due to an AE or clinicall y 
significant laboratory  value, must be followed- up at least once a week (or more if clinically 
indicated) for 4 weeks, and subsequently at approximately 4- week in tervals, until resolution or 
stabilization of the event, whichever comes first. 
The emergence of Immune -Related AE (irAE) may  be anticipated based on the mechanism of 
action of immunomodulatory  therapies.
An irAE is any clinically significant adverse even t affecting any organ that is associated with 
study  drug exposure, is consistent with an immune -mediated mechanism, and where alternative 
explanations have been investigated and ruled out or are considered to be unlikely . Serologic, 
histologic (tumor sampl e) and immunological assessments should be performed as deemed 
appropriate by the Investigator or specialist consultant to verify  the immune -related nature of 
the AE. An empiric trial of corticosteroids may also contribute to understanding the etiology of 
a potential irAE. 
Consensus management algorithms for irAEs have been developed and are available to assist 
investigators in assessing and managing irAEs (refer to Section 6.3.1 Dose modifications).
In case of a toxicity  suspected to be a cytokine release syndrome, the assessments outlined in 
Section 7.2.2.5.6 must be performed.
All patients must be followed up for irAEs, AEs,and SAEs for 150 days following the last 
doses of LAG525 and/or PDR001.
6.3.3 Permitted concomitant therapy
In general, concomitant medications and therapies deemed necessary  for the supportive care 
(e.g. such as anti -emetics, anti -diarrhea) and safety of the patient are allowed.

Novartis Confidential Page 84
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
For patients with hormone resistant prostate cancer receiving luteinizing hormone -releasing 
hormone agonists or antagonists, or for patients with metastatic carcinoid tumors receiving 
somatostatin analogs to control symptoms of carcinoid syndrome ,these treatm ents must have 
been initiated ≥4 weeks prior to first dose of stud y treatment and may be continued throughout 
the study . 
Bisphosphonates are generall y allowed for the management of bone metastas es and 
osteoporosis. However, chronic concomitant bisphosphonate therap y for the prevention of bone 
metastasis is not permitted.  If bisphosphonate therapy  is to be started after the first dose of 
study  drug, prior consultation and approval by Novartis is required and the reason for its use 
must be clearl y documente d.
Patients must be told to notify  the investigational site about any new medications, herbal 
remedies and dietary  supplements he/she takes after the start of the study  treatment. All 
medications (other than study  treatment) and significant non-drug therap ies (including physical 
therap y, herbal/natural medications and blood transfusions) administered during the study  must 
be listed on the Prior and Concomitant Medications or the Surgical and Medical Procedures 
CRF. Prior antineoplastic therapies including m edications, radiotherapy , and surgery  are to be 
recorded on the separate Prior Antineoplastic Therapy  eCRF during screening.
6.3.4 Permitted concomitant therapy  requiring caution and/or action
Treatment with hematopoietic colony -stimulating growth factors (e.g. G
-CSF, GM-CSF, M-
CSF) may not be initiated during the DLT observation window (see Section 6.2.3 ) in the dose 
escalation part of the study , unless the patient has already  experienced a DLT. Treatment with 
erythroid stimulating agents (ESAs) may  not be initiated during the DLT observation window 
in the dose 
escalation part of the study , unless the patient has alread y experienced a DLT. If a 
patient is using ESA prior to enrollment (at least 2 weeks prior to the first dose of study  
treatment), they  may  continue at the same dose.
Anticoagulation is permitted if the patients are alread y at stable doses for >2 weeks at time of 
first dose and INR should be monitored as clinically indicated per investigator’s discretion. 
However, ongoing anticoagulant therap y should be temporaril y discontinued to allow tumor 
biopsy  according to the institutional guidelines.
Antihy pertensives are allowed as concomitant medications; however, because transient 
hypotension has occurre d during infusions of monoclonal antibodies, consideration should be 
given to withholding anti-hypertensive medications for 12 hours prior to infusion with the study 
drugs including LAG525 or its combination with PDR001.
6.3.5 Prohibited concomitant therapy
During the course of the study , patients may  not receive other additional investigational drugs, 
agents, devices, chemotherap y, or any other therapies that may be active against cancer. 
However, limited -field palliative radiotherap y to non-target lesion(s) may be allowed as 
concomitant therap y after documented discussion with Novartis. Such local therapies 
administered during the study  treatment must be listed on the corresponding CRF. Additionally , 
no other therapeutic monoclonal antibodies and no immunosuppre ssive medication may be 

Novartis Confidential Page 85
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
administered while on this study .Denosumab may be used for the management of bone 
metastases. 
The use of s ystemic steroid therap y (at doses greater than 10 mg/day prednisone or equivalent) 
and other immunosuppressive drugs is not allowed, with the exception of: 
Prophy lactic use for patients with imaging contrast dy e allergy .
Replacement -dose steroids (defined as 10mg/day  (or lower dose) of prednisone or 
equivalent dose of corticosteroids) in the setting of adrenal insufficiency . 
Transient exacerbations of chronic inflammatory  conditions such as COPD. Steroids must 
be reduced to 10 mg/day  (or lower dose) of prednisone or equivalent dose of 
corticosteroids prior to the next treatment with L AG525 and/or PDR001.
Upon treatment of LAG5 25 and/or PDR001 infusion reactions or LAG525 and/or 
PDR001 -related irAEs, steroids must be reduced to 10 mg/day  (or lower dose) of 
prednisone or equivalent dose of corticosteroids prior to the next treatment with L AG525 
and/or PDR001.
Topical, inhaled, nasal and ophthalmic steroids are allowed. The use of live vaccines is not 
allowed through the whole duration of the stud y.Inactivated vaccines are allowed.
6.4 Patient numbering, treatment assignment or randomization
6.4.1 Patient numbering
Each patient is identifie d in the study  by a Subject Number (Subject No.), that is assigned when 
the patient is first pre -screened (if applicable) or when the patient is enrolled for screening. The 
subject number is retained as the primary  identifier for the patient throughout his/her entire 
participation in the trial. The Subject No. consists of the Center Number (Center No. is assigned 
by Novartis to the investigative site) with a sequential patient number suffixed to it, so that each 
subject is numbered uniquely  across the entire database. Upon signing the informed consent 
form, the patient is assigned to the next sequential Subject No. available to the investigator 
through the Oracle Clinical RDC interface.
6.4.2 Treatment assignment or randomization
The assignment of a patient to a particular cohort will be coordinated by the sponsor. No 
randomization will be performed in this study .
6.5 Stud y drug preparation and dispensation
LAG525 is supplied as liquid in vial (100 mg per vial). PDR001 100 mg is formulated as powder
for solution forinfusion. Further instructions for the preparation and dispensation of LAG525 
and PDR001 are described in the [Pharmacy  Manual] .
All dosages prescribed to the patient and all dose changes during the study must be recorded on 
the Dosage Administration Record CRF.

Novartis Confidential Page 86
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
6.5.1 Study drug packaging and labeling
LAG525 100 mg liquid in vial.
PDR001 (100 mg powder for solution for infusion) will be supplied b y Nov artis to Investigator 
as open label bulk medication.
Medication labels will be in the local language and comply w ith the legal requirements of each 
country . They  will include storage conditions for the drug but will not supply  information about 
the patient.
6.5.2 Drug supply  and storage
Study  treatments must be received by designated personnel at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, LAG525 and PDR001 should be stored according to 
the instructions specified on the drug labels.
6.5.3 Study drug c ompliance and accountability
6.5.3.1 Study drug compliance
Study  treatment will be administered to the patient by the study  site staff at the study  sites. 
Compliance will be assured by administration of the study  treatment under the supervision of 
investigator or his/her designee.
6.5.3.2 Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment according to local institutional drug accountability  processes. Drug 
accountability  will be noted by the field monitor during site visits and at the completion of the 
study .
At study  close-out, and, as appropriate during the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the co mpleted drug 
accountability  log to the Novartis monitor or to the Novartis address provided in the investigator 
folder at each site.
6.5.4 Disposal and destruction
The study  drug suppl y can be destro yed at the local Novartis facility , Drug Supply  group or 
third party , as appropriate.
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtaine d from these assessments must be supported in the patient’s source 
documentation. The table (“Category” column) indicates which assessments produce data to be 
entered into the clinical database (D) or remain in source documents only  (S).

Novartis Confidential Page 87
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
No CRF will be used as a source document.
Screening/baseline evaluations must be performed ≤ 21 day s before Cy cle 1 Day  1, except for 
baseline radiological evaluations which must be done within 28 days. Assessments required on 
Cycle 1 Da y 1 that  are performed as part of the screening evaluations and within 72 hours prior 
to the first dose of study treatment, do not need to be repeated on Cycle 1 Day 1. Laboratory 
and radiological assessments performed as part of standard of care prior to signing informed 
consent may  be used if performed within the screening time window.
During the course of the study  visits, test and/or procedures should occur on schedule whenever 
possible. A visit window of +/ -7 days is allowed. If the infusion of LAG525 or its combination 
with PDR001 is delayed, the assessments will be shifted accordingl y. On PK collection days 
the windows are provided in Section 7.2.3.
Radiological assessments must be performed +/-
7 days of the scheduled date of the assessment.

Novartis Confidential Page 88
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 7-1 Visit evaluation schedule
Screening 
Phase Treatment Phase Follow -up
Visit name
Category
Protocol 
Section
ScreeningCycle 1 Cycle 2 Cycle 3
Subsequent 
cycles
EoT
Safety Follow -
Upg
Disease 
Progression 
F/U
Day of cycle -21 to -1 1 2 8 11 15 1 15 1 2 8 11 15 1
Obtain Informed Consent D 7.1.1 X
Demography D 7.1.1.2 X
Inclusion/ exclusion criteria D 5.2/ 5.3 X
Medical History D 7.1.1.2 X
Diagnosis and extent of 
cancerD 7.1.1.2 X
MSI status if applicable D 7.1.1.2 X
EGFR, ALK, BRAF V600 
status (if applicable) and 
BRCA (if known)D 7.1.1.2 X
Prior antineoplastic therapy D 7.1.1.2 X
Prior/concomitant medications D 7.1.1.2 X Continuous
Physical examination S 7.2.2.1 X X X X X X X X X
Height D 7.2.2.3 X
Weight D 7.2.2.3 X X X X X X
Vital signs D 7.2.2.2 X X X X X X X XhX
Performance status D 7.2.2.4 X X
Hematology D 7.2.2.5.1 X X X X X X X XhX
Chemistry D 7.2.2.5.2 X X X X X X X XhX
Coagulation D 7.2.2.5.3 X

Novartis Confidential Page 89
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Screening 
Phase Treatment Phase Follow -up
Visit name
Category
Protocol 
Section
ScreeningCycle 1 Cycle 2 Cycle 3
Subsequent 
cycles
EoT
Safety Follow -
Upg
Disease 
Progression 
F/U
Day of cycle -21 to -1 1 2 8 11 15 1 15 1 2 8 11 15 1
Urinalysis D 7.2.2.5.4 X
Thyroid function D 7.2.2.5.5 X X X X X X
Cytokines ( IL-6) D 7.2.2.5.6 X In case of a suspected cytokine release syndrome
Pregnancy test D 7.2.2.5.7 X X X X X
S 7.2.2.5.7 Xg
Antineoplastic therapies since 
discontinuation of study 
treatmentD 7.1.5 X X X
Tumor evaluation as per 
RECIST 1.1 and as per irRC.D 7.2.1 X Every 8 weeks ± 1 week after Cy cle 1 Day  1 until 40 weeks , then every 12 weeks until 
progression of disease per irRC or patient withdrawal.
For disease progression f/u, every 8 weeks ± 1 week until 40 weeks, then every 12 weeks ± 1 
week until progression of disease per irRC, or lost to follow -up.
ECG D 7.2.2.6.1 X X X X XaXj
Adverse events D 8 Continuous

Novartis Confidential Page 90
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Screening 
Phase Treatment Phase Follow -up
Visit name
Category
Protocol 
Section
ScreeningCycle 1 Cycle 2 Cycle 3
Subsequent 
cycles
EoT
Safety Follow -
Upg
Disease 
Progression 
F/U
Day of cycle -21 to -1 1 2 8 11 15 1 15 1 2 8 11 15 1
Study Drug administration D 6.1.1 i.v. every 2 weeks (potential alternative schedules, e.g., every 3 or 4 
weeks).
PK samplingcD 7.2.3 X X X X X X X X X X X Xa, iXk
Immunogenicity (IG) sampling D 7.2.3 X X X Xa, iX
a.Cycles 4 -6 only.
b. Anytime from Cycle 3 Day 1 through Cycle 3 Day 15.
c. Japanese patients enrolled in dose escalation are required to be hospitalized during the DLT evaluation period
 
 
 
g. Safety evaluations for 150 days after the last dose of study treatment with contacts at 30 -, 90-, and 150-day. Pregnancy tests every month until the 150 -day safety 
follow -up; can be performed at home or at a local doctor’s office if the patient is not coming to the clinic.
h. For patients who switch from single -agent LAG525 to LAG525 in combination with PDR001, patients will resume the standard visit schedule; hematology/chemistry 
labs and vital signs will be collected on Days 8 and 15 as unscheduled assessments for the first cycle upon switch to the LAG525 in combination with PDR001 .
i. For patients who switch from single -agent LAG525 to LAG525 in combination with PDR001, immunogenicity samples will be collected as unscheduled 
assessments (instead of their standard PK collection schedule) on Day 1 pre -dose for the first 6 cycles upon switch t o the LAG525 in combination with PDR001, and 
PK blood samples will be collected on Days 1 (pre -infusion) and 8 as unscheduled assessments (instead of their standard PK collection schedule) for the first cycle 
upon switch to the LAG525 in combination with P DR001.
j. After the primary CSR cut -off date is reached, EOT ECGs will be performed at the discretion of the investigator .
k.After the primary CSR cut -off date is reached, EOT PK s will notbe performed .

Novartis Confidential Page 91
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
7.1.1 Screening
The study  IRB/IEC informed consent form must be signed and dated before any screening 
procedures are performed, except for laboratory and radiological eva luations performed as part 
of standard of care within the screening window.
Patients will be evaluated against study  inclusion and exclusion criteria and safet y assessments. 
For details of assessments, refer to Table 7-1. Screening assessments must be repeated if 
performed outside of the specified screening window Section 7.1. Patients are allowed to re-
screen after abnormal labs or sy mptoms are 
corrected or treated.
7.1.1.1 Information to be collected on screening failures
A patient who signed an Informed Consent Form but failed to be started on treatment for any 
reason will be considered a screen failure. If patients are found not eligible after signing the 
main study  consent, the patients will be considered as screening failures, and data will be 
handled in the same manner.
The demographic information, informed consent, and Inclusion/Exclusion pages must also be 
completed for screen failure patients. Noother data will be entered into the clinical database for 
patients who are screen failures, unless the patient experienced a SAE during screening.
7.1.1.2 Patient demographics and other baseline characteristics
Data to be collected will include general patient demographics, relevant medical history  and 
current medical conditions, diagnosis and extent of tumor, details of prior anti-neoplastic 
treatments, prior medication, procedures, significant non-drug therapies and any other 
assessments that are done for the purpose of determining eligibility  for inclusion in the study . 
For patients with CRC, the MSI status will be collected. If the MSI status determination is not 
performed routinely  as part of the patient standard follow -
up, it is requested to be determined 
locally during screening. In the phase II part of the study , for patients with NSCL C, the EGFR 
and ALK mutation status will be collected; for patients with melanoma, the BRAF V600 
mutation status will be collected; for patients with TNBC, if known, the BRCA status willbe 
collected. If the EGFR, ALK or BRAF V600 status is not known, it is requested to be 
determined locall y during screening. These test results are not required to qualify  for enrollment.
7.1.2 Treatment period
A treatment cycle is defined as 28 days for the purposes of scheduling procedures and 
evaluations (21 days for patients on Q3W dosing schedule). Please refer to Table 7-1for details 
of the timing of required assessments and Section 7.1for visit windows. Based on emerging 
available safet y, PK,  and efficacy  data generated during the study , the treatment cycle length 
may be switched to 21 day s.
For Japan only, patients enrolled in dose escalation are required to be hospitalized during the 
DLT evaluation period.
Patients will be treated until they experience unacceptable toxicity , progressive disease per irRC 
and/or treatment is discontinued at the discretion of the investigator or the patie nt, as described 
in Section 7.1.3 andSection 4.3.

Novartis Confidential Page 92
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Patients may continue treatment with LAG525 or its combination with PDR001 until the patient 
expe riences unacceptable toxicity  that precludes any further treatment, disease progression, 
and/or treatment is discontinued at the discretion of the investigator or by patient request. 
Patients who have disease progression and have evidence of clinical benef it, such as disease 
shrinkage at other sites or sy mptomatic improvement, may continue treatment with LAG525 or 
its combination with PDR001. I n addition, LAG525 or its combination with PDR001 treatment 
may be temporarily  interrupted to permit local therapy for symptomatic metastases after disease 
progression has been documented. Patients who continue on treatment after disease progression 
should discontinue study treatment once they  are no longer deriving benefit as assessed by  the 
investigator.
7.1.3 Discontinuat ion of study treatment
Patients may voluntarily  discontinue from the study  treatment for any reason at any time. If a 
patient decides to discontinue from the study  treatment, the investigator must make every  effort 
(e.g. telephone, e -mail, letter) to determine the primary  reason for this decision and record this 
information in the patient’s chart and on the appropriate CRF pages. They may be considered 
withdrawn if they state an intention to withdraw, fail to return for visits, or become lost to 
follow -up f or an y other reason.
The investigator should discontinue study  treatment for a given patient if, on balance, he/she 
believes that continuation would be detrimental to the patient’s well -being.
Study  treatment may  be discontinued if any  of the following occ ur:
Adverse event
Lost to follow -up
Physician’s decision
Progressive disease per irRC , RECI ST 1.1, or as determined clinicall y by t he Investigator
Study  terminated by  the sponsor
Subject/guardian decision
Protocol deviations that result in significant risk to the patients’ safety
Technical problems
Patients will be withdrawn if any  of the following occur:
Death
Pregnancy
At the time patients discontinue study  treatment, a visit should be scheduled as soon as possible, 
and within 14 days of the last dose of study  drug or within 14 days of the decision to 
permanentl y discontinue study  treatment, at which time all of the assessments listed for the 
EOT visit will be performed (Table 7-1). If the decision to withdraw the patient occurs at a 
regularl y scheduled visit, that visit may become the EOT visit rather than having the patient 
return for an additional visit. An End of Treatment Phase Disposition CRF page should be 
completed, giving the date and reason for stopping the study  treatment. End of 
treatment/Premature withdrawal visit is not considered as the end of the study .

Novartis Confidential Page 93
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Patients who discontinue study  treatment should NOT be considered withdrawn from the study . 
They  should return for the assessments indicat ed in Section 7.1.5. If the y fail to return for these 
assessments for unknown reasons, every effort (e.g. telephone, 
email, letter) should be made to 
contact them as specified in Section 7.1.6. If a patient discontinues study  treatment, but 
continues study  assessments, the patient remains on study  until such time as he/she completes 
protocol criteria for ending study  assessments. At that time, the reason for study  completion 
should be recorded on the Study  Phase Completion Disposition CRF page.
Patients who transfer into another study  or an alternative treatment option to continue provision 
of study  treatment will perform the end of treatment procedures .
7.1.3.1 Replacement policy
Phase I dose escalation part:
Patients will not be replaced on study . However, if a patient is considered to be non -evaluable 
for the Dose Determining Set (DDS), enrollment of a new patient to the current cohort will be 
considered if there is less than the required number of evaluable patients. Enrollment of new 
patients may be considered until at least the minimum number or at most the maximum number 
of evaluable patients is achieved within the cohort. Minimum and maximum numbers of 
evaluable patients per cohort are defined in Section 6.2.3 .
Phase II expansion part: during the phase II expansion part no replacements will be needed.
7.1.4 Withdrawal of Consent
Patients may voluntaril y withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a patient :
Does not want to participate in the study  any longer, and 
Does not 
allow further collection of personal data
In this situation, the inv estigator should make reasonable effort (e.g. telephone, email, letter) to 
understand the primary reason for the patient 's decision to withdraw his/her consent and record 
this information. Study  treatment must be discontinued and no further assessments con ducted. 
The data that would have been collected at subsequent visits will be considered missing. 
Further attempts to contact the patient are not allowed unless safety  findings require 
communication or follow up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient 's study  withdrawal should be made as detailed in the 
assessment table. 
Novartis will continue to keep and use collected study  information (including any data resulting 
from the analysis of a patient's sample until their time of withdrawal) according to applicable 
law. 
For US and Japan: All biological samples not yet analyzed at the time of withdrawal may  still 
be used for further testing/analy sis in accordance with the terms of this protocol and the 
informed consent form. 

Novartis Confidential Page 94
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
For E uropean Union and Rest of World: All biological samples not y et analy zed at the time of 
withdrawal will no longer be used, unless permitted by applicable law. They  will be stored 
according to applicable legal requirements.
7.1.5 Follow up period
150-day safety follow up period
All patients must have safety  evaluations 30 day s, 90 day s, and 150 day s after the last dose of 
study  treatment. The follow -up can be done by telephone call or a visit. Concomitant 
medications will be collected until the 30 -day safety  follow -up has been co mpleted, or the start 
of a new antineoplastic therap y, whichever occurs first. Information related to AEs (including 
concomitant medication taken for on-going AEs) will be collected for 150 days after the last 
dose of study  drug. All AEs suspected to be related to study  treatment should be followed up 
weekl y or as clinicall y indicated until resolution or stabilization.
Antineoplastic therapies since discontinuation of study  drug will be collected during this 
follow -
up period. After initiation of new post-treatment antineoplastic therap y, only AEs 
suspected to be related to study  treatment will be collected in the Adverse Events CRF.
For a female participant of child bearing potential, a pregnancy test will be performed on Days 
30, 60, 90, 120 and 150 after stopping the study  treatment. If the patient is not coming to the 
clinic for the safet y follow -up visits, a pregnancy  test will be performed at home or at a local 
doctor’s office at each of the safety  follow -up time points described above, and the results will 
be communicated to the site staff and will be recorded only  in the source documentation, not in 
the CRF.
Disease progression follow  up period
Patients who discontinue study  treatment for any reason other than death, disease progression 
per irRC, lost to follow -up, consent withdrawal, start of new cancer therapy  or study  termination, 
also should return for tumor evaluation assessments every  8 weeks until 40 weeks, and then 12 
weeks until progression of disease per irRC. If patients refuse to return for these visits or are 
unable to do so, every  effort should be made to contact them or a knowledgeable informant by 
telephone to determine if the patient had disease progression.
Antineoplastic therapies since discontinuation of study  drug will be collected during this 
follow -up period.
 
 
 
 
 
 

Novartis Confidential Page 95
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
7.1.6 Lost to follow  up
For patients whose status is unclear because t hey fail to appear for study  visits without stating 
an intention to withdraw consent, the investigator should show "due diligence" by contacting 
the patient, family  or family  physician as agreed in the informed consent and by documenting 
in the source docu ments steps taken to contact the patient, e.g. dates of telephone calls, 
registered letters, etc. A patient should not be considered lost to follow -up until due diligence 
has been completed. Patients lost to follow up should be recorded as such on the appropriate 
Disposition CRF.
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
Tumor response will be determined locall y according to two sets of criteria:
1.RECI ST v1.1 ( Appendix 1 )
2.irRC ( Appendix 2 )
The local investigator’s assessment will be used for the anal ysis of response according to both 
RECI ST 1.1 and irRC, and for treatment decision making (study  discontinuation due to PD as 
per i
rRC). Patients experiencing progressive disease per RECIST v. 1.1 criteria may continue 
to be treated according to irRC guidelines until progression is documented via irRC. Imaging 
data may be centrall y collected and checked for quality  by an imaging Contr act Research 
Organization (CRO) designated by Novartis. The local investigator’s assessment will be used 
for the data analy sis and for treatment decision making. Central review of the imaging data may 
be performed if deemed necessary . 
At screening, all patients will undergo CT with i.v. contrast of the chest, abdomen and pelvis. 
MRI  should only  be used to evaluate sites of disease that are not adequately  imaged by  CT. If 
a patient is intolerant of iodine -based contrast agents, CTs may  be performed without contrast. 
MRI  may  be used to evaluate sites of disease where a CT without i.v. contrast is not adequate. 
Visible skin lesions and easily  palpable subcutaneous tumors may be measured by physical 
examination using a ruler or calipers. Ultrasound should not be used to measure sites of disease. 
See Table 7
-2for further details.
Tumor assessments will be performed at the following time points:
Screening
Every  8 weeks ± 1 week after C ycle 1 Day 1 until 40 wee ks, then every  12 weeks ± 1 
week until progression of disease per irRC or patient withdrawal. After EOT, during 
disease progression f/u, every  8 weeks ± 1 week until 40 weeks, then every 12 weeks ± 1 
week until progression of disease per irRC, or lost to f ollow -up.
PR or CR, per both RECIST 1.1 and irRC, will be confirmed b y a new assessment after at 
least 4 weeks. Also PD, as per irRC, needs to be confirmed after at least 4 weeks.
At the End of Treatment, if a scan was not conducted within 30 day s prior to End of 
Treatment
Disease progression follow -up should be performed as described in Section 7.1.5.

Novartis Confidential Page 96
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 7-2 Disease assessment collection plan
Procedure Screening/Baseline During Treatment/Follow-up
CT or MRI
with contrast 
enhancement
(Chest, Abdomen, 
Pelvis)Mandated Every 8 weeks ± 1 week after Cycle 1 Day 1 until 40 
weeks, then every 12 weeks ± 1 week until 
progression of disease per irRC or patient 
withdrawal. After EOT, during disease progression 
f/u, every 8 weeks ± 1 week until 40 weeks, then 
every 12 weeks ± 1 week until progression of 
disease per irRC, or lost to follow -up
Brain CT or MRI with 
contrastMandated If disease was detected at baseline, or if clinically 
indicated
Localized bone CT, 
MRI or x -rayFor any lesions identified on 
the bone scan that are not 
visible on the chest, abdomen 
and pelvis CT or MRIIf lesions were documented at baseline, follow same 
schedule as CT/MRI of chest, abdomen, and pelvis
Whole body bone 
scanIf clinically indicated If clinically indicated
Any other procedure allowed as per RECIST 1.1 guidelines and not conflicting with this section

Novartis Confidential Page 97
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
7.2.2 Safety  and tolerability assessments
Safety  will be monitored by assessing physical examination, vital signs, body height and weight, 
performance status, hematology , chemistry , coagulation, urinaly sis, thyroid function, 
pregnancy , ECG, cytokine testing, as well as collecting of th e AEs at every visit. For details on 
AE collection and reporting, refer to Section 8.
7.2.2.1 Physical examination
Physical examination will be performed according to Table 7 -1.
At Screening and Cycle 1 Day 1, prior to LAG525 infusion, a complete physical examination 
will be performed and will include the examination of general appearance, skin, neck (including 
thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities and 
neurological system. If indicated based on medical history  and/or symptoms, rectal, external 
genitalia, breast, and pelvic exams will be performed.
From Cycle 1 Day 8 onwards, a short physical examination will be performed. A short physical 
exam will include the examination of general appearance, vital signs (temperature, blood 
pressure [BP] and pulse) and body  sites as directed by  symptoms.
Significant findings that were present prior to the signature of the informed consent must be 
included in the Medical History  CRF page. Significant new findings that begin or worsen after 
informed consent must be recorded on the Adverse Event CRF page.
7.2.2.2 Vital signs
Vital signs (bod y temperature, pulse rate, blood pressure ) must be performed before dosing and 
as indicated in Table 7 -1as per institutional standards.
Vital signs should be assessed on the scheduled day , even if study  treatment is being withheld. 
More frequent examinations may be performed at the discretion of the Investigator if medicall y 
indicated, and will be recorded as unscheduled assessment.
7.2.2.3 Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor clothin g, 
but without shoes) will be measured as indicated in Table 7
-1.
7.2.2.4 Performance status
Performance status is determined as indicated in Table 7-3.
Table 7
-3 ECOG performance status
Grade ECOG Status
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature (e.g., light house work, office work)
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair

Novartis Confidential Page 98
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
7.2.2.5 Laboratory  evaluations
All laboratory  parameters assessed for safet y purposes will be evaluated locally  (except 
cytokine release syndrome testing, which will be performed and anal yzed centrally for sites not 
capable of local testing). Refer to Table 7
-4for a summary  of the parameters to be evaluated 
according to Table 7 -1. On dosing day s of LAG525 or its combination with PDR001, samples 
for these parameters will be collected prior to the infusion of LAG525 or its combination.
More frequent evaluations may be performed at the investigator’s discretion if medicall y 
indicated; results should be recorded as unscheduled laboratory  assessments.
Novartis will be provided with a copy of the laboratory  certification and tabulation of the normal 
ranges for each parameter required. In addition, if at any time a patient has laboratory 
parameters obtained from a different outside laboratory , Novartis must be provided with a copy 
of the certification and a tabulation of the normal ranges for that laboratory .
Table 7
-4 Local clinical laboratory  parameters collection plan
Test Category Test Name
Hematology Hematocrit, Hemoglobin, Platelets, W hite blood cells with Differential (Basophils, 
Eosinophils, Lymphocytes, Monocytes, Neutrophils)
Chemistry Albumin, Alkaline phosphatase, ALT (SGPT), AST (SGOT), Bicarbonate, Calcium, 
Chloride, Creatinine, Glucose*
Magnesium, Inorganic Phosphate, Potassium, Sodium, Total Bili rubin (also measure 
direct and indirect bilirubin if total bilirubin is > grade 1), Blood Urea Nitrogen (BUN) or 
Urea, amylase, and lipase. 
Additionally for melanoma and TNBC patients: LDH 
Coagulation Prothrombin time (PT) or International normalized ratio [INR]), activated partial 
thromboplastin time (APTT)
Urinalysis Macroscopic Panel (Dipstick) (Bilirubin, Blood, Glucose, Ketones, pH, Protein, Specific 
Gravity, W hite Blood Cells)
Thyroid Total or free T4, TSH
Cytokines  Interleukein-6 (IL -6)
*See Section 7.2.2.5.2 regarding fasting glucose testing
7.2.2.5.1 Hematology
Hematology  panel outlined in Table 7-4will be performed as per the assessment schedule in 
Table 7-1.
7.2.2.5.2 Clinical chemistry
Clinical chemistry  panel outlined in Table 7-4will be performed as per the assessment schedule 
in Table 7-1. Patients without pre-existing diabetes or previously determined to be 
normogl ycemic shown to have 
an abnormal random blood glucose at screening must have a 
fasting blood glucose test performed and an y subsequently  diagnosed h yperglycemia should be 
managed appropriatel y as per Institutional guidelines.

Novartis Confidential Page 99
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
7.2.2.5.3 Coagulation
Coagulation panel outlined in Table 7-4will be performed as per the assessment schedule in 
Table 7
-1.
7.2.2.5.4 Urinalysis
Urinaly sis panel outlined in Table 7 -4will be performed as per the asses sment schedule in Table 
7-1.
7.2.2.5.5 Thyroid function
Thyroid function panel outlined in 
Table 7-4 will be performed as per the assessment schedule 
in Table 7-1.
7.2.2.5.6 Cytokines
The cytokine panel outlined in Table 7-4will be performed on an as needed basis in case a 
patient has an adverse event suspected to include cytokine release syndrome. This assessment 
is in addition to the pharmacod ynamic cytokine panels described in Section 7.2.4.3.2.
Baseline cytokine samples must be collected at screening for all patients. If a suspected cytokine 
release sy ndrome occurs, additional sample(s) must be collected at the following time points:
within 5 hours after the occurrence of the adverse event
One week after the occurrence of the adverse event.
Samples collected for cy tokine tests will be stored at -
700C. The samples will be anal yzed 
retrospectivel y in batches for those patients who experience an AE that is suspected to be 
cytokine release s yndrome.
7.2.2.5.7 Pregnancy and assessment of fertility
Pregnancy  tests will be performed for women of child bearing potential.
At screening, a serum pregnancy  test must be performed within 72 hours before the first dose. 
During the study  (Day 1 of each cycle starting with Cycle 2) a serum or urine pregnancy  test 
must be performed. At End of Treatment, a serum or urine pregnancy test must also be 
performed.
Pregnancy  test will also be performed during the follow -up period on Days 30, 60, 90, 120, and 
150 after stopping the study  treatment. If the patient is not coming to the clinic for the safet y 
follow -up visits, a pregnancy test will be performed at home or at a local doctor’s office at each 
of the safet y follow -up time points described above, andthe results will be communicated to 
the site staff and will be recorded onl y in the source documentation, not in the CRF.
7.2.2.6 Cardiac assessments
7.2.2.6.1 Electrocardiogram (ECG)
A standard 12 lead ECG will be performed as per the assessment schedule in Table 7-1and 
Table 7-5. Blood samples scheduled at the same time point should be taken after the ECGs are 

Novartis Confidential Page 100
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
completed. The ECGs on C1D1, C2D1, C3D1, C4D1, C5D1 andC6D1 must be performed in 
triplicate.
The post-dose ECGs in the combination arm will be collected after the completion of the last 
dose of infusion.
Table 7-5 12 Lead ECG co llection plan
Cycle Day Time
Screening -21 to -1 Anytime
1 1 *Pre-dose
1 1 *1h (±5 min) hour post dose
2 1 *Pre-dose
2 1 *1h (±5 min) hour post dose
3 1 *Pre-dose
3 1 *1h (±5 min) hour post dose
4 1 *Pre-dose
4 1 *1h (±5 min) hour post dose
5 1 *Pre-dose
5 1 *1h (±5 min) hour post dose
6 1 *Pre-dose
6 1 *1h (±5 min) hour post dose
EoT - Anytime
Unscheduled** - Anytime
*ECGs Performed in triplicate.
**A PK sample should be collected just after an ECG performed due to an unexpected cardiac signal.
All ECGs will be independently  reviewed by a central laboratory . Instructions for the collection 
and transmission of ECGs to the central ECG laboratory  will be provided in the ECG Manual.
After the primary  CSR cut- off date is reached, ECGs will be performed at the discretion of the 
investigator and will be recorded on an unscheduled CRF page. These ECGs will not be 
reviewed b y the central laboratory .
Clinically  significant abnormalities present at screening should be reported on the Medical 
History CRF page. New or worsened clinicall y significant findings occurring after informed 
consent must be recorded on the Adverse Events CRF page. All eligibility  and patient 
management decisions should be made based on the local reading of the ECG.
7.2.3 Pharmacokine tics and immunogenicity  assessments
The following PK parameters will be determined for LAG525 alone, LAG525 in combination 
with PDR001 and PDR001 in combination with LAG525 using non-compartmental methods: 
Cmax, Tmax, AUC0 -tlast (AUC0 -
336h - Cycle 1 Day 1 and Cycle 3 Day 1), time to last 
measurable concentration (Tlast), t1/2, and the accumulation ratio of LAG525 and PDR001. 
 
.
The data wil l be analy zed-using WinNonlin Phoenix (Pharsight Corporation; Mountain View, 
CA). PK profiles to assess PK properties of single -agent LAG525 and LAG525 in combination 

Novartis Confidential Page 101
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
with PDR001 will be collected from all enrolled patients. Please refer to Table 7-6for details 
on PK and immunogenicity (IG) sample collections. For patients who switch from single -agent 
LAG525 to L AG525 in combination with PDR001, immunogenicity  samples will be collected 
as unscheduled assessments (instead of their standard PK collection schedule) on Day 1
 pre-
dose for the first 6 cycles upon switch to the LAG525 in combination with PDR001, and PK 
blood samples will be collected on Days 1 (pre-infusion) and 8 as unscheduled assessments 
(instead of their standard PK collection schedule) for the first cycle upon switch to the LAG525 
in combination with PDR001.
If the dosing of Cycle 3 Day 1 is delay ed, the PK sampling for PK profile should be delay ed 
accordingl y to match the scheduled time po ints for cy cle 3 as outlined in Table 7 -6. PK and IG 
samples will be collected also at the End of Treatment Visit and in the event of a clinicall y 
significant AE (such as infusion reaction/anaph ylaxis) or if IG is suspected, at which time those 
samples could be used to measure any relevant biomarkers, to understand the infusion 
reaction/adverse event better. After the primary CSR data cut -off date is reached, no additional 
PK and IG samples will be colle cted for the patients still on -going on the study .
 
 
 
Table 7
-6 Pharmacokinetic blood collection log for LA G525 alone, LA G525 in 
combin ation with PDR001 and PDR001 in combination with LA G525 in 
all patientsb
Cycle Day Scheduled Time Point (h)a, fAnal ytesc d
1 1 Pre-infusion of Cycle 1 mAb and IG
1 1 1h post infusion (± 5 min) mAb
1 2e24h post infusion (± 2h)* mAb
1 8 168h post infusion (± 8h)* mAb
1 11e240h post infusion (± 24h)* mAb
1 15 Q2W : Pre -infusion / 336h post infusion (±24h)*
Q3W : 336h post infusion (±24h)*
Q4W : 336h post infusion (±24h)* mAb
2 1 Q2W : Pre -infusion*
Q3W : Pre -infusion / 504h post infusion (±24h)*
Q4W : Pre -infusion / 672h post infusion (±24h)*mAb and IG
2 1e1h post infusion (± 5 min) mAb
3 1 Pre-infusion of Cycle 3 mAb and IG
3 1 1h post infusion (± 5 min) mAb
3 2e24h post infusion (± 2h)* mAb
3 8 168h post infusion (± 8h)* mAb
3 11e240h post infusion (± 24h)* mAb
3 15 Q2W : Pre -infusion / 336h post infusion (±24h)
Q3W : 336h post infusion (±24h)
Q4W : 336h post infusion (±24h) *mAb

Novartis Confidential Page 102
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Cycle Day Scheduled Time Point (h)a, fAnal ytesc d
4 1 Q2W : Pre -infusion
Q3W : Pre -infusion / 504h post infusion (±24h)
Q4W : Pre -infusion / 672h post infusion (±24h)* )mAb and IG
5 1 Pre-infusion of Cycle 5 mAb and IG
5 1e1h post infusion (± 5 min) mAb
6 1 Pre-infusion of Cycle 6 mAb and IG
6 1e1h post infusion (± 5 min) mAb
EOT mAb and IG
UnscheduledgmAb and IG
a.Time points are taken from the infusion completion time.
b.PK samples are to be collected from the arm opposite from infusion site, or alternatively, infusion site will need 
to be flushed with 10 mL of saline.
c.Analytes for PK (mAb) will include LAG525 alone, LAG525 in combination with PDR 001PDR001 in 
combination with LAG525, and analytes for IG will include LAG525 alone, LAG525 in combination with 
PDR001, PDR001 in combination with LAG525
 
e.PK samples to be collected at this timepoint for Phase I patients only
f.For LAG525 in combination with PDR001 patients, the 1 -hour post infusion sample should be taken after each
infusion
g.For patients who switch from single -agent LAG525 to LAG525 in combination with PDR001, immunogenicity 
samples will be collected as unscheduled assessments (instead of their standard PK co llection schedule) on 
Day 1 pre -dose for the first 6 cycles upon switch to the LAG525 in combination with PDR001, and PK blood 
samples will be collected on Days 1 (pre -infusion) and 8 as unscheduled assessments (instead of their 
standard PK collection sche dule) for the first cycle upon switch to the LAG525 in combination with PDR001.   
*Collection of these samples may be stopped if sufficient data have been collected
7.2.3.1 Bioanaly tics
Bioanal ysis for pharmacokinetic studies will employ  2 validated assay s:
1.The a ssay to quantify  LAG525 and PDR001 will be a validated LCMS. 
2.The assay  to quantify  and assess the IG against LAG525 and PDR001 will be using a 
validated homogeneous ELISA. 
7.2.3.2 PK and immunogenicity  sample handling, labeling, and shipping 
instructions
Blood samples should be collected from the arm opposite from the investigational drug 
infusion, or from another site. A total of 5 mL of blood will be collected at each time point. 
For time points when LAG525 or PDR001 (mAb) PK and IG are to be measured, a single blood 
sample will be collected for both IG and PK. After clotting and centrifugation, the resulting 
serum will be separated in aliquots and will be stored frozen until analy sis. Please see the 
Laboratory  Manual for detailed instructions about collection, handling and shipment of samples.
The actual collection date and time of each sample will be entered on the 
Pharmacokinetics/Immunogenicity  Blood Collection eCRF pages.

Novartis Confidential Page 103
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C

Novartis Confidential Page 104
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C

Novartis Confidential Page 105
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C

Novartis Confidential Page 106
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C

Novartis Confidential Page 107
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), s ymptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinica l signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events CRF. 
Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  page of the patient’s CRF. Adverse event monitoring should 
be continued for at leas t 150 day s following the last dose of study  treatment. After initiation of 
new post -treatment antineoplastic therapy , only AEs suspected to be related to study  treatment 
will be collected in the Adverse Events CRF. Adverse events (including lab abnormaliti es that 
constitute AEs) should be described using a diagnosis whenever possible, rather than individual 
underly ing signs and symptoms. When a clear diagnosis cannot be identified, each sign or 
symptom should be reported as a separate Adverse Event.
Adverse events will be assessed according to the Common Terminology  Criteria for Adverse 
Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the 
severit y of mild, moderate, severe, and life -threatening, corresponding to Grades 1 - 4, will be 
used. CTCAE Grade 5 (death) will not be used in this study  but is collected as a seriousness 
criteri on. Information about deaths will be collected through a Death form.

Novartis Confidential Page 108
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
The occurrence of adverse events should be sought by  non-directive questionin g of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by the patient 
(subject) during the screening process or between visits , or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:
1.The severit y grade (CTCAE Grade 1 -4)
2.Its duration (Start and end dates)
3.Its relationship to the study  treatme nt (Reasonable possibility  that AE is related: No, Yes)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5.Whether medication or therap y was give n (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6. Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with seque lae, fatal, unknown)
7.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
and which seriousness criteria have been met.
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, t his action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by use 
of appropriate 
method (for example, as per irRC or as per RECI ST), should not be reported as a serious adverse 
event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.2 Laboratory  test abnormalities
8.1.2.1 Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are consi dered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatment), should be recorded on the Adverse Events CRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory 
abnormalities that meet the criteria for Adverse Events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.

Novartis Confidential Page 109
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A dose hold or medication for the lab abnormality  may be required b y 
the protocol in which case the lab abnormality  would still, by definition, be an adverse event 
and must be reported as such.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent o ne of the outcomes listed above
Requires inpatient hospitalization or prolongation of existing hospitalization,
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:
Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (specify what this includes)
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospital 
admission and involves an event not fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event
Progression of underly ing malignancy  is not reported as an adverse event if it is clearl y 
consistent with the suspected progression of the underly ing cancer as defined by RECIST or 
irRC. Hospi talization due solely  to the progression of underly ing malignancy  should NOT be 
reported as a serious adverse event.
Clinical sy mptoms of progression may  be reported as adverse events if the symptom cannot be 
determined as exclusively  due to the progressio n of the underly ing malignancy , or does not fit 
the expected pattern of progression for the disease under study .
Symptomatic deterioration may  occur in some patients. I n this situation, progression is evident 
in the patient’s clinical symptoms, but is not supported by the tumor measurements. Or, the 
disease progression is so evident that the investigator may elect not to perform further disease 
assessments. In such cases, the determination of clinical progression is based on symptomatic 
deterioration. These determinations should be a rare exception as every  effort should be made 
to document the objective progression of underl ying malignancy .

Novartis Confidential Page 110
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
If there is any  uncertainty  about an adverse event being due only  to the disease under study , it 
should be reported as an AE or SAE.
8.2.2 Reporting
For patients who sign the study  ICF, SAE collection starts at time of main study  informed 
consent whether the patient is a screen failure or not.
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has provided informed consent and until at least 150 days after the patient has stopped 
study  treatment must be reported to Novartis within 24 hours of learning of its occurrence. If a 
patient starts a post treatment antineoplastic therapy, then only  SAEs suspected to be related to 
study  treatment will be reported.
Any additional information for the SAE including complications, progression of the initial SAE, 
and recurrent episodes must be reported as follow -up to the original episode within 24 hours of 
the investigator receiving the follow -up information. An SAE occurring at a different time 
interval or otherwise considered completely  unrelated to a previousl y reported one should be 
reported separatel y as a new event.
Any SAEs experienced after this 150 days period should only be reported to Novartis if the 
investigator suspects a causal relationship to the study  treatment. Recurrent episodes, 
complications, or progression of the initial SAE must be reported as follow -up to the original 
episode within 24 hours of the investigator receiving the follow -up information. An SAE 
occurring at a different time interval or otherwise considered completely  unrelated to a 
previously  reported one should be reported separately  as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English [For Japan: sites participating in FIH studies must complete the SAE report 
form in English], and submit the completed form within 24 hour s to Novartis. Detailed 
instructions regarding the submission process and requirements for signatures are to be found 
in the investigator folder provided to each site.
Follow -up information is submitted in the same way as the original SAE Report. Each re-
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of 
when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, an d whether the patient 
continued or withdrew from study  participation.
If the SAE is not previously  documented in the Investigator’s Brochure and is thought to be 
related to the Novartis study  treatment, an oncology  Chief Medical Office and Patient Safet y
(CMO&PS ) department associate may urgently  require further information from the 
investigator for Health Authority  reporting. Novartis may need to issue an Investigator 
Notification (IN), to inform all investigators involved in any stud y with the same drug t hat this 
SAE has been reported. Suspected Unexpected Serious Adverse Reactions (SUSARs) will be 
collected and reported to the competent authorities and relevant ethics committees in 

Novartis Confidential Page 111
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
accordance with Directive 2001/20/EC or as per national regulatory  require ments in 
participating countries.
8.3 Pregnancies
To ensure patient safet y, each pregnancy occurring while the patient is on study treatment must 
be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications. After the mother has provided consent, these data will be 
collected for up to 12 months after the birth of the child.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to the oncology  CMO&PS . Pregnancy follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the investigational 
treatment and any pregnancy  outcome. Any SAE experienced during pregnancy  must be 
reported on the SAE Report Form.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
8.4 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided [I nvestigator 
Brochure]. Additional safety  information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the stud y as needed.
8.5 Data Monitoring Committee
A data monitoring board will not be used for this study . This is an open -label, Phase I -II stud y 
in which all patients receive either LAG525 or the combination of LAG525 with PDR001. 
Novartis will have access to the Safety  Data on a regular basis. Novartis will host investigator 
teleconferences on a regular basis during the stud y. Further, during the phase I part of the study 
Novartis and the investigators will meet at the end of each treatment cohort to discuss and 
evaluate all of the gathered safet y data. At the dose escalation teleconference the clinical course 
(safet y information including both DLTs and all CTC AE Grade 2 or higher toxicity  data during 
the DLT observation period, and PK data) for each patient in the current dose cohort will be 
described in detail. Updated safet y data on other ongoing patients, including data in later cycles, 
will be discussed as well.
Dose escalation decisions will be based on a clinical synthesis of all relevant available data and 
not solely  on DLT information. Selection of the actual dose for the next cohort of patients will 
be guided by the BLRM with EWOC, and a medical review of relevant clinical, PK and 
laboratory  data. Novartis and the investigator parties must reach a consensus on whether to 
declare MTD, escalate the dose any further, or whether to de-escalate and/or recruit an 
additional cohort of patients at the current do se level Section 10.4.2, Section 10.7.

Novartis Confidential Page 112
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
During the phase II part of the study  Individual patient data will be reviewed on an ongoing 
basis. Overall resp onse rate (ORR) per RECIST V1.1, ORR per irRC and aggregate safety data 
will be monitored quarterly  by the study  team across the duration of the trial. The data review 
and anal ysis will be based on the available investigator reported data in the clinical database at 
that time Section 10.7.
9 Data collection and management
9.1 Data confidentiality
Information 
about study  subjects will be kept confidential and managed under the applicable 
laws and regulations. Thos e regulations require a signed subject authorization informing the 
subject of the following:
What protected health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose tha t information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the subject 
experienced an y new o r worsened AEs) at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
inform ation. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.
Prior to entering key sensitive personally  identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify  that this data is allowed to be collected. If 
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the subject satisfies protocol age requirements and 
to enable appropriate age -related normal ranges to be used in assessing laboratory  test results.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, Novartis 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatm ent is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.

Novartis Confidential Page 113
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to sourc e documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the CRF entries. Novartis monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria and documentation 
of SAEs. Additional checks of the consistency  of the source data with the CRFs are performed 
according to the stud y-specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by the protocol into the Electronic Case Report Forms (eCRF). The eCRFs 
have been built using fully validated secure web-enabled software that conforms to 21 CFR Part 
11 requirements, Investigator site staff will not be given access to the EDC system until they 
have been trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator is responsible for assuring that the data entered into eCRF is complete, 
accurate, and that entry  and updates are performed in a timely  manner.
PK and biomarker (blood, serum, plasma and/or tissue) samples obtained during the course of 
the study  will be collected from the Investigator sites and analyzed by a Novartis designated 
laboratory , contracted central laboratories. ECG data collected during the study  will be 
reviewed and processed centrally b y a sp ecialist CRO. During the course of the study, Novartis 
may decide to have a central review of the radiological assessments performed. In such case, 
the investigator’s staff will be instructed on how to send data from these radiological 
assessments to a Contract Research Organization (CRO) for central review when needed. 
Designated investigational site staff will enter the information required b y the p rotocol into the 
appropriate eCRF and/or designated laboratory  requisition forms. Field monitors will review 
the eCRFs and laboratory  paper requisition forms for accuracy  and completeness and instruct 
site personnel to make any  required corrections or additions. One copy  of the requisition form 
will be forwarded to each analy tical laboratory with the respective sample(s) by the field 
monitor or by the designated investigational site staff; and one copy will be retained at the 
investigational site.
9.4 Database management and quality  control
For studies using eCRFs, Novartis personnel (or designated CRO) will review the data entered 
by investigational staff for completeness and accuracy . Electronic data queries stating the nature 
of the problem and requesting cla rification will be created for discrepancies and missing values 
and sent to the investigational site via the EDC system. Designated investigator site staff is 
required to respond promptly  to queries and to make any  necessary  changes to the data.

Novartis Confidential Page 114
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Concomitan t treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Samples and/or data will be processed 
centrall y and the results will be sent electronically to 
Novartis (or a designated CRO).
For EDC studies, after database lock, the investi gator will receive a CD -ROM or paper copies 
of the patient data for archiving at the investigational site.
10 Statistical methods and data analy sis
It is planned that the data from participating centers in this protocol will be combined, so that 
an adequate number of patients will be available for analysis. Data will be summarized using  
descriptive statistics (continuous data) and/or contingency  table (categorical data) for 
demographic and baseline characteristics, efficacy measurements, safet y measurements an
d all 
relevant PK  measurements. Categorical data will be presented as frequencies and 
percentages. For continuous data, mean, standard deviation, median, minimum, and maximum 
will be presented.
The study  data will be analy zed and reported based on a ll patients’ data of the dose escalation 
and expansion parts up to the time when all patients have potentially  completed at least six 
cycles of treatment or discontinued the study . Any additional data for patients continuing to 
receive study  treatment past the data cutoff date for the primary  Clinical Study  Report, as 
allowed b y the protocol, will be reported at completion of the study as defined in Section 4.3.
The following rules will be followed for r eporting results unless stated otherwise:
For the phase I part data will be anal yzed by Arm and cohorts treated with the same dose or 
dose combination (dose levels and schedules) will be pooled into a single treatment group 
by Arm. All summaries, listings, figures and analyses will be performed by treatment group 
and Arm. Arms to be analy zed are:
Arm A: Single -
agent LAG525
Arm B: Combination L AG525 + PDR001
Arm C: Single- agent LAG525 dose escalation in Japanese patients
For the phase II, all summaries, listings, figures for primary  efficacy  analysis and safet y 
analyses will be presented by  disease group and/or by  dose group for one or more disease 
groups whenever applicable. Patients from the expansion part will be classified according 
to the disease group t
o which they  were assigned at baseline based on the disease t ype.
The different groups to be anal yzed are:
Group 1: single -agent LAG525, NSCLC (naïve to PD -1/PD -L1)
Group 2: single -agent LAG525, Melanoma (naïve to PD -1/PD -L1)
Group 3: single -agent LAG525, Renal cancer (naïve to PD -1/PD -L1)
Group 4: single -agent LAG525, NSCL C (pre -treated with PD -1/PD -L1)
Group 5: single -agent LAG525, Melanoma (pre -treated with PD -1/PD -L1)

Novartis Confidential Page 115
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Group 11: single -agent LAG525, Renal cancer (pre- treated with PD -1/PD -L1)
Group 6: combo LAG525+PDR001, NSCLC (naïve to PD -1/PD -L1)
Group 7: combo LAG525+PDR001, Melanoma (naïve to PD- 1/PD -L1)
Group 8: combo LAG525+PDR001, Renal cancer (naïve to PD- 1/PD -L1)
Group 9: combo LAG525+PDR001, NSCL C (pre -treated with PD -1/PD -L1)
Group 10: combo LAG525+PDR001, Melanoma (pre -treated with PD -1/PD -L1)
Group 12: combo LAG525+PDR001, Renal cancer (pre -treated with PD -1/PD -L1)
Group 13: combo LAG525+PDR001, Mesothelioma (naïve with PD- 1/PD -L1
Group 14: combo LAG525+PDR001, TNBC (naïve with PD- 1/PD -L1)
Group 15: combo LAG525+PDR001, Mesothelioma (pre -treated with PD -1/PD -L1)
Group 16: combo LAG525+PDR001, TNBC (pre- treated with PD -1/PD -L1)
Patients in groups 1to 5 and 11 will receive the recommended dose of single -agent LAG525; 
patients in groups 6to 10 and 12to 16will receive the recommended combination doses of 
LAG525 and PDR001.
Note: patients from the dose escalation and the expansion will not be pooled in any analyses 
unless otherwise specified.
Alternative dosing (i.e. flat dose (mg) and/or dosing schedules (e.g. Q4W)) may be 
implemented during the study  as described in Section 6.1.1. Patients treated with flat dosing 
(mg) or an alternative dosing schedule will be analy zed as separate treatment groups unless 
otherwise specified. Details on dose pooling will be provided in the reporting and anal ysis plan 
(RAP).
Screen failure 
patients are those who signed the informed consent, but never started the study 
treatment for any reason. For these patients, the eCRF data collected will not be included in 
analyses, but will be reported in the CSR as separate listings.
10.1 Analysis Sets
10.1.1 Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all patients who received at least one dose of assigned 
single -agent LAG525, or at least one full or partial dose of assigned combination of study  drugs. 
Patients will be analy zed according to the planned treatment. The FAS will be used for all 
listings of raw data. Unless otherwise specified, the FAS will be the default analy sis set used 
for all anal yses.
10.1.2 Safety
 Set
The Safet y Set includes all patients from the FAS who have received at least one dose of 
LAG525 or PDR001. Patients will be classified according to treatment received, where 
treatment received is defined as:
1.The treatment assigned if it was received at least once, or
2.The first treatment received when starting therap y with study  treatment if the assigned 
treatment was never received.

Novartis Confidential Page 116
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
The safet y set will be used for the safet y summary of the study.
10.1.3 Per-Protocol Set
The Per Protocol Set (PPS) consists of a subset of FAS patients in the phase II part who meet 
the following criteria:
Presence of at least one measurable lesion according to RECI ST 1.1 as per Appendix 1
At least 2 post -baseline tumor assessments (unless di sease progression is observed before 
that time)
Have received the planned treatment
Have not been pre -treated with PD -1 or PD -L1 inhibitors except patients in the pretreated 
groups, who must have previously  received a PD -1-or PD -L1-directed therapy .
Patients will be classified according to planned treatment.
The PPS will be used in the phase II part of the study  only  and will define the patients used in 
the sensitivity  analysis of the primary  endpoint Section 10.4. If the PPS and the FAS are 
identical, then anal yses described b y the PPS below will not be performed.
10.1.4 Dose -Determining A nalysis Set
Single -agent LA G525 escalation cohort
The dose -determining analy sis set (DDS) consists of all patients from the safety set in the dose 
escalation part who either meet the minimum exposure criterion and have sufficient safet y 
evaluations, or have experienced a DLT during C ycle 1.
A patient is considered to have met the minimum exposure criterion if having received at least 
two of the planned 
dose of LAG525 during Cycle 1 for the Q2W schedule or at least one planned 
dose of LAG525 during Cycle 1 for the Q3W and Q4W schedules. Patients who do not 
experience a DLT during the first cycle are considered to have sufficient safety  evaluations if 
they have been observed for ≥ 28 days following the first dose (21 days for patients on Q3W 
dosing schedule), and are considered by both the Sponsor and Investigators to have enough 
safet y data to conclude that a DLT did not occur.
For patients who switch from single agent LAG525 to combination with PDR001, the DLTs 
occurring after the switch will not be considered in the BLRM.
Combination of LA G525 and PDR001 dose escalation cohort
The dose -determining analy sis set (DDS) consists of a ll patients from the safety set in the dose 
escalation part who either meet the minimum exposure criterion and have sufficient safet y 
evaluations, or have experienced a DLT during the first two cy cles.
A patient is considered to have met the minimum exposu re criterion if both of the following 
criteria are met
1. The patient has received at least three doses of LAG525  during the first 2 cy cles for the 
Q2W schedule or at least two doses of LAG525 during the first 2 cy cles for the Q3W and 
Q4W schedules and

Novartis Confidential Page 117
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
2.The p atient has received at least three doses of PDR001  during the first 2 cy cles  for the 
Q2W schedule or at least two doses of PDR001 during the first 2 cy cles  for the Q3W and 
Q4W schedules
Patients who do not experience a DLT during the first two cycles are considered to have 
sufficient safet y evaluations if they have been observed for ≥ 56 days following the first dose 
(42 days for patients on Q3W dosing schedule), and are considered by both the Sponsor and 
Investigators to have enough safet y data to concl ude that a DLT did not occur.
In the dose escalation part, patients who do not meet these minimum safet y evaluation 
requirements will be regarded as ineligible for the DDS and an additional patient(s) may be 
recruited.
10.1.5 Pharmacokinetic analy sis set
The pharmacokinetic analy sis set (PAS) consists of all patients who have at least one blood 
sample providing evaluable PK data. The PAS will be used for all PK analyses.
Note: Patients may  be removed from the estimation of certain PK parameters on an individual 
basis depending on the number of available blood samples. These patients will be identified at 
the time of anal ysis.
10.2 Patient demographics / other baseline characteristics
Demographic and other baseline data (including disease characteristics) will be liste d in detail.
Qualitative data (e.g. performance status) and quantitative data (e.g. weight) will be 
summarized by appropriate descriptive statistics for each treatment group in phase I and for 
each group in phase II.
10.3 Treatments (study  treatment, concomitan t therapies, 
compliance)
For each of LAG525 and PDR001, the actual dose and duration in day s of treatment as well as 
the dose intensity (actual dose received/actual duration) and relative dose intensity (the ratio of 
dose intensity  to planned dose/planned duration) will be listed and summarized by means of 
descriptive statistics by treatment group. Categories for relative dose intensity  of LAG525 or 
PDR001 will be specified as < 0.5, ≥ 0.5 - < 0.75, ≥ 0.75 - < 0.9, ≥ 0.9 - < 1.1 and ≥ 1.1. The 
number and pr oportion of patients within each category  will be presented by  treatment group.
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be listed by  patient and summarized by  ATC term and treatmen t group.
The reason for discontinuation from treatment will be summarized and listed, along with dates 
of first and last dose of LAG525 and PDR001 (if applicable), duration of exposure to L AG525 
and PDR001 (if applicable) and date of discontinuation for ea
ch patient.
Compliance with the protocol will be assessed by the number and proportion of patients with 
protocol deviations. Protocol deviations will be identified prior to database lock and will be 
listed and summarized.

Novartis Confidential Page 118
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
10.4 Primary  Objective
Phase I part:
Toestimate the recommended phase 2 dose (RP2D) or the maximum tolerated dose (MTD) for 
single -agent LAG525 (including for Japanese patients) and for the combination of LAG525 and 
PDR001.
Phase II part:
To assess preliminary  anti-tumor activity  of single -agent LAG525 and combinations of 
LAG525 and PDR001.
10.4.1 Variable
Phase I
For the single -agent LAG525 dose escalation arm, the primary  variable is the incidence of DLTs 
in the first cycle of treatment. For the combo dose escalation arm, the primary  variable is the
incidence of DLTs in the first two cycles of treatment. Estimation of the MTD(s)/RP2D(s) will 
be based upon the estimation by the BLRM of the probability of a DLT in the DLT window for 
patients in the dose-determining set. In addition, the dose-exposure r elationship for LAG525 
and PDR001 will be estimated and used to support dose decisions.
Phase II
The primary  variable is the Overall Response Rate (ORR), defined as the proportion of patients 
with a best overall response of complete response (CR) or partia l response (PR) based on local 
Investigator assessment, as defined in RECI ST v1.1. Estimation of the true ORR in this part of 
the study  will be based upon the observed ORR for patients in FAS, using a Bayesian anal ysis.
10.4.2 Statistical hy pothesis, model, and m ethod of analy sis
Phase I
An adaptive Bayesian logistic regression model (BLRM) guided by the escalation with 
overdose control (EWOC) principle will be used to make dose recommendations and estimate 
the MTD(s)/ RP2D(s) during the dose escalation part of th e study. The BLRM will be fit on the 
dose-limiting toxicity  data (i.e. absence or presence of DLT) during the DLT window 
accumulated throughout the dose escalation to model the dose-toxicity  relationship. In the 
single -agent LAG525 dose escalation part, th e dose- toxicity  (DLT) relationship is described by 
the following 2 -parameter BLRM:
logit(π 1(d1)) = log(α 1) + β 1log(d 1/d1*), α 1>0, β 1>0
where logit(π 1(d1))= log (π1(d1)/(1-π1(d1))), and π1(d1) is the probability  of a DLT at dose d1, 
where d1represents the Q2W dose of LAG525. Doses are rescaled as d1/d1* with reference dose 
d1*=3 mg/kg of LAG525. As a consequence α1is equal to the odds of DLT rate at d1*. Note 
that for a dose equal to zero, the probability  of toxicity  is zero.

Novartis Confidential Page 119
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
For Japanese patients, the same model as above will be applied to guide single agent dose 
escalation decisions. Currentl y available information about the dose-DLT relationships of 
single -agent LAG525 in Arm A will be used to derive informative priors for the BLRM 
parame ters describing the dose-DLT relationships of this agent taking into consideration the 
heterogeneity  between the global population and Japanese patients. For further details on the 
statistical model including the prior specification for the model parameter s refer to in Appendix 
14.4 ( Appendix 4 )
In the dose escalation for the combinations, the dose -toxicity  (DLT) relationship is modeled b y 
a 5-parameter BLRM as follows. Let π 1(d1) be the probability  of DL T if LAG525 is given as a 
single agent at Q2W dose d 1, and π 2(d2) the probability of DLT if PDR001 is given as a single 
agent at Q2W dose of d2. π12(d1,d2) denotes the probability  of DLT if LAG525 is given in 
combination with PDR001 at Q2W dose d1of LAG52 5 and Q2W dose d2of PDR001. The 
possibility  of synergism or antagonism between the safet y profiles of the two drugs is captured 
in the model of odds of DL T rate with combination doses.
LAG525: logit(π 1(d1)) = log(α 1) + β 1log(d 1/d1*)
PDR001: logit(π 2(d2)) = log(α 2) + β 2log(d 2/d2*)
Odds(π 12(d1,d2))) = π 12(d1,d2)/(1- π12(d1,d2))
= exp(η(d 1/d1*)(d 2/d2*))(π 1(d1)+ π 2(d2) – π1(d1) π2(d2))/((1 - π1(d1))(1- π2(d2))),
where logit(π.(d.)) = log[π.(d.)/{1- π.(d.)}], d1* = 3 mg/kg and d 2*= 3 mg /kg are the reference 
doses of LAG525 and PDR001 respectively , α1, α2, β1, β2> 0 and -∞ < η < ∞ is the interaction 
coefficient.
At the time of each LAG525+PDR001 dose escalation analysis, DLT data up to, and including, 
the last completed cohort from the single agent dose escal ation will be included in the 
LAG525+PDR001 BLRM. Single agent LAG525 data will be incorporated directl y into the 
BLRM since this data comes from the same study . Single agent PDR001 data from study 
PDR001X2101 dose escalation will also be utilized. In order to account for between study 
variability , the DLT data obtained from PDR001X2101 will be discounted (e.g.using down -
weighting approach).
The Bayesian approach requires the specification of prior distributions for the model parameters. 
The prior distribu tions for the BLRM are derived based on available pre-clinical data on 
LAG525 and PDR001 and also clinical data for nivolumab and pembrolizumab. For further 
details 
on the BLRM model including the prior specification for the model parameters, and 
examples of hypothetical decisions that may be followed during the dose escalation, refer to 
Appe ndix 14.3.1 .
After each cohort of patients, the posterior distributions for the probabilities of DLT rates at 
different dose levels (or combinations) are obtained. Dose recommendation will be based on 
posterior summaries including the mean, median, standar d deviation, 95%-credible interval, 
and the probability  that the true DLT rate for each dose lies in one of the following categories:
[0,16% ]under -dosing
[16%,33% ]targeted toxicity
[33%,100%] excessive toxicity

Novartis Confidential Page 120
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Dose recommendation will also be guided by the EWOC principle, which mandates the dose 
for the next cohort to have less than 25% chance of excessive toxicity . The final estimate of the 
MTD(s)/ RP2D(s) will also satisfy  this condition.
In case of changes in dosing schedule during dose -escalation, a BLRM of the same functional 
form described in Appendix 14.3.1 will be used to estimate the dose -DLT relationship for each 
schedule based on a newly derived prior incorporating the historical trial data and the on -study 
data from previous schedule. At each time the model is updated, all available information on 
the dose -DLT relationship from all explored dosing schedules will be used. In order to account 
for between schedule variability  in the assessment of a given dosing schedule, the DLT data 
obtained from other explored dosing schedules will be down -weighted. A similar approach will 
be taken in the event of a change from weight -based dosing to flat dosing. A new BLRM with 
the same functional form will be developed to evaluate the flat dose. All DLT data obtained 
from the weight -based dosing cohorts will be incorporated and down- weighted appropriately .
Phase II
A Bayesian design will be used in order to estimate ORR within each group as defined in 
Section 4.1, and it will be used to provide inferential summaries (e.g., mean, median, interval 
probabilities) in relation to the patient population.
Each group will enroll approximately  20 patients, and may be extended to 40 patients if at least 
3 patients have an objective response for NSCL C, renal cancer, melanoma and mesothelioma ,
and at least 2 
patients have an objective response for TNBC as the target ORR is lower for 
TNBC . The primary  analysis will be performed when all patients have completed at least 6 
cycles of treatment or discontinued prior to that time for any  reason.
For a Bayesian design, a prior distribution for the parameter of interest, ORR, must be specified. 
For the current study , the prior clinical assumption for single -agent LAG525 and its 
combination with PDR001 in the selected patient populations is used in order to derive a 
minimally  informative unimodal Beta prior distribution that reflects the level of uncertaint y 
around ORR before starting the current trial. The prior mean ORR is conservativel y set to be 
equal to 20% and the parameters of the minimally informative Beta prior distribution of ORR 
have been set up as follows:
a/(a+b) = 0.2
a = 0.25
b = 1.0
At primary  analysis, this prior distribution w ill be updated with all the data available from the 
patients in the FAS. See sample size estimation in section 10.8.
Single -agent LAG525 (groups 1 to 5 and group 11): Estimates of the ORR for each group 
along with mean, median, standard deviation, and 95% credible intervals and the interval 
probabilities for the true ORR ly ing within [0%, 10%], [10%, 20%], [20%, 30%], [30%, 50%] 
and [50%, 100%] will be presented.
If the observed ORR is equal to or greater than 20% for NSCL C and renal cancer (i.e. ≥ 8 
respon ses (CR or PR) out of 40 patients) and 30% for melanoma (i.e. ≥ 12 responses [CR or 

Novartis Confidential Page 121
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
PR)out of 40 patients), then this will be considered as preliminary  evidence of antitumor 
activity  of single -agent LAG525 in the respective patient groups.
Note that for a sample size of n = 40,
for NSCL C and renal cancer, if the observed ORR is 20% then the posterior probability  of 
true ORR greater than 15% is 78.2%.
for melanoma, if the observed ORR is 30% then the posterior probability  of true ORR 
greater than 20% is 92. 3%.
LAG525+PDR001 combination (groups 6 to 10 and group s 12 to 16): Estimates of the ORR 
for each group along with mean, median, standard deviation, and 95% credible intervals and 
the interval probabilities for the true 
ORR lying within [0%, 20%], [20%, 30%],[30%, 45%], 
[45%, 60%] and [60%, 100%] will be presented.
If the observed ORR is equal to or greater than 30% for NSCL C
, mesothelioma and renal cancer 
(i.e. ≥ 12 responses (CR or PR) of out 40 patients) , 20% for TNBC (i.e. ≥ 8 responses [CR or 
PR] of out 40 patients) and 45% for melanoma (i.e. ≥ 18 responses [CR or PR] of out 40 
patients), then this will be considered as preliminary  evidence of antitumor activity  of 
LAG525+PDR001 in the respective patient group.
Note that for a sample size of n = 40,
forNSCL C
, mesothelioma and renal cancer, if the observed ORR is 30% then the 
posterior probability  of true ORR greater than 20% is 92.3%.
for TNBC, if the observed ORR is 20% then the posterior probability  of true ORR greater 
than 1
0%is 96.6%.
for melanoma, if the observed ORR is 45% then the posterior probability  of true ORR 
greater than 30% is 97.2% (See Section 10.8).
10.4.3 Handling of missing values/censoring/discontinuations
Patients in the dose escalation part who are ineligible for the DDS will be excluded from the 
primary  anal ysis, although their data will be used for all remaining analy ses.
Patients in the phase II part who have BOR of Unknown (UNK) or not assessed (NA) will be 
considered as a treatment failure in the primary  analy sis of ORR. Patients with individual scans 
of UNK or NA will be handled according to RECIST 1.1 as per Appendix 1 .
Other missing data will simply  be noted as missing on appr opriate tables/listings.
10.4.4 Supportive analy ses
For the phase I part, dose-
exposure relationships will be estimated for LAG525 and PDR001 
via Bayesian linear models, in order to further guide the dose recommendation to targeted 
exposure of LAG525 and PDR001. Further details will be given in the RAP.
From the estimation of the two dose- exposure models, the following posterior summaries 
will be derived for each dose combination: Mean, median, standard deviation and 95% -
credible interval for the exposure of both drugs
The probability  that the true AUC (0-336h)after first dose of treatment achieves the target 
exposure.

Novartis Confidential Page 122
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
For the phase II part, the primary  anal ysis on ORR will be repeated using the PPS.
If there are a substantial number of patients receiving palliativ e radiotherap y, sensitivit y 
analyses of ORR will be performed where the tumor response assessments are censored at the 
time of palliative radiotherap y. BOR is determined by the best response recorded between the 
date of first dose of treatment and date of objectively  documented progression or date of 
subsequent anticancer therapy  (including on-treatment palliative radiotherap y of non-target 
lesions), whichever occurs first.
In addition, a Bayesian hierarchical model will be applied to the overall response data from 
patients in the phase II part. Response rates jwill be inferred for j = 1,…, 1 6, for groups 1 to 
16respectivel y.
For each group j, the number of responders follows a binomial distribution
rj~ Bin( n j, j )
We further let the parameters j= log(j/(1
-j)) be either exchangeable with some of the other 
group parameters, or non-exchangeable with any of them. Based on the number of groups in 
the phase II part, we allow for two exchangeability distributions, which, for example, accounts 
for the ca se where some indication show no activity  and some are promising.
Thus, for each group j three possibilities arise, with respective probabilities p j= ( pj1, pj2, pj3 ), 
as follows:
1.With probability  pj1the parameter jfollows a normal distribution with e xchangeabilit y 
parameters 1and 1:
j~ N(1,12)
2.With probability  pj2, jfollows a normal distribution with exchangeability  parameters 
2< 1 and 2:
j~ N(2,22)
3.With remaining probability  pj3 = 1pj1pj2, j follows a weakl y -informative prior 
distribution
j~ N(m w,vw)
For the detailed specifications of mw, vw, the a-priori weights pj(j=1,…,J), and the prior 
distributions for  1, 1, 2, and 2, see Appendix 14.3.2.
At completion of the study, the HM will be updated with all the data available from the patients 
in the FAS by group. All responses and progressions will be determined as per RECIST v1.1.
Single -agent LAG525 (groups 1 to 5 and group 11): For each of the groups where patients 
take the recommended dose of single agent LAG525, estimates of the ORR along with mean, 
median, standard deviation, and 95% credible intervals and the interval probabilities for the true 
ORR ly ing within [0%, 10%], [1 0%, 20%], [20%, 30%], [30%, 50%] and 50%, 100%] will be 
presented.
Success will be declared for the single agent LAG525 if both of the following two criteria are 
fulfilled:

Novartis Confidential Page 123
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
a.the true ORR for the indication has posterior mean of at least 20%, and
b.there is at least 90% posterior probabilit y that the true ORR exceeds 10%.
LAG525+PDR001 combination (groups 6 to 10 and groups 12 to 16):For each of the groups 
where patients take the recommended combination doses of LAG525+PDR001, estimates of 
the ORR along with mean, median, standard deviation, and 95% credible intervals and the 
interval probabilities for the true 
ORR lying within [0%, 20%], [20%, 30%],[30%, 45%], [45%, 
60%] and [60%, 100%] will be presented.
Success will be declared for the combo of LAG525 and PDR001 if both of the following two 
criteria are fulfilled:
a.the true ORR for the indication has posterior mean of at least 30%, and
b.there is at least 90% posterior probabilit y that the true ORR exceeds 20%.
Additional supportive  analyses will be conducted to support the primar y 
objective, if appropriate, and the details of these analy ses will be defined in the RAP.
10.5 Secondary  Objectives
10.5.1 Key secondary  objective(s)
Not applicable
10.5.2 Other secondary  objectives
Analy sis of efficacy  endpoints will be performed separately  for the single agent LAG525 arm 
and for the combo arm using the FAS.
Tumor response will be determined per local investigators’ assessment. All efficacy  secondary 
endpoints will be defined and anal yzed based on tumor assessment by RECIST 1.1 and irRC as 
described in Appendix 14.1 and Appendix 14.2 , respectivel y.
Efficacy  endpoints will include ORR, PFS, DOR and DCR for phase I and phase II. In Phase II 
secondary  endpoints BOR and ORR will be defined based on irRC only. Definitions for these 
endpoints are provided in Appendix 14.1.
For irRC the key difference from RECIST in the assessments of these endpoints is the 
requirement for confirmation of PD no less than 4 weeks after the criteria for PD are first met. 
The date of the first of these two assessments is then the date of confirmed progression. For 
patients who have ended treatm ent without a valid confirmation assessment, for the purposes 
of analy sis the single assessment of PD will be treated as a confirmed PD. A single assessment 
of PD followed by a subsequent assessment of SD or better will be considered as a pseudo -
progressio n, and will not be used for anal ysis.
Individual lesion measurements and overall response assessments will be listed by  patient and 
assessment date. BOR, PFS, DOR and DCR will be listed by  patient.
BOR and ORR will be summarized by treatment group for all patients treated in the phase I 
part. The following anal yses will be presented by  disease group for patients treated in the phase 
II part. 

Novartis Confidential Page 124
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
BOR will be summarized
ORR and DCR will be summarized with an accompany ing [90%] exact binomial 
confidence interval (CI)
For PFS the survival function will be estimated using the Kaplan -Meier (KM) product 
limit method and display ed graphically . Median duration, with a two- sided [90%] CI , and 
25thand 75thpercentiles (Brookmey er et al 1982, Klein et al 1997) will be presented. KM 
estimates of survival proportions at specified time points, along with corresponding [90%] 
CIs (Greenwood’s formula, Kalbfleisch et al 1980) will also be provided.
For DOR, KM est imates may  be provided if sufficient numbers of patients respond.
For patients switching from single -agent LAG525 to combination, efficacy  endpoints (like 
BOR, ORR, PFS, etc.) will be censored at the time the patients start receiving PDR001. All 
efficacy  assessments from these patients will be listed and the assessments performed under 
combination will be flagged .
Any additional anal yses of efficacy  endpoints will be described in the RAP.
10.5.3 Safety  Objectives
10.5.3.1 Analysis set and grouping for the analy ses
For summaries of DLTs, the DDS will be used. For all other safet y analyses, the safet y set will 
be used. All listings and tables will be presented by  treatment group.
The overall observation period will be divided into three mutually  exclusive segments:
1. pre- treatment period: from day  of patient’s informed consent to the day  before first dose 
of study  medication
2. on- treatment period: from day  of first dose of study  medication to 30 day s after last dose 
of study  medication
3.post-treatment period: starting at da y 31 after last dose of study  medication.
Safety  summaries will primarily  be based on all data from the on-treatment period. Following 
last administration of study  medication, adverse events (including serious adverse events), and 
new antineoplastic therap ies are collected for a period of 150 days. Following start of new 
antineoplastic therap y, only study treatment related adverse events will be collected. Select 
summaries of related adverse events will be produced for the overall period starting from the 
first dose of study  treatment until the end of the post
-treatment period.  
For patients who switch from single -agent LAG525 to combination with PDR001 , the on-
treatment period will be defined from day  of first dose of study  medication to 30 day s after the 
last dose of single -
agent LAG525.
All safet y assessments from these patients will be listed and the assessments performed under 
combination will be flagged.
10.5.3.2 Adverse events (A Es)
Primary  summary  tables for AEs have to include only  AEs that started or worsen ed during the 
on-treatment period, the treatment - emergent AEs. Additional select summaries will be 

Novartis Confidential Page 125
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
produced using all related AEs that started or worsened during the combined on- treatment and 
post-treatment periods. 
The incidence of treatment -emergent AEs (new or worsening from baseline) will be 
summarized by system organ class and or preferred term, severit y (based on CTCAE grades), 
type of AE, relation to study  treatment by  treatment group.
Serious adverse events and non-serious adverse events will be ta bulated.
All deaths (on- treatment and post -treatment) will be summarized.
All AEs, deaths and serious adverse events (including those from the pre and post-treatment 
periods) will be listed and those collected during the pre-treatment and post-treatment period 
will be flagged.
10.5.3.3 Laboratory  abnormalities
For laboratory  tests covered by the Common Terminology  Criteria for Adverse Events (CTCAE) 
version 4.03 the study ’s biostatistical and reporting team will grade laboratory  data accordingl y. 
For laboratory  tests covered by  CTCAE, a Grade 0 will be assigned for all non -missing values 
not graded as 1 or higher. Grade 5 will not be used.
For laboratory  tests where grades are not defined by CTCAE, results will be graded by the 
low/normal/high classifications based o n laboratory  normal ranges.
The following by-treatment summaries will be generated separately  for hematology , 
biochemistry  and urinary laboratory  tests:
Frequency  table for newly  occurring on -treatment grades 3 or 4 (see below for details).
Shift tables using CTCAE grades to compare baseline to the worst on -treatment value.
Listing of all clinicall y relevant laboratory data with values flagged to show the 
corresponding CTCAE grades and the classifications relative to the laboratory  normal 
ranges.
In additio n to the above mentioned tables and listings, other exploratory  analy ses, for example 
figures plotting time course of raw or change in laboratory  tests over time or box plots might 
be specified in the RAP.
10.5.3.4 Other safety  data
ECG
shift table baseline to worst on -treatment result for overall assessments
listing of ECG evaluations for all patients with at least one abnormality .
Vital signs
Definitions of notably  abnormal results will be specified in the RAP.
shift table baseline to worst on-treatment result
10.5.3.5 Supportive analy ses for secondary  objectives
Not applicable.

Novartis Confidential Page 126
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
10.5.3.6 Tolerability
Tolerability  of study  treatment will be assessed by  summarizing the number of treatment dose 
interruptions and dose reductions. Reasons for dose interruptions and dose reductions will be 
listed by  patient and summarized ( Section 10.3).
10.5.3.7 Pharmacokinetics
The pharmacokinetic parameters that will be assessed are presen
ted in Table 10-1.
Table 10
-1 Pharmacokinetic Parameters to be analy zed
AUClast The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x 
time x volume -1)
AUCinf The AUC from time zero to infinity (mass x time x volume -1)
Cmax The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration 
after single dose administration (mass x volume -1)
Tmax The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug 
concentration after single dose administration (time)
T1/2 The elimination half -life associated with the terminal slope ( z) of a semi logarithmic 
concentration -time curve (time). Use qualifier for other half-lives
CL The total body clearance of drug from the plasma (volume x time -1)
Vz The apparent volume of distribution during terminal phase (associated with z) (volume)
AR Accumulation Ratio=Cmax (multiple Dose)/Cmax (single dose)
PAS will be used in all pharmacokinetic data analysis and PK summary  statistics. PK data from 
Japanese patients treated on the single agent Japanese dose escalation (Arm C) will be analyzed 
separately .
Pharmacokinetic variables:
The following pharmacokinetic parameters will be determined by profile using non-
compartmental method(s) for single agent LAG525, LAG525 in combination with PDR001and 
PDR001 in combination with L AG525:
AUCinf, AUClast (AUC0 -336h), Cmax, Tmax, T1/2, CL , Vz and accumulation ratio.
Biofluid concentrations will be expressed in mass per volume units. All concentrations below 
the limit of quantitation or missing data will be reported as such in the concentration data listings. 
Concentrations below the limit of quantitation will be treated as zero in summary  statistics.
Descriptive statistics of all pharmacokinetic parameters will include arithmetic and geometric 
mean, median, SD, and CV, geometric CV, minimum and maximum. Zero concentrations will 
not be included in the geometric mean calculation. Since Tmax isgenerally evaluated by a 
nonparametric method, median values and ranges will be given for this parameter.
Summary  statistics will be presented for LAG525 serum concentrations at each scheduled time 
point. Descriptive graphical plots of individual serum concentration versus time profiles and 
mean concentration versus time profiles will be generated.
Missing concentration values will be reported as is in data listings. Concentration values below 
Lower limit of quantitation (LLOQ) will be handled as zero in s ummary  statistics, and reported 
as is in data listings. An
y missing pharmacokinetic parameter data will not be imputed.

Novartis Confidential Page 127
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Further analyses may be conducted using population PK approaches.  
 
Any analyses 
performed will be specified either in the RAP prior to clinical database lock or in a stand -alone 
analysis plan document. Al l analyses will be reported either in the CSR or a stand -alone report.
Dose proportionality
The analysis of dose proportionality  will be conducted for AUC and Cmax of single agent 
LAG525, LAG525 in combination with PDR001 and PDR001 in combination with LAG 525 
using a power model on log-transformed scale. The log-transformed PK parameters will each 
be regressed onto a fixed factor for log (dose). The 90% confidence interval (CI) of the slope 
for each PK parameter will be computed from the model and presented in a summary  table.

Novartis Confidential Page 128
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
10.7 Interim Analysis
No formal interim anal yses are planned.
However, in phase I, the dose-escalation design foresees that decisions based on the current 
data are taken before the end of the study . More precisel y, after each cohort in the dose 

Novartis Confidential Page 129
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
escalation part, the next dose will be chosen depending on the observed data (based on safety , 
tolerability , PK, PD and efficacy  data, guided by the recommendations from the BLRM of DLT 
using EWOC, and recommendations from participating investigators). Details of this procedure 
and the process for communication with I nvestigators are provided in Section 6.2.3 .
Data from patients in the phase II part will be reviewed on an ongoing basis to monitor the 
safet y and tolerability  of the RP2D in that part of the study . The sample size in any of the 16
groups (1 to 16) may be extended to approximately 40 patients, if at least 3 patients have a 
response (PR or CR) per RECI ST 1.1 or irRC for NSCL C, melanoma, renal cancer and 
mesothelioma ,and if at least 2 patients have a response (PR or CR) per RECI ST 1.1 or irRC 
for TNBC. The Investigators and Novartis study  personnel will make the decision based on a 
synthesis of all relevant data available including safety , PK  information.
10.8 Sample size calculation
Phase I
Cohorts of 3 to 6 evaluable patients will be enrolled in the dose-escalation part including at least 
six patients at the MTD(s)/ RP2D(s) level, as described in Section 6.2.3 . Multiple cohorts may  
be sequentiall y enrolled to the same dose level. Additional cohort s of 1 to 6 patients may be 
enrolled at any dose level below the estimated MTD(s)/ RP2D(s) for further elaboration of 
safet y and pharmacokinetic parameters as required. At least 21 patients are required to be 
treated in the single agent LAG525 dose escalat ion (Arm A), at least 12 patients are required to 
be treated in the Japanese dose escalation (Arm C), and at least 15 patients are required to be 
treated in the combo dose escalation (Arm B), for the model to have reasonable operating 
characteristics relating to estimation of the MTD.
Phase II
Approximately  20 patients will be initially  enrolled to each of the groups 1 to 1 6.Any of the 1 6
groups may  be extended to approximately  40 patients.
Single -agent LA G525 (groups 1 to 5 and group 11):
Assume that efficacy  will be claimed for single agent LAG525 if observing an ORR of ≥ 20% 
for NSCL C or renal cancer and ≥ 30% for Melanoma, the operating characteristics of the design 
are provided in Table 10
-2, including the probability  of stopping the enrollment at 20 patients 
(fewer than 3 responses in the first 20 patients), and the probabilities to extend the enrollment 
to 40 patients and observe an ORR ≥ 20% and ≥ 30%.
Specificall y,
If the true ORR is 10% for NSCL C or renal cancer (i.e. in the unacceptable efficacy  
range), the probability  of observing an ORR ≥ 20% is 3.8% (< 5%).
If the true ORR is 15% for melanoma (i.e. in the unacceptable efficacy  range), the 
probability  of observing an ORR ≥ 30% i s 1.2% (< 5%).
If the true ORR is 30% for NSCL C or renal cancer (i.e. in the clinicall y significant 
efficacy  range), the probability  of observing an ORR ≥ 20% is 92.6%.

Novartis Confidential Page 130
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
If the true ORR is 40% for melanoma (i.e. in the clinically  significant efficacy  range) , the 
probability  of observing an ORR ≥ 30% is 92.8%.
Table 10-2 Operating characteristics of the design (single agent LA G525)
True 
ORRProbability  to 
observe <3 
responses in first 
20 patientsGroups 1,3,4 and 11: NSCLC and Renal 
cancer Groups 2 & 5: Melanoma
probability  to observe an ORR ≥ 20%  
with 40 patientsprobability  to observe an ORR 
≥ 30%  with 40 patients
10% 67.7% 3.8% < 0.1%
15% 40.5% 22.5% 1.2%
20% 20.6% 53.1% 8.7%
25% 9.1% 78.8% 28.4%
30% 3.5% 92.6% 55.8%
40% 0.4% 99.5% 92.8%
Combination LA G525+PDR001 (groups 6 to 10 and groups 12to 16 ):
Assume that efficacy  will be claimed for the combination of LAG525 +PDR001 if observing 
an ORR of ≥ 30% for NSCL C or renal cancer or mesothelioma, ≥ 20% for TNBC and ≥ 45% 
for melanoma, the operating characteristics of the design are provided in Table 10 -3and Table 
10-4, including the probability  of stopping the enrollment at 20 patients (fewer than 3 responses 
in the first 20 patients for NSCL C, renal cancer, melanoma and mesothelioma and fewer than 
2 responses in the first 20 patients for TNBC ), and the probabilities to extend the enrollment to 
40 
patients and observe an ORR ≥ 30% (for NSCL C, renal cancer, mesothelioma), 20% (for 
TNBC) and ≥ 45% % (for melanoma) .
Specificall y,
If the true ORR is 15% for NSCL C, m esothelioma or renal cancer (i.e. in the un acceptable 
efficacy  range), the probability  of observing an ORR ≥ 30% is 1.2% (< 5%).
If the true ORR is 30% for melanoma (i.e. in the unacceptable efficacy  range), the 
probability  of observing an ORR ≥ 45% is 3.2% (< 5%).
If the true ORR is 40% for NSCL C
, mesothelioma or renal cancer (i.e. in the clinically  
significant efficacy  range), the probability  of observing an ORR ≥ 30% is 92.8%.
If the true ORR is 55% for melanoma (i.e. in the clinically  significant efficacy  range), the 
probability  of observing an ORR ≥ 45% is 92.3%.
If the true ORR is 10% for TNBC (i.e. in the unacceptable efficacy  range), the probability  
of observing an ORR ≥ 20% is 4.1% (< 5%).
If the true ORR is 30% for TNBC (i.e. in the clinically  significant efficacy  range), the 
probability  ofobserving an ORR ≥ 20% is 94.2%.

Novartis Confidential Page 131
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 10-3 Operating characteristics of the design (LA G525+PDR001)
True 
ORRProbability  to 
observe <3 
responses in first 
20 patientsGroups 6,8,9,12 ,13,15 : NSCLC, r enal and 
mesothelioma Groups 7 & 10: melanoma
probability  to observe an ORR ≥ 30%  
with 40 patientsprobability  to observe an ORR 
≥ 45%  with 40 patients
15% 40.5% 1.2% <0.1%
20% 20.6% 8.7% <0.1%
30% 3.5% 55.8% 3.2%
40% 0.4% 92.8% 31.1%
45% 0.1% 98.2% 56.1%
55% <0.1% >99.9% 92.3%
Table 10-4 Operating characteristics of the design (LA G525 +PDR001)
True 
ORRProbability  to observe <2 
responses in first 20 
patientsGroups  14, 16: TNBC
probability  to observe an ORR ≥ 20%  with 40 patients
10% 39.2% 4.1%
15% 17.6% 24.1%
20% 6.9% 55.7%
25% 2.4% 81.3%
30% 0.8% 94.2%
40% 0.1% 99.8%
10.9 Power for analy sis of key secondary  variables
Not applicable.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/EC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent 
Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is required 
to sign a protocol signature page confirming his/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to Novar tis monitors, auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.

Novartis Confidential Page 132
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providi ng written (witnessed, where 
required by law or regulation), IRB/IEC/REB -approved informed consent or, if incapable of 
doing so, after such consent has been provided by a legally  acceptable representative of the 
patient. In cases where the patient’s repres entative gives consent, the patient should be informed 
about the study  to the extent possible given his/her understanding. If the patient is capable of 
doing so, he/she should indicate assent by personally  signing and dating the written informed 
consent document or a separate assent form.
Informed consent must be obtained before conducting an y stud y-specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
documented in the patient source documents. The date when a subject’s Informed Consent was 
actuall y obtained will be captured in their CRFs.
Novartis will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by Novartis before submission to the IRB/IEC/REB, and a copy of the 
approved version must be provided to the Nova rtis monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
 
 
 
 
 
11.4 Discontinuation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the clinical 
study  agreement. Specific conditions for terminating the study are outlined in 
Secti on 4.4.
11.5 Publication of study  protocol and results
Novartis is committed to following high ethical standards for reporting study  results for its 
innovative medicine, including the timel y communication and publication of clinical trial 
results, whatever 
their outcome. Novartis assures that the key  design elements of this protocol 
will be posted on the publicly  accessible database, e.g. clinicaltrials.gov , before study  start. In 
addition, results of interventional clinical trials in adult patients are posted on 
novartisclinicaltrials.com, a publicl y accessible database of clinical study  results within 1 year 

Novartis Confidential Page 133
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
of study  completion (i.e., L PLV)and those for interventional clinical trials involving pediatric 
patients within 6 months of study  completion .
Novartis follows the ICMJE authorship guidelines (icmje.org) and other specific guidelines of 
the journal or congress to which the publication will be submitted .
Authors will not receive remuneration for their writing of a publication, either directl y from 
Novartis or through the professional medical writing agency . Author(s) may be requested to 
present poster or oral presentation at scientific congress; however, there will be no honorarium 
provided for such presentations.
As part of its commitment to full transparenc y in publications, Novartis supports the full 
disclosure of all funding sources for the study  and publications, as well as any actual and 
potential conflicts of interest of financial and non-financial nature by all authors, including 
medical writing/editor ial support, if applicable.
For the Novartis Guidelines for the Publication of Results from Novartis -sponsored Research, 
please refer to www.novartis.com. 
11.6 Stud y documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality  of subjects. As part of participating in a Novartis -sponsored 
study, each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examine (and when required by  applicable law, to copy ) clinical records for the purposes of 
quality  assurance reviews, audits and evaluation of the study  safety and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospital records, 
clinical and office charts, laboratory  notes, memoranda, subjects’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated instruments, copies or 
transcriptions certified after verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, and subject files and records kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical 
trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal I nvestigator. The study  case report form (CRF) is the primary  data collection 
instrument for the stud y. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported on 
the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF should 
be dated, initialed, and explained (if necessary ) and should not obscure the original entry .For 
electronic CRFs an audit trail will be maintained by  the sy stem. The investigator should retain 
records of the changes and corrections to paper CRFs.

Novartis Confidential Page 134
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by applicable 
regulations and/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.7 Confidentiality  of study  documents and patient records
The investigator must ensure anon ymity of the patients; patients must not be identified by names 
in any documents submitted to Novartis. Signe d informed consent forms and patient enrollment 
log must be kept strictl y confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involved in the 
treatment or evaluation of patients at the site -prior to study  start.
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the study 
to request approval of a protocol deviation, as no 
authorized deviations are permitted. If the 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC/REB it cannot be implemented. All significant protocol 
devia tions will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety  of any patient 
included in this study , even if this action represents a deviation from the protocol. In such cases, 
Novartis should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. UK requires the notification of urgent safet y measures 
within 3 day s) but not later than 10 working days.

Novartis Confidential Page 135
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
13 References (available upon request)
Alley  EW, Lopez J, Santoro A et al (2017). Clinical safet y and activity of pembrolizumab in 
patients with malignant pleural mesothelioma (KEYNOTE -028): preliminary  results from a 
non-randomised, open - label, phase 1b trial. Lancet Oncol 18(5):623-630.
Baitsch L, Legat A, Barbara L et al (2012). Extended co- expression of inhibitory  receptors b y 
human CD8 T -cells depending on differentiation, antigen- specificity  and anatomical 
localization. PLoS One 7(8): e30852.
Brahmer JR, L acchetti C, Schneider BJ et al (2018) Management of Immune -Related Advers e 
Events in Patients Treated With I mmune Checkpoint I nhibitor Therapy : American Societ y of 
Clinical Oncology  Clinical Practice Guideline. J Clin Oncol; Epub ahead of print.
Camisaschi C, Casati C, Rini F et al (2010). LAG -3 expression defines a subset of 
CD4(+)CD25(high)Fox3(+) regulatory  T cells that are expanded at tumor sites. J I mmunol, 
184(11):6545-51
Chen J, Chen Z (2014) The effect of immune microenvironment on the progression and 
prognosis of colorectal cancer. Med Oncol 2014, 31:82
Drake CG, Lipson EJ, Brahmer JR (2014) Breathing new life into immunotherapy : review of 
melanoma, lung and kidney  cancer: Nat Rev Clin Onc 11, 24 -37
Freeman, G. (2008) Structures of PD -1 with its ligands: Sideway s and dancing cheek to 
cheek. Proc Natl Acad Sci USA; 105:30.
Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from 
Immunotherap y: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -up. 
Ann Oncol; 28:iv119–iv142.
Huang CT, Workman CJ, Flies D et al (2004) Roles if LAG -3 inregulatory T cells. I mmunit y 
21(4):503
-13
Huard B, Gaulard P, Faure F et al (1994) Cellular expression and tissue distribution of the 
human LAG -3-encoded protien, an MHC class II ligand. Immunogenetics; 1994;39(3):213 - 7.
Huard B, Mastrangeli R, Prigent P et al (1997) Characterization of the major 
histocompatibility  complex class II binding site on L AG-3 protein. Proc Natl Acad Sci, 
94(11):5744-9
Keir ME, Butte MJ, Freeman GJ, et al (2008) PD- 1 and its ligands in tolerance and immunity . 
Ann Rev I mmunol: 26 :677–704
Kisielow M, Kisielow J, Capoferri -Sollami G et al (2005). Expression of lymphocy te 
activation gene 3 (LAG -3) on B cells induced b y T cells. Eur J I mmunol 35(7):2081 -
8.
Leen AM, Rooney  CM, Foster AE (2007). Improving T cell therapy  for cancer. 2007 : 25:243 -
236
Mangsbo SM, Sandin L C, Anger K, et al (2010) Enhanced tumor eradication by  combining 
CTL A-4 or PD -1 blockade with CpG therap y. J Immunother; 33:225 –35

Novartis Confidential Page 136
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Matsuzaki J, Gnjatic S, Beck A et al (2010) Tumor -infiltrating NY -ESO -1-specific CD8+ T 
cells are negativel y regulated b y LAG3 and PD1 in human ovarian cancer. Proc Natl Acad Sci 
107(17):7875
-7880
Mkrtichy an M, Najjar YG, Raulfs EC, et al (2011) Anti -PD-1 synergizes with 
cyclophosphamide to induce potent anti- tumor vaccine effects through novel m echanisms. 
Eur J I mmunol 41: 2977 –86
Murphy  K (2011) Janeway ’s Immunobiology . 8th ed; New York: Garland Science
Nanda R, Chow LQ, Dees EC et al (2016) Pembrolizumab in Patients With Advanced Triple -
Negative Breast Cancer: Phase Ib KEYNOTE -012 Study .J Clin Oncol 20;34(21):2460 -
7.
Riley  JL (2009) PD -1 signaling in primary  T cells. I mmunol Rev; 229:114-25
Rizvi NA, Hellmann MD, Sry der A, et al (2015) Mutational landscape determines sensitivity  
to PD -1 blockade in non -small cell lung cancer. Science; 348:124.8.
Robert, C Ribas, A, Wolchok, JD, et al. ( 2014) Anti -programmed death -receptor -1 treatment 
with pembrolizumab in ipilimumab
-refractory  advanced melanoma: a randomized dose -
comparison cohort of a phase 1 trial. Lancet 384(9948):1109-17.
Rosenblatt, J, Glotzbecker B, Mills H, et al (2011) PD
-1 blockade b y CT -011, anti -PD-1 
antibody , enhances ex vivo T -cell responses to autologous dendritic cell/my eloma fusion 
vaccine. J I mmunother; 34:409 –18
Scurr M, Ladell K, Besneux M et al (2014). Highl y prevalent colorectal cancer -iniltrating 
LAP+Fox3-T cells exhibit more potent immunosuppressive activit y than Fox3+regulatory  T 
cells. Mucosal Immunol 7(2):428 -
39
Thall PF, Wathen JK, Bekele BN, et al. (2003) Hierarchical Bayesian approaches to phase II
trials in diseases with multiple subty pes. Stat Med; 22:763-80.
Topalian, SL , Sznol, M, McDermott, D, et al. (2014) Survival, durable tumor remission and 
long-term safet y in patients with advanced melanoma receiving nivolumab. J Clin Onc. 32 
(10): 1020-1029
Triebel F, Jitsukawa S, Baixeras E et al (1990) LAG -3, a noval l ymphocy te activation gene 
closely  related to CD4. J Exp Med 171(5):1393 -405
Wang W, Lau R, Yu D, et al (2009) PD -1 blockade reverses the suppression of melanoma 
antigen -specific CTL by  CD4+ CD25(Hi) regulatory  T cells. Int. Immunol. 21, 1065–77
Wolchok JD, Kluger H, Callahan MK, et al (2013) Nivoluman plus ipilimumab in advanced 
melanoma, N Engl J Med; 369(2):122-33
Woo SR, Turnis ME, Goldberg MV, et al (2012) Immune inhibitory  molecules L AG-3 and 
PD-1 synergistically  regulate T -cell function to promote tumoral immune escape, Cancer 
Research, 72(4) :917-27
Workman AL , Delgoffe GM, Green DR et al (2011) Cutting edge: regulatory  T cells do not 
mediate suppression via programmed cell death pathw ays. The Journal of Immunology . 
187(9):4416-4420.
Workman CJ and Vignali DA (2003). The CD4 -related molecule, LAG -3 (CD223), regulates 
the expression of activated T cells. Eur J I mmunol 33(4):970 -9

Novartis Confidential Page 137
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14 Appendices
14.1 Appendix 1: Guidelines for Response, Duration of Overall 
Response, TTF, TTP, Progression -Free Survival  
 (based on RECIST 1.1)
Harmonization of Efficacy  Analysis of Solid Tumor Studies
Document type: TA Specific Guideline
Document status: Version 3.1: 29-Nov-2011
Version 3:0: 19-Oct-2009
Version 2:0: 18-Jan-2007
Version 1:0: 13-Dec- 2002
Release date: 29-Nov-2011
Authors (Version 3.1):  
 
Authors (Version 3):  
Authors (Version 2):  
Authors (Version 1):

Novartis Confidential Page 138
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Glossary
CR Complete response
CRF Case Report Form
CSR Clinical Study Report
CT Computed tomography
DFS Disease -free survival
eCRF Electronic Case Report Form
FPFV First patient first visit
GBM Glioblastoma multiforme
MRI Magnetic resonance imaging
LPLV Last patient last visit
PD Progressive disease
PFS Progression -free survival
PR Partial response
RAP Reporting and Analysis Plan
RECIST Response Evaluation Criteria in Solid Tumors
SD Stable disease
SOD Sum of Diameter
TTF Time to treatment failure
TTP Time to progression
UNK Unknown

Novartis Confidential Page 139
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.1.1 Introduction
The purpose of this document is to provide the working definitions and rules necessary  for a 
consistent and efficient analy sis of efficacy  for oncology  studies in solid tumors. This document 
is based on the RECI ST criteria for tumor responses (Therasse et al 2000 ) and the revised 
RECI ST 1.1 guidelines ( Eisenhauer et al 2009 ).
The efficacy  assessments described in Section 14.1.2 and the definition of best response in 
Section 
14.1.17 are based on the RECIST 1.1 criteria but also give more detailed instructions 
and rules for determination of best response. Section 14.1.18 is summarizing the “time to event” 
varia bles and rules 
which are mainl y derived from internal discussions and regulatory 
consultations, as the RECI ST criteria do not define these variables in detail. Section 14.1.28 of 
this guideline describe s data handling and programming rules. This section is to be referred to 
in the RAP (Reporting and Analy
sis Plan) to provide further details needed for programming.
14.1.2 Efficacy  assessments
Tumor evaluations are made based on RECIST criteria ( Therasse et al 2000 ), New Guidelines 
to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, 
Vol. 92; 205-16 and revised RECI ST guidelines (version 1.1) (Eisenhauer et al 2009) European 
Journal of Cancer; 45:228 -
247.
14.1.3 Definitions
14.1.4 Disease measurability
In order to evaluate tumors throughout a study , definitions of measurability  are required in order 
to classify  lesions appropriately  at baseline. In defining measurability , a distinction also needs 
to be made between nodal lesions (pathological l ymph nodes) and non -nodal lesions.
Measurable disease -the presence of at least one measurable nodal or non -nodal lesion. If the 
measurable disease is restricted to a solitary  lesion, its neoplastic nature should be confirmed 
by cytology /histology .
For patients without measurable disease see Section 14.1.26.
Measurable lesions (both nodal and non-nodal)
Measurable non
-nodal - As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baseline should be no less than double the slice thickness or 10mm 
whichever is greater -e.g. the minimum non -nodal lesion size for CT/MRI  with 5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16 mm.
Lytic bone lesions or mixed ly tic-blastic lesions with identifiable soft tissue components, 
that can be evaluated b y CT/MRI , can be considered as measurable lesions, if the soft 
tissue component meets the definition of measurability .

Novartis Confidential Page 140
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Measurable nodal lesions (i.e. ly mph nodes) - Lymph nodes 15 mm in short axis can be 
considered for selection as target lesions. Lymph nodes measuring 10 mm and <15 mm 
are considered non -measurable. Ly mph nodes smaller than 10 mm in short axis at 
baseline, regardless of the slice thickness, are normal and not considered indicative of 
disease.
Cystic lesions:
Lesions that meet the criteria for radiographicall y defined simple cy
sts (i.e., sphe rical 
structure with a thin, non -irregular, non -nodular and non-enhancing wall, no 
septations, and low CT density  [water -like] content) should not be considered as 
malignant lesions (neither measurable nor non -measurable) since they  are, by  
definition, sim ple cy sts.
‘Cystic lesions’ thought to represent cy stic metastases can be considered as 
measurable lesions, if they meet the definition of measurability  described above. 
However, if noncy stic lesions are present in the same patient, these are preferred for
selection as target lesions.
Non-measurable lesions - all other lesions are considered non -measurable, including small 
lesions (e.g. longest diameter <10 mm with CT/MRI  or pathological ly mph nodes with 
10 to < 15 mm short axis), as well as trul y non -measurable lesions e.g., blastic bone 
lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory  breast 
disease, l ymphangitis cutis/pulmonis, abdominal masses/abdominal organomegaly
identified by  physical exam that is not measurable by  reproducible imaging techniques.
14.1.5 Eligibility  based on measurable disease
If no measurable lesions are identified at baseline, the patient may  be allowed to enter the study 
in some situations (e.g. in P hase III studies where PFS is the primary  endpoint). However, it is 
recommended that patients be excluded from trials where the main focus is on the Overall 
Response Rate (ORR). Guidance on how patients with just non- measurable disease at baseline 
will be evaluated for response and also handled in the statistical analy ses is given in Section 
14.1.26.
14.1.6 Methods of tumor measurement -general guidelines
In this document, the term “contrast” refers to intrave nous (i.v) contrast.
The following considerations are to be made when evaluating the tumor:
All measurements should be taken and recorded in metric notation (mm), using a ruler or 
calipers. All baseline evaluations should be performed as closel y as possibl e to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment.
Imaging
-based evaluation is preferred to evaluation by clinical examination when both 
methods have been used to assess the antitumor effect of a treatment.

Novartis Confidential Page 141
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
For optimal evaluation of patients, the same methods of assessment and technique should 
be used to characterize each identified and reported lesion at baseline and during follow-
up. Contrast
-enhanced CT of chest, abdomen and pelvis should preferably  be perf ormed 
using a 5 mm slice thickness with a contiguous reconstruction algorithm. CT/MRI  scan 
slice thickness should not exceed 8 mm cuts using a contiguous reconstruction algorithm. 
If, at baseline, a patient is known to have a medical contraindication to CT contrast or 
develops a contraindication during the trial, the following change in imaging modalit y will 
be accepted for follow up: a non- contrast CT of chest (MRI  not recommended due to 
respiratory  artifacts) plus contrast-enhanced MRI of abdomen and pelvis.
A change in methodology  can be defined as either a change in contrast use (e.g. keeping 
the same technique, like CT, but switching from with to without contrast use or vice -
versa, 
regardless of the justification for the change) or a change in technique (e.g. from CT to 
MRI , or vice -versa), or a change in an y other imaging modality . A c hange in methodology  
will r esult by default in a UNK overall lesion response assessment . However, another 
response assessment than the Novartis calculated UNK response may be accepted from the 
investigator or the central blinded reviewer if a definitive response assessment can be 
justified, based on the available information.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease) . New lesions on the basis of FDG -PET imaging can be identified according 
to the following algorithm:
Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion.
No FDG -PET at baseline with a positive FDG- PET a t follow -up:
If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed by  
CT, this is PD.
If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow -up CT are needed to determine if the re is trul y progression occurring at 
that Site (if so, the date of PD will be the date of the initial abnormal CT scan).
If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT 
that is not progressing on the basis of the an atomic images, this is not PD.
Chest x -ray: Lesions on chest x -ray are acceptable as measurable lesions when they  are 
clearl y defined and surrounded by aerated lung. However, CT is preferable.
Ultrasound : When the primary  endpoint of the study  is objective response evaluation, 
ultrasound (US) should not be used to measure tumor lesions. I t is, however, a possible 
alternative to clinical measurements of superficial palpable l ymph nodes, subcutaneous 
lesions and thy roid nodules. US might also be useful to confirm the complete 
disappearance of superficial lesions usually  assessed by  clinical examination.

Novartis Confidential Page 142
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Endoscopy and laparoscopy : The utilization of endoscopy  and laparoscopy  for objective 
tumor evaluation has not y et been full y and widely validated. Their uses in this specific 
context require sophisticated equipment and a high level of expertise that may  only be 
available in some centers. Therefore, the utilization of such techniques for objective tumor 
response should be restricted to validation purposes in spe cialized centers. However, such 
techniques can be useful in confirming complete pathological response when biopsies are 
obtained.
Tumor markers : Tumor markers alone cannot be used to assess response. However, 
some disease specific and more validated tumor markers (e.g. CA -125 for ovarian cancer, 
PSA for prostate cancer, alpha -FP, LDH and Beta- hCG for testicular cancer) can be 
integrated as non -target disease. If markers are initially  above the upper normal limit they  
must normalize for a patient to be consi dered in complete clinical response when all 
lesions have disappeared.
Cytology and histology: Cy tology  and histology  can be used to differentiate between PR 
and CR in rare cases (i.e., after treatment to differentiate between residual benign lesions 
and r esidual malignant lesions in tumor ty pes such as germ cell tumors). Cytologic 
confirmation of neoplastic nature of an y effusion that appears or worsens during treatment 
is required when the measurable tumor has met the criteria for response or stable disea se. 
Under such circumstances, the cy tologic examination of the fluid collected will permit 
differentiation between response and stable disease (an effusion may  be a side effect of the 
treatment) or progressive disease (if the neoplastic origin of the fluid is confirmed).
Clinical examination : Clinical lesions will only  be considered measurable when they  are 
superficial (i.e., skin nodules and palpable l ymph nodes). For the case of skin lesions, 
documentation by  color photography , including a ruler to estima te the size of the lesion, is 
recommended.
14.1.7 Baseline documentation of target and non -target lesions
For the evaluation of lesions at baseline and throughout the study , the lesions are classified at 
baseline as either target or non -target lesions:
Target les ions: All measurable lesions (nodal and non-nodal) up to a maximum of five 
lesions in total (and a maximum of two lesions per organ), representative of all involved 
organs should be identified as target lesions and recorded and measured at baseline. Target
lesions should be selected on the basis of their size (lesions with the longest diameter) and 
their suitability  for accurate repeated measurements (either by  imaging techniques or 
clinically ). Each target lesion must be uniquely  and sequentially  numbered on the CRF 
(even if it resides in the same organ).
Minimum target lesion size at baseline
Non-nodal target : Non- nodal target lesions identified by  methods for which slice 
thickness is not applicable (e.g. clinical examination, photograph y) should be at lea st 10 
mm in longest diameter. See Section 14.1.4.
Nodal target : See 
Section 14.1.4 .
A sum of diameters (long axis for non -nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of 

Novartis Confidential Page 143
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
diameters will be used as reference by which to characterize the objective tumor response. Each 
target lesion identified at baseli ne must be followed at each subsequent evaluation and 
documented on eCRF.
Non-target lesions : All other lesions are considered non- target lesions, i.e. lesions not 
fulfilling the criteria for target lesions at baseline. Presence or absence or worsening of 
non-target lesions should be assessed throughout the study ; measurements of these lesions 
are not required. Multiple non -target lesions involved in the same organ can be assessed as 
a group and recorded as a single item (i.e. multiple liver metastases). Ea ch non -target 
lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.
14.1.8 Follow -up evaluation of target and non -target lesions
To assess tumor response, the sum of diameters for all target lesions will be calculate d (at 
baseline and throughout the study ). At each assessment response is evaluated first separately 
for the target (Table 14-1) and non-target lesions (Table 14 -2) identified at baseline. These 
evaluations are then used to calculate the overall lesion response considering both the target and 
non-target lesions together ( Table 14 - 3) as well as the p resence or absence of new lesions.
14.1.9 Follow -up and recording of lesions
At each visit and for each lesion the actual date of the scan or procedure which was used for the 
evaluation of each specific lesion should be recorded. This applies to target and non-target 
lesions as well as new lesions that are detected. At the assessment visit all of the separate lesion 
evaluation data are examined by the investigator in order to derive the overall visit response. 
Therefore all such data applicable to a particular vis
it should be associated with the same 
assessment number.
14.1.10 Non- nodal lesions
Following treatment, lesions may  have longest diameter measurements smaller than the image 
reconstruction interval. Lesions smaller than twice the reconstruction interval are subjec t to 
substantial “partial volume” effects (i.e., size may be underestimated because of the distance of 
the cut from the longest diameter; such lesions may appear to have responded or progressed on 
subsequent examinations, when, in fact, they  remain the sam e size).
If the lesion has completely disappeared, the lesion size should be reported as 0 mm.
Measurements of non-nodal target lesions that become 5 mm or less in longest diameter are 
likely  to be non -reproducible. Therefore, it is recommended to report a default value of 5 mm, 
instead of the actual measurement. This 
default value is derived from the 5 mm CT slice 
thickness (but should not be changed with varying CT slice thickness). Actual measurement 
should be given for all lesions larger than 5 mm in longest diameter irrespective of slice 
thickness/reconstruction interval.
In other cases where the lesion cannot be reliably measured for reasons other than its size (e.g., 
borders of the lesion are confounded by neighboring anatomical structures), no measur ement 
should be entered and the lesion cannot be evaluated.

Novartis Confidential Page 144
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.1.11 Nodal lesions
A nodal lesion less than 10 mm in size by short axis is considered normal. Lym ph nodes are not 
expected to disappear completely , so a “non- zero size” will alway s persist.
Measurements of nodal target lesions that become 5 mm or less in short axis are likely  to be 
non-reproducible. Therefore, it is recommended to report a default value of 5 mm, instead of 
the actual measurement. This default value is derived from the 5 mm CTslice thickness 
(but 
should not be changed with varying CT slice thickness).Actual measurement should be given 
for all lesions larger than 5 mm in short axis irrespective of slice thickness/reconstruction 
interval.
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be 
considered normal for response purpose determination. The lymph node measurements will 
continue to be recorded to allow the values to be included in the sum of diameters for target 
lesions, which may  be required subsequentl y for response determination.
14.1.12 Determination of target lesion response
Table 14-1 Response criteria for target lesions
Response Criteria Evaluation of target lesions
Complete Response (CR): Disappearance of all non -nodal target lesions. In addition, any pathological lymph 
nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1
Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as 
reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, 
taking as reference the smallest sum of diameter of all target lesions recorded at 
or after baseline. In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in l esions 
which would qualify for PD.
Unknown (UNK) Progression has not been documented and one or more target lesions have not 
been assessed or have been assessed using a different method than baseline.3
1. SOD for CR may not be zero when nodal lesions are part of target lesions
2. Following an initial CR, a PD cannot be assigned if all non -nodal target lesions are still not present and all nodal 
lesions are <10 mm in size. In this case, the target lesion response is CR
3. Methodology change See Section 14.1.6 .
Notes on target lesion response
Reappearance of lesions: I f the lesion appears at the same anatomical location where a target 
lesion had previousl y dis appeared, it is advised that the time point o f lesion disappearance (i.e., 
the “0 mm” recording) be re-evaluated to make sure that the lesion was not actually  present 
and/or not visualized for technical reasons in this previous assessment. If it is not possible to 
change the 0 value, then the investi gator/radiologist has to decide between the following three 
possibilities:
The lesion is a new lesion, in which case the overall tumor assessment will be considered 
as progressive disease
The lesion is clearl y a reappearance of a previously  disappeared lesion, in which case the 
size of the lesion has to be entered in the CRF and the tumor assessment will remain based 

Novartis Confidential Page 145
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
on the sum of tumor measurements as presented in Table 14-1 above (i.e., a PD will be 
determined if there is at least 20% increase in the sum of diameters of allmeasured target 
lesions, taking as reference the smallest sum of diameters of all target lesions recorded at or 
after baseline with at least 5 mm increase in the absolute sum of the diameters). Proper 
documentation should be available to support this decision. This applies to patients who 
have not achieved target response of CR. For patients who have achieved CR, plea se refer 
to last bullet in this section.
For those patients who have onl y one target lesion at baseline, the reappearance of the 
target lesion which disappeared previousl y, even if still small, is considered a PD.
Missing measurements : In cases where measurements are missing for one or more target 
lesions it is sometimes still possible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for 5 target lesions at baseline is 
100 mm at baseline and the sum of di ameters for 3 of those lesions at a post -baseline visit 
is 140 mm (with data for 2 other lesions missing) then a PD should be assigned. However, 
in other cases where a PD cannot definitel y be attributed, the target lesion response would 
be UNK.
Nodal lesio n decrease to normal size : When nodal disease is included in the sum of target 
lesions and the nodes decrease to “normal” size they  should still have a measurement 
recorded on scans. This measurement should be reported even when the nodes are normal 
in order not to overstate progression should it be based on increase in the size of nodes.
Lesions split : In some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub -lesions. 
When this occurs, the diameters (long axis - non- nodal lesion, short axis -nodal lesions) of 
the two split lesions should be added together and the sum recorded in the diameter field on 
the case report form under the original lesion number. This valu e will be included in the 
sum of diameters when deriving target lesion response. The individual split lesions will not 
be considered as new lesions, and will not automatically  trigger a PD designation.
Lesions coalesced : Conversel y, it is also possible tha t two or more lesions which were 
distinctly  separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may  be maintained that would aid in obtaining diameter 
measurements of each individual lesion. I f the lesions have trul y coalesced such that they 
are no longer separable, the maximal diameters (long axis - non- nodal lesion, short axis -
nodal lesions) of the “merged lesion” should be used when calculating the sum of 
diameters for target lesions. On the
case report form, the diameter of the “merged lesion” 
should be recorded for the size of one of the original lesions while a size of “0”mm should 
be entered for the remaining lesion numbers which have coalesced.

Novartis Confidential Page 146
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
The measurements for nodal lesions , even if less than 10 mm in size, will contribute to 
the calculation of target lesion response in the usual way  with slight modifications.
Since lesions less than 10 mm are considered normal, a CR for target lesion response 
should be assigned when all nodal target lesions shrink to less than 10 mm and all 
non-nodal target lesions have disappeared.
Once a CR target lesion response has been assigned a CR will continue to be 
appropriate (in the absence of missing data) until progression of target lesions.
Following a 
CR, a PD can subsequently  only be assigned for target lesion response if 
either a non- nodal target lesion “reappears” or if any  single nodal lesion is at least 10 
mm and there is at least 20% increase in sum of the diameters of all nodal target 
lesions rel ative to nadir with at least 5 mm increase in the absolute sum of the 
diameters.
14.1.13 Determination of non -target lesion response
Table 14-2 Response criteria for non -target lesio ns
Response Criteria Evaluation of non -target lesions
Complete Response (CR): Disappearance of all non -target lesions. In addition, all lymph nodes assigned a 
non-target lesions must be non -pathological in size (< 10 mm short axis)
Progressive Disease (PD): Unequivocal progression of existing non -target lesions.1
Non-CR/Non-PD: Neither CR nor PD
Unknown (UNK) Progression has not been documented and one or more non -target lesions have 
not been assessed or have been assessed using a different method than baseline.
1. Although a clear progression of non -target lesions only is exceptional, in such circumstances, the opinion of the 
treating physician does prevail and the progression status should be confirmed later on by the review panel (or 
study chair).
Notes on non -target lesion response
The response for non- target lesions is CRonly if all non- target non- nodal lesions which 
were evaluated at baseline are now all absent and with all non -target nodal lesions 
returned to normal size (i.e. < 10 mm). If an y of the non -target lesions are still present, or 
there are an y abnormal nodal lesions (i.e. 10 mm) the response can onl y be ‘ Non-
CR/Non -PD’ unless an y of the lesions was not assessed (in which case response is UNK ) 
or there is unequivocal progression of the non -target lesions (in which case response is 
PD).
Unequivocal progression : To achieve “unequivocal progression” on the basis of non -
target disease there must be an overall level of substantial worsening in non -target disease 
such that, even in presence of CR, PR or SD in target disease, the overall tumor burden 
has increased sufficiently to merit discontinuation of therap y. A modest “increase” in the 
size of one or more non- target lesions is usually  not sufficient to qualify  for unequivocal 
progression status. The designation of overall progression solely  on the basis of change in 
non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare. In order for a PD to be assigned on the basis of non -
target lesions, the increase in the 
extent of the disease must be substantial even in cases where the re is no measurable 
disease at baseline. If there is unequivocal progression of non- target lesion(s), then at least 

Novartis Confidential Page 147
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
one of the non -target lesions must be assigned a status of “Worsened”. Where possible, 
similar rules to those described in Section 14.1.12 for assigning PD following a CR for the 
non-target lesion response in the presence of non -target lesions nodal lesions should be 
applied.
14.1.14 New lesions
The appearance of a new lesion is alway s associated w ith Progressive Disease (PD) and has to 
be recorded as a new lesion in the New Lesion CRF page.
If a new lesion is 
equivocal , for example because of its small size, continued therap y and 
follow -up evaluation will clarify  if it represents truly  new disease. If repeat scans confirm 
there is definitel y a new lesion, then progression should be declared using the date of the 
first observation of the lesion.
If new disease is observed in a region which was not scanned at baseline or where the 
particular baseline scan is not available for some reason, then this should be considered as 
a PD. The one exception to this is when there are no baseline scans at all available for a 
patient in which case the response should be UNK, as for an y of this patient's assessment 
(see Section 14.1.15).
A lymph node is considered as a “new lesion” and, therefore, indicative of progressive 
disease if the short axis increases in size to 10 mm for the first time in the study  plus 5 
mm absolute increase.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). See 
Section 14.1.6 .
14.1.15 Evaluation of overall lesion response
The evaluation of overall lesion response at each assessment is a composite of the target lesion 
response, non-target lesion response and presence of new lesions as shown below in
Table 14
-3.
Table 14-3 Overall lesion response at each assessment
Target lesions Non-target lesions New LesionsOverall
lesion response
CR CR No CR1
CR Non-CR/Non-PD3No PR
CR, PR, SD UNK No UNK
PR Non-PD and not UNK No PR1
SD Non-PD and not UNK No SD1, 2
UNK Non-PD or UNK No UNK1
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1. This overall lesion response also applies when there are no non -target lesions identified at baseline.
2. Once confirmed PR was achieved, all these assessments are considered PR.
3. As defined in Section 14.1.8 .
If there are no baseline scans available at all, then the overall lesion response at each assessment 
should be considered Unknown (UNK).

Novartis Confidential Page 148
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
If the evaluation of any of the target or non-target lesions identified at baseline could not be 
made during follow -up, the overall status must be ‘unknown’ unless progression was seen.
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspirate/biopsy ) to confirm the CR.
14.1.16 Efficacy  definitions
The following definitions primarily  relate to patients who have measurable disease at baseline. 
Section 14.1.26 outlines the special considerations that need to be given to patients with no 
measurable disease at baseline in order to appl y the same concepts.
14.1.17 Best overall response
The best overall response is the best response recorded 
from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started) . In general, the patient's best response assignment will depend on 
the achievement of both measurement and confirmation criteria.
The best overall response will usually  be determined from response assessments undertaken 
while on treatment. However, if an yassessments occur after treatment withdrawal the protocol 
should specificall y describe if these will be included in the determination of best overall 
response and/or whether these additional assessments will be required for sensitivity  or 
supportive anal yses. As a default, an y assessments taken more than 150 days after the last dose 
of study  treatment will not be included in the best overall response derivation. If any alternative 
cancer therapy  is taken while on study  any subsequent assessments would ordinarily  be 
excluded from the best overall response determination. If response assessments taken after 
withdrawal from study  treatment and/or alternative therap y are to be included in the main 
endpoint determination, then this should be described and justifi ed in the protocol.
Where a study  requires confirmation of response (PR or CR), changes in tumor measurements 
must be confirmed by  repeat assessments that should be performed not less than 4 weeks after 
the criteria for response are first met.
Longer intervals may  also be appropriate. However, this must be clearl y stated in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear 
when reporting the outcome of such studies that the responses are not confirmed.
-For non -randomized trials where response is the primary  endpoint, confirmation is 
needed.
-For trials intended to support accelerated approval, confirmat ion is needed
For all other trials, confirmation of response may  be considered optional.
The best overall response for each patient is determined from the 
sequence of overall (lesion) 
responses according to the following rules:
CR = at least two determinations of CR at least 4 weeks apart before progression where 
confirmation required or one determination of CR prior to progression where confirmation 
not required

Novartis Confidential Page 149
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
PR = at least two determinations of PR or better at least 4 weeks apart before progression 
(and not qualify ing for a CR) where confirmation required or one determination of PR 
prior to progression where confirmation not required
SD = at least one SD assessment (or better) > 6 weeks after randomization/start of 
treatment (and not qualifying for CR or PR).
PD = progression  12 weeks after randomization/ start of treatment (and not qualify ing 
for CR, PR or SD).
UNK = all other cases (i.e. not qualify ing for confirmed CR or PR and without SD after 
more than 6 weeks or early  progression within the first 12 weeks)
Overall lesion responses of CR must stay the same until progression sets in, with the exception 
of a UNK status. A patient who had a CR cannot subsequently  have a lower status other than a 
PD, e.g. PR or SD, as this would imply  a progression based on one or more lesions reappearing, 
in which case the status would become a PD.
Once an overall lesion response of PR is observed (which may have to be a confirmed PR 
depending on the study) this assignment must stay the same or improve over time until 
progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is required, if a patient has a single PR (30% reduction of tumor 
burden compared to baseline) at one assessment, followed by  a
 <30% reduction from baseline 
at the next assessment (but not 20% increase from previous smallest sum), the objective status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (or UNK) until progression is docum ented or the lesions totally  
disappear in which case a CR assignment is applicable. In studies where confirmation of 
response is not required after a single PR the overall lesion response should still be considered 
PR (or UNK) until progression is document ed or the lesion totally  disappears in which case a 
CR assignment is applicable.
Example: In a case where confirmation of response is required the sum of lesion diameters is 
200 mm at baseline and then 140 mm - 150 mm - 140 mm - 160 mm - 160 mm at the subsequent 
visits. Assuming that non -target lesions did not progress, the overall lesion response would be 
PR -SD - PR -PR -PR. The second assessment with 140 mm confirms the PR for this patient. 
All subsequent assessments are considered PR even if tumor measurements decrease only by 
20% compared to baseline (200 mm to 160 mm) at the following assessments.
If the patient progressed but continues study  treatment, further assessments are not considered 
for the determination of best overall response.
Note : these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates.
The best overall response for a patient is alway s calculated, based on the sequence of overall 
lesion responses. However, the overa ll lesion response at a given assessment may  be provided 
from different sources:

Novartis Confidential Page 150
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Investigator overall lesion response
Central Blinded Review overall lesion response
Novartis calculated overall lesion response (based on measurements from either 
Investigator or Central Review)
The primary  analysis of the best overall response will be based on the sequence of 
investigator/central blinded review/calculated (investigator)/calculated (central) overall lesion 
responses.
Based on the patients’ best overall response during the study , the following rates are then 
calculated:
Overall response rate (ORR) is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some protocols or publications.
Disease control rate (DCR) is the proportion of patients with a best overall response of CR or 
PR or SD.
Another approach is to summarize the progression rate at a certain time point after baseline. In 
this case, the following definition is used:
Early progression rate (EPR) is the proportion of patients with progressive disease within 
8weeks of the start of treatment.
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study  specific. EPR is used for the multinomia l designs of Dent and Zee (2001) and 
counts all patients who at the specified assessment (in this example the assessment would be at 
8 weeks ± window) do not have an overall lesion response of SD, PR orCR. Patients with an 
unknown (UNK) assessment at that time point and no PD before, will not be counted as early 
progressors in the anal ysis but may  be included in the denominator of the EPR rate, depending 
on the analy sis population used. Similarly  when examining overall response and disease control, 
patients with a best overall response assessment of unknown (UNK) will not be regarded as 
“responders” but may be included in the denominator for ORR and DCR calculation depending 
on the anal ysis population (e .g. populations based on an ITT approach).
14.1.18 Time to event variables
The protocol should state which of the following variables is used in that study.
14.1.19 Progression -free survival
Usually  in all Oncology  studies, patients are followed for tumor progression after 
discontinuation of study  medication for reasons other than progression or death. If this is not 
used, e.g. in Phase I or II studies, this should be clearl y stated in the protocol. Note that 
randomized trials (preferably blinded) are recommended where PFS is to be the primary 
endpoint.
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progression- free survival is censored at the date of last adequate 
tumor assessment.

Novartis Confidential Page 151
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
 
 
 
 
 
14.1.21 Time to progression
Some studies might consider only death related to underly ing cancer as an event which indicates 
progression. In this case the variable “Time to progression” might be used. TTP is defined as 
PFS except for death unrelated to underl ying cancer.
Time to progression (TTP) is the time from date of randomization/start of treatment to the 
date of event defined as the first documented progression or death due to underly ing cancer. If 
a patient has not had an event, time to progression is censored at the date of last adequate tumor 
assessment.
14.1.22 Time to treatment failure
This endpoint is often appro priate in studies of advanced disease where early discontinuation is 
typicall y related to intolerance of the study  drug. In some protocols, time to treatment failure 
may be considered as a sensitivity  analysis for time to progression. The list of discontin uation 
reasons to be considered or not as treatment failure may be adapted according to the specificities 
of the study  or the disease.
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest of date of progression, date of death due to any cause, or date of discontinuation due 
to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to treatment 
failure for patients who did not experience treatment failure will be censored at last adequate 
tumor assessment.
14.1.23 Duration of response
The analy sis of the following variables should be performed with much caution when restricted 
to responders since treatment bias could have been introduced. There have been reports where 
a treatment with a significantly  higher response rate had a significantly shorter duration of 
response but where this probabl y primaril y reflected selection bias which is explained as 
follows: I t is postulated that there are two groups of patients: a good risk group and a poor r isk 
group. Good risk patients tend to get into response readily  (and relativel y quickly ) and tend to 
remain in response after they  have a response. Poor risk patients tend to be difficult to achieve 
a response, may have a longer time to respond, and tend to relapse quickly  when they do respond. 
Potent agents induce a response in both good risk and poor risk patients. Less potent agents 
induce a response mainly in good risk patients only. This is described in more detail by Morgan 
(1988) .

Novartis Confidential Page 152
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
It is recommended that an analysis of all patients (both responders and non-responders) be 
performed whether or not a “responders onl y” descriptive anal ysis is presented. An analy sis of 
responders should only be performed to provide descriptive statistics and even then interpreted 
with caution by evaluating the results in the context of the observed response rates. If an 
inferential comparison between treatments is required this should only be performed on all 
patients (i.
e. not restricting to “responders” only ) using appropriate statistical methods such as 
the techniques described in Ellis et al (2008) . It should also be stated in the protocol if duration 
of response is to be calculated in addition for unconfirmed response.
For summary  statistics on “responders” only the following definitions are appropriate. (Specific 
definitions for an all-patient analysis of these endpoints are not appropriate since the status of 
patients throughout the study  is usuall y taken into account in the anal ysis).
Duration of overall response (CR or PR) : For patients with a CR or PR (which may  have to 
be confirmed the start date is the date of first documented response (CR or PR) and the end date 
and censoring is defined the same as that for time to progression.
The following two durations might be calculated in addition for a large Phase III study  in which 
a reasonable number of responders is seen.
Duration of overall complete response (CR ): For patients with a CR (which may  have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for time to progression.
Duration of stable disease (CR/PR/SD) : For patients with a CR o r PR (which may have to be 
confirmed) or SD the start and end date as well as censoring is defined the same as that for time 
to progression.
14.1.24 Time to response
Time to overall response (CR or PR) is the time between date of randomization/start of 
treatment u ntil first documented response (CR or PR). The response may  need to be confirmed 
depending on the ty pe of study  and its importance. Where the response needs to be confirmed 
then time to response is the time to the first CR or PR observed.
Although an analysis on the full population is preferred a descriptive analysis may be performed 
on the “responders” subset only, in which case the results should be interpreted with caution 
and in the context of the overall response rates, since the same kind of selection bias may be 
introduced as described for duration of response in Section 14.1.23. I t is recommended that an 
analysis of all patients (both responders and non-responders) be performed whether or not a 
“responders only” descriptive analysis is presented. Where an inferential statistical comparison 
is required, then all patients should definitely  be included in the analysis to ensure the statistical 
test is valid. For anal ysis including all patients, patien ts who did not achieve a response (which 
may have to be a confirmed response) will be censored using one of the following options.

Novartis Confidential Page 153
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
at maximum follow -up (i.e. FPFV to LPLV used for the anal ysis) for patients who had a 
PFS event (i.e. progressed or died due to an y cause). In this case the PFS event is the 
worst possible outcome as it means the patient cannot subsequently  respond. Since the 
statistical analy sis usually  makes use of the ranking of times to response it is sufficient to 
assign the worst possible censoring time which could be observed in the study  which is 
equal to the maximum follow- up time (i.e. time from FPFV to L PLV)
at last adequate tumor assessment date otherwise. In this case patients have not y et 
progressed so they  theoretically  still have a chance of responding
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment until first documented CR. Similar analy sis considerations including (if appropriate) 
censoring rules apply  for this endpoint descri bed for the time to overall response endpoint.
14.1.25 Definition of start and end dates for time to event variables
Assessment date
For each assessment (i.e. evaluation number), the assessment date is calculated as the latest of 
all measurement dates (e.g. X -ray, CT-scan) if the overall lesion response at that assessment is 
CR/PR/SD/UNK. Otherwise -if overall lesion response is progression -the assessment date is 
calculated as the earliest date of all measurement dates at that evaluation number.
Start dates
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start will be used as the start date.
For the calculation of duration of response the fol lowing start date should be used:
Date of first documented response is the assessment date of the first overall lesion 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively , when this status i s later confirmed.
End dates
The end dates which are used to calculate ‘time to event’ variables are defined as follows:
Date of death (during treatment as recorded on the treatment completion page or during 
follow -up as recorded on the study  evaluation completion page  
).
Date of progression is the first assessment date at which the overall lesion response was 
recorded as progressive disease.
Date of last adequate tumor assessment is the date the last tumor assessment with over all 
lesion response of CR, PR or SD which was made before an event or a censoring reason 
occurred. In this case the last tumor evaluation date at that assessment is used. If no post -
baseline assessments are available (before an event or a censoring reason occurred) the 
date of randomization/start of treatment is used.
Date of next scheduled assessment is the date of the last adequate tumor assessment plus 
the protocol specified time interval for assessments. This date may  be used if back-dating 

Novartis Confidential Page 154
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
is considere d when the event occurred bey ond the acceptable time window for the next 
tumor assessment as per protocol (see Section 14.1.26
).
Example (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing -missing -PD. Date of next scheduled assessment 
would then correspond to 9 months.
Date of discontinuation is the date of the end of treatment visit.
Date of last contact is defined as the last date the patient was known to be alive. This 
corresponds to the latest date for either the visit date, lab sample date or tumor assessment 
date.  
If no survival follow- up is available, the date of discontinuation is used as last 
contact date.
Date of secondary  anti- cancer therap y is defined as the start date of an y additional 
(secondary ) antineoplastic therap y or surgery .
14.1.26 Handling of patients with non -measurable disease only  at baseline
It is possible that patients with only non- measurable disease present at baseline are entered into 
the study , either because of a protocol violation or by design (e.g. in Phase III studies with PFS 
as the primary  endpoint). In such cases the handling of the response data requires special 
consideration with respect to inclusion in any analysis of endpoints based on the overall 
response evaluations.
It is recommended that any patients with only non-measurable disease at baseline should be 
included in the main (ITT) anal ysis of each of these endpoints.
Although the text of the definitions described in the previous sections primarily relates to 
patients with measurable disease at baseline, patients without measurable disease should also 
be incorporated in an appropriate manner. The overall response for patients with measurable 
disease is derived slightly differentl y according to Table 14 -
4.
Table 14-4 Overall lesion response at each assessment: patients with non -target 
disease only
Non-target lesions New Lesions Overall lesion response
CR No CR
Non-CR/Non-PD1No Non-CR/non -PD
UNK No UNK
PD Yes or No PD
Any Yes PD
1As defined in Section 14.1.8 .
In general, the non-CR/non -PD response for these patients is considered equivalent to an SD 
response in endpoint determination. In summary  tables for best overall response patients with 
only non- measurable disease may  be highlighted in an appropriate fashion e.g. in particular by 
display ing th e specific numbers with the non -CR/non -PD category .
In considering how to incorporate data from these patients into the analy sis the importance to 
each endpoint of being able to identify  a PR and/or to determine the occurrence and timing of 
progression nee ds to be taken into account.

Novartis Confidential Page 155
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
For ORR it is recommended that the main (I TT) analy sis includes data from patients with only 
non-measurable disease at baseline, handling patients with a best response of CR as “responders” 
with respect to ORR and all other pat ients as “non -responders”.
For PFS, it is again recommended that the main ITT analyses on these endpoints include all 
patients with only non -measurable disease at baseline, with possible sensitivity analyses which 
exclude these particular patients. Endpoin ts such as PFS which are reliant on the determination 
and/or timing of progression can incorporate data from patients with only non
-measurable 
disease.
14.1.27 Sensitivity analy ses
This section outlines the possible event and censoring dates for progression, as well as addresses 
the issues of missing tumor assessments during the study . For instance, if one or more 
assessment visits are missed prior to the progression event, to what date should the progression 
event be assigned? And should progression event be ignor ed if it occurred after a long period 
of a patient being lost to follow -up? It is important that the protocol and RAP specify  the 
primary  analysis in detail with respect to the definition of event and censoring dates and also 
include a description of one o r more sensitivity  analy ses to be performed.
Based on definitions outlined in Section 14.1.25, and using the draft FDA guideline on 
endpoints (Clini
cal Trial Endpoints for the Approval of Cancer Drugs and Biologics, April 2005) 
as a reference, the following analy ses can be considered:
Table 14
-5 Options for event dates used in PFS, TTP, duration of response
SituationOptions for end -date (progression or 
censoring)1
(1) = default unless specified differently  in 
the protocol or RAP Outcome
A No baseline assessment (1) Date of randomization/start of treatment3Censored
B Progression at or before next scheduled 
assessment(1) Date of progression
(2) Date of next scheduled assessment2Progressed
Progressed
C1 Progression or death after exactly  one
missing assessment(1) Date of progression (or death)
(2) Date of next schedu led assessment2Progressed
Progressed
C2 Progression or death after two or more
missing assessments(1) Date of last adequate assessment2
(2) Date of next scheduled assessment2
(3) Date of progression (or death)Censored
Progressed
Progressed
D No progression (1) Date of last adequate assessment Censored
E Treatment discontinuation due to ‘Disease 
progression’ without documented 
progression, i.e. clinical progression based 
on investigator claim(1) N/A
(2) Date of discontinuation (visit date at which 
clinical progression was determined)Ignored
Progressed
F New anticancer therapy given (1) Date of last adequate assessment
(2) Date of secondary anti -cancer therapy
(3) Date of secondary anti -cancer therapy
(4) N/ACensored
Censored
Event
Ignored
G Deaths due to reason other than 
deterioration of ‘Study indication’(1) Date of last adequate assessment Censored 
(only TTP and 
duration of 
response)

Novartis Confidential Page 156
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
SituationOptions for end -date (progression or 
censoring)1
(1) = default unless specified differently  in 
the protocol or RAP Outcome
1.=Definitions can be found in Section 14.1.25
2.=After the last adequate tumor assessment. “Date of next scheduled assessment” is defined in Section 14.1.25 .
3.=The rare exception to this is if the patient dies no later than the time of the second sc heduled assessment as 
defined in the protocol in which case this is a PFS event at the date of death.
The primary  analysis and the sensitivity  analyses must be specified in the protocol. Clearl y 
define if and wh y options (1) are not used for situations C, E and (if applicable) F.
Situations C (C1 and C2): Progression or death after one or more missing assessments: The 
primary  anal ysis is usually  using options (1) for situations C1 and C2, i.e.
(C1) taking the actual progression or death date, in the case o f only  one missing 
assessment.
(C2) censoring at the date of the last adequate assessment, in the case of two or more 
consecutive missing assessments.
In the case of two or missing assessments (situation C2), option (3) may  be considered jointly 
with optio n (1) in situation C1 as sensitivity  analysis. A variant of this sensitivity  analysis 
consists of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2.
Situation E: Treatment discontinuation due to ‘Disease progression’ without documented 
progression :By default, option (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment. However, option (2) may 
be used as sensitivity  analy sis. If progression is claimed based on clinical deterioration instead 
of tumor assessment by e.g. CT-scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess the tumor due to clinical deterioration.
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.
Additional suggestions for sensitivity ana lyses
Other suggestions for additional sensitivity  analyses may include analy ses to check for potential 
bias in follow -up schedules for tumor assessments, e.g. by assigning the dates for censoring and 
events only  at scheduled visit dates. The latter could be han dled b y replacing in Table 14 - 5the 
“Date of last adequate assessment” by the “Date of previous scheduled assessment (from 
baseline)”, with the following definition:

Novartis Confidential Page 157
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly  
followed from baseline, immediately before or on the date of the last adequate tumor 
assessment.
In addition, analy ses could be repe ated using the Investigators’ assessments of response rather 
than the calculated response. The need for these types of sensitivity  anal yses will depend on the 
individual requirements for the specific study  and disease area and have to be specified in the 
protocol or RAP documentation.
14.1.28 Data handling and programming rules
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates).
14.1.29 Study/project specific deci sions
For each study  (or project) various issues need to be addressed and specified in the protocol or 
RAP documentation. Any  deviations from protocol must be discussed and defined at the latest 
in the RAP documentation.
The proposed primary  analysis and potential sensitivity  analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the RAP 
documentation before database lock).
14.1.30 End of treatment phase completion
Patients may voluntarily withdraw fr
om the study  treatment or may be taken off the study 
treatment at the discretion of the investigator at any time. For patients who are lost to follow -
up, the investigator or designee should show "due diligence" by documenting in the source 
documents steps taken to contact the patient, e.g., dates of telephone calls, registered letters, etc.
The end of treatment visit and its associated assessments should occur within 7 days of the last 
study  treatment.
Patients may  discontinue study  treatment for an y of the following reasons:
Adverse event(s)
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
Progressive disease
Study  terminated by  the sponsor
Non-compliant with study  treatment

Novartis Confidential Page 158
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
No longer requires treatment
Treatment duration completed as per protocol (optional, to be used if only  a fixed number 
of cy cles is given)
14.1.31 End of post -treatment follow -up (study  phase completion)
End of post-treatment follow -up visit will be completed after disconti nuation of study  treatment 
and post -treatment evaluations but prior to collecting .
Patients may  provide study  phase completion information for one of the following reasons:
Adverse event
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
New therap y for stud y indication
Progressive disease
Study  terminated by  the sponsor
14.1.32 Medical validation of programmed overall lesion response
As RECI ST is very strict regarding measurement methods (i.e. any assessment with more or 
less sensitive method than the one used to assess the lesion at baseline is considered UNK) and 
not available evaluations (i.e. if any target or non-target lesion was not evaluated the whole 
overall lesion response is UNK unless remaining lesions qualified for PD), these UNK 
assessments may  be re -evaluated by  clinicians at Novartis or external experts. I n addition, data 
review reports will be available to identify  assessments for which the investigators’ or central 
reader’s opinion does not match the programmed calculated response based on RECI ST criteria. 
This may be queried for clarification. However, the investigator or central reader’s response 
assessment will never be overruled.
If Novartis elect to invalidate a
n overall lesion response as evaluated by the investigator or 
central reader upon internal or external review of the data, the calculated overall lesion response 
at that specific assessment is to be kept in a dataset. This must be clearl y documented in the
RAP documentation and agreed before database lock. This dataset should be created and stored 
as part of the ‘raw’ data.
Any discontinuation due to ‘Disease progression’ without documentation of progression by 
RECI ST criteria should be carefull y reviewed. Only  patients with documented deterioration of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or stud y evaluation.

Novartis Confidential Page 159
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.1.33 Programming rules
The following should be used for programming of efficacy  results:
14.1.34 Calculation of ‘time to event’ variables
Time to event = end date -start date + 1 (in day s)
When no post-baseline tumor assessments are available, the date of randomization/start of 
treatment will be used as end date (duration = 1 day ) when time is to be c ensored at last tumor 
assessment, i.e. time to event variables can never be negative.
14.1.35 Incomplete assessment dates
All investigation dates (e.g. X -ray, CT scan) must be completed with day , month and y ear.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section 14.1.25). If all measurement dates have no 
day recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective 
assessment will be 
considered to be at the date which is exactly  between previous and following assessmen t. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.
14.1.36 Incomplete dates for last known date patient alive or death
All dates must be completed with day, month and year. If the day is missing, the 15thof the 
month will be used for incomplete death dates or dates of last contact.
14.1.37 Non
-target lesion response
If no non- target lesions are identified at baseline (and therefore not followed throughout the 
study ), the non
-target lesion response at each assessment will be considered ‘not applicable 
(NA)’.
14.1.38 Study/project specific programming
The standard anal ysis programs need to be adapted for each study /project.
14.1.39 Censoring reason
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page .

Novartis Confidential Page 160
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
For PFS and TTP (and therefore duration of responses) the following censoring reasons are 
possible:
Ongoing without event
Lost to follow -up
Withdrew consent
Adequate assessment no longer available*
Event documented after two or more missing tumor assessments (optional, see Table 14 -5)
Death due to reason other than underl ying cancer (only used for TTP and duration of 
response)
Initiation of new anti
-cancer therapy
*Adequate assessment is defined in Section 14.1.25 . This reason is applicable when adequate 
evaluations are missing for a specified period prior to data cut-off (or prior to any other 
censoring reason) corresponding to the unavailability  of two or more planned tumor 
assessments prior to the cut-off date. The following clarifications concerning this reason should 
also be noted:
This may  be when there has been a definite decision to stop evaluation (e.g. 
reason=“Sponsor decision” on study  evaluation completion page), when patients are not 
followed for progression after treatment completion or when onl y UNK assessments are 
available just prior to data cut -off).
The reason "Adequate assessment no longer available" also prevails in situations when 
another censoring reason (e.g. withdrawal of consent, loss to follow -up or alternative anti -
cancer therap y) has occurred more than the specified period following the last adequate 
assessment.
This reason will also be used to censor in case of no baseline assessment.
14.1.40 Refere nces (available upon request)
Dent S, Zee (2001) application of a new multinomial phase II stopping rule using response 
and earl y progression, J Clin Oncol; 19: 785
-791
Eisenhauer E, et al (2009) New response evaluation criteria in solid tumors: revised RE CIST 
guideline (version 1.1). European Journal of Cancer, Vol.45: 228 -47
Ellis S, et al (2008) Analysis of duration of response in oncology  trials. Contemp Clin Trials 
2008; 29: 456-465
FDA Guidelines: 2005 Clinical Trial Endpoints for the Approval of Canc er Drugs and 
Biologics, April 2005
FDA Guidelines: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May  2007
Morgan TM (1988) Analy sis of duration of response: a problem of oncology  trials. Cont Clin 
Trials; 9: 11-18
Therasse P , Arbuck S, Eisenhauer E, et al (2000) New Guidelines to Evaluate the Response to 
Treatment in Solid Tumors, Journal of National Cancer Institute, Vol. 92; 205 -16

Novartis Confidential Page 161
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.2 Appendix 2: Guidelines for immune -related response criteria 
(IrRC) using one -dimensional measurements (simulating RECIST 
1.1)
14.2.1 Introduction
The currently  used immune -related response criteria (irRC) uses unidimensional measurements 
to assess tumor response and it is an adaptation of the original irRC published by Wolchok 
(Wolchol et al. 2009 and Nishino et al. 2013 ).
The purpose of this document is to summarize the irRC guidelines in details focusing on 
differences in tumor response assessment s between irRC and RECI ST v1.1.
The primary  difference between irRC and RECIST 1.1 is the definition of progressive disease. 
The definitions of baseline target/non target lesions, number of lesions selected at baseline, the 
criteria for lesion measurement method of evaluation of response and definition of response are 
the same for irRC and RECI ST 1.1 and are available in the RECIST 1.1 guidelines ( Appendix 
14.1).
14.2.2 New Lesions and non -target lesions
In irR C a new lesion does not automatically  indicate progressive disease.
New measurable lesions are added to the sum of diameters of the previously  existing target 
lesions, and the sum of diameters is followed at each subsequent tumor assessment.
New measureable lesions are defined using the same criteria as for baseline target lesions in 
RECI ST v1.1. New 
measurable lesions shall be prioritized according to size, and the largest 
lesions shall be selected as new measured lesions.   Up to five new measura ble lesions (and a 
maximum of two per organ) are allowed in total and will be included in the overall tumor 
assessment .
Non-target lesions (baseline and new non-measurable lesions) are used primarily  for 
determination of Complete Response (CR). The RECI ST v1.1 definitions for the assessment of 
non-target lesions apply . A CR requires that all non-target lesions disappear (both those present 
at baseline and any new non-measurable lesions that have appeared during the study ). If after 
worsening a non-target lesion becomes measurable, it should still be followed as a non-target 
lesion. Worsening of non -target lesions and new non -measurable lesions only  indicate disease 
progression if there is unequivocal evidence of disease progression
(Table 14-6 ).
14.2.3 Follow -up evaluation of target and non -target lesions
To assess tumor response, the sum of diameters for all target lesions is calculated (at baseline 
and throughout the study). The diameters of any new measurable lesions are included in the 
sum of diameters at each assessment to provide the total tumor burden. At each assessment, 
percent change in the sum of diameters is calculated and compared to baseline or to nadir in 
order to evaluate the target lesion response (including new measurable lesions) (Section 14.2.4). 
This evaluation combined with the status of non-target lesions (baseline and new non-

Novartis Confidential Page 162
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
measurable lesions) is then used to determinate the overall lesion response. The measurement 
thresholds for irPR and irPD assessment are the same as for RECIST v1.1 ( Table 14
-6).
14.2.4 Definitions of response categories and evaluation of overall lesion 
response
In irRC, th e overall response is primarily based on target lesions (baseline and new measurable 
lesions). The non-target lesions only contribute to define irCR, and irPD in the case of 
unequivocal progression, as shown below in Table 14 -6.
Like in RECI ST 1.1, irCR and irPR must be confirmed at a new assessment after at least 4 
weeks. Unlike RECI ST 1.1, irPD also requires confirmation at a new assessment after at least 
4 weeks.
The response categories are defined as follows:
Immune related Complete Response (irCR) : Disappearance of all non -nodal target 
lesions and non -
target lesions in two consecutive observations not less than 4 weeks apart. 
In addition, any  pathological ly mph nodes assigned as target lesions must have a reduction 
in short axis to < 10 mm. (Sum of diameters may  be greater than zero at the time of CR, if 
nodal lesions are included as target lesions).
Immune related Partial Response (irPR) : At least a 30% decrease in the sum of 
diameters of all target lesions including new target lesions in two consecutive observations 
not less than 4 weeks apart, taking as reference the baseline sum of diameters.
Immune related Progressive Disease (irPD) : At least a 20% increase in t he sum of 
diameters of all measured target lesions including new measurable lesions. The irPD must 
be confirmed in a second evaluation not less than 4 weeks later, taking as reference the 
smallest sum of diameter of all target lesions recorded at or after baseline (nadir). In 
addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm. Worsening of non -target lesions (existing or new) only  indicate 
PD when there is unequivocal evidence of progression, confir med in a second evaluation 
not less than 4 weeks later.
Immune related Stable Disease (irSD) : Neither a sufficient shrinkage to qualify  for irPR 
or irCR, nor an increase in lesions which would qualify  for irPD.
Unknown (UNK) : Progression has not been docum ented and one or more target lesions or 
new measurable lesions observed at earlier assessment have not been/could not be
assessed or have been assessed using a method significantly  different from baseline 
(target lesions) or assessment of first occurrence (for new measurable lesions) that 
prevents reasonable comparison to the prior assessments.
Table 14
-6 Overall response at each assessment
Measurable response
Target and new measurable lesions 
(Tumor burden), * (% )Non-measurable response
Non-target lesions
(both baseline and new non- measurable)Overall response
Using irRC
-100 Absent irCRa
-100 Stable/not evaluated irPRa
≤-30 Absent/Stable/not evaluated irPRa
>-30 and<+20 Absent/Stable/not evaluated irSD

Novartis Confidential Page 163
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
≥+20 Any irPDa
Any Unequivocal progression irPDa
*the diameter of new measurable lesions is included in the calculation of the sum of diameters.
aTo be confirmed after at least 4 weeks.
If the evaluation of anyof the target lesions could not be made during follow -up, the overall 
status must be ‘unknown’ unless progression was documented.
If the evaluation of any  non-target lesions is not made, and all target lesions disappeared, irCR 
cannot be determined and ov erall response must be “irPR”.
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspirate/biopsy ) to confirm the irCR.
14.2.5 Only  non -measurable disease at baseline
For patients with only non-measurable disease at baseline, unequivocal progression of non-
target lesions will constitute an irPD (i.e. worsening of the overall tumor burden which is 
substantial enough to lead to discontinuation or change of therap y). In addition, the appearance 
of new lesions (measurable or non
-measurable) consistent with unequivocal progression taking 
into account the overall disease burden will constitute an irPD. The absence of all non-target 
lesions and no new lesions will qualify  for irCR. Otherwise the overall response will be 
considered as irNon -CR/Non -PD (irNCRNPD) similar to RECI ST 1.1. Confirmation of irPD 
and irCR as specified above in (Section 14.2.4) is required. If an y baseline non -target lesion or 
a new lesion observed at an earlier post -baseline evaluation was not/could not be assessed at a 
later post -baseline tumor evaluation then th e overall response will be irUNK. No confirmation 
is required for irNCRNPD
.
14.2.6 Reference (available upon request)
Wolchok JD, Hoos A, O'Day  S et al (2009) Guidelines for the Evaluation of I mmune Therapy  
Activity  in Solid Tumors: I mmune -Related Response Criter ia. Clin Cancer Res; 15:7412-20.
Nishino M, Giobbie -Hurder A, Gargano M, et al (2013) Developing a Common L anguage for 
Tumor Response to I mmunotherapy : Immune -Related Response Criteria Using 
Unidimensional Measurements. Clin Cancer Res; 19:3936 -3943.

Novartis Confidential Page 164
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.3 Appendix 3: Statistical details of Phase I Bay esian logistic 
regression models (BLRM) and Phase II hierarchical models
14.3.1 Phase I BLRM
An adaptive Bayesian logistic regression model (BLRM) guided by the escalation with 
overdose control (EWOC) principle will b e used to make dose recommendations and estimate 
the maximum tolerated dose (MTD) and/or identify  the recommended dose for Phase II (RP2D)
during the dose escalation part of the study . The use of Bay esian response adaptive models for 
Phase I  studies has been advocated b y the EMEA guideline on small populations (2006) and by 
Rogatko (2007) and is one of the key  elements of the FDA’s Critical Path Initi ative.
In the single -agent LAG525 dose escalation part, the dose-toxicity  (DLT) relationship is 
described b y the following 2
-parameter BLRM:
logit(π 1(d1)) = log(α 1) + β 1log(d 1/d1*), α1>0, β 1>0
where logit(π 1(d1))= log (π1(d1)/(1-π1(d1))), and π1(d1) is the probability  of a DLT at dose d1, 
where d1represents the Q2W dose of LAG525. Doses are rescaled as d1/d1* with reference dose 
d1*=3 mg/kg of LAG525. As a consequence α1is equal to the odds of DLT rate at d1*. Note 
that for a dose equal to zero, the prob ability  of toxicity  is zero.
In the dose escalation for the combinations, the dose -toxicity  (DLT) relationship is modeled b y 
a 5-parameter BLRM as follows. Let π 1(d1) be the probability  of DLT if LAG525 is given as a 
single agent at Q2W dose d 1, and π 2(d2)the probability  of DLT if PDR001 is given as a single 
agent at Q2W dose of d2. π12(d1,d2) denotes the probability  of DLT if LAG525 is given in 
combination with PDR001 at Q2W dose d1of LAG525 and Q2W dose d2of PDR001. The 
possibility  of synergism or antagonism between the safet y profiles of the two drugs is captured 
in the model of odds of DL T rate with combination doses.
LAG525: logit(π 1(d1)) = log(α 1) + β 1log(d 1/d1*)
PDR001: logit(π 2(d2)) = log(α 2) + β 2log(d2/d2*)
Odds(π 12(d1,d2))) = π 12(d1,d2)/(1- π12(d1,d2))
= exp(η(d 1/d1*)(d 2/d2*))(π 1(d1)+ π 2(d2) – π1(d1) π2(d2))/((1 - π1(d1))(1- π2(d2))),
where logit(π.(d.)) = log[π.(d.)/{1- π.(d.)}], d1* = 3 mg/kg and d 2*= 3 mg /kg are the reference 
doses of LAG525 and PDR001 respectively , α1, α2, β1, β2> 0 and -∞ < η < ∞ is the interaction 
coefficient.
The Bayesian approach requires the specification of prior distributions for all model parameters. 
This section provides details of the statistical model, the derivation of prior distributions for the 
model parameters, and the properties of the adaptive design (dosing recommendations for 
hypothetical data scenarios and operating characteristics).

Novartis Confidential Page 165
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.3.1.1 Prior specifications for single agent model parameters
Prior for PDR001 param eters (log(α 2), log(β 2)):
Because more clinical data are available on the class of anti -PD-1 antibody  than the anti -LAG -
3 antibody , we first derive the prior for single -agent PDR001. This prior will be checked based 
upon the available single agent data of PDR from CPDR001X2101 study .
This study  uses a mixture prior consisting of two components, as specified in Table 14-7. 
Component 1 is the distribution derived based on PDR001 preclin
ical data and clinica l data on 
Nivolumab and Pembrolizumab, and is also the component that reflects the low toxicity  profile. 
The assigned weight for component 1 is 80%. Component 2 allows for a case assuming higher 
toxicity . The assigned weight for component 2 is 20%.
Table 14-7 Prior distribution of model parameters –phase I single agent PDR001
Parameter Means Standard deviations Correlation Weight
Component 1: priors for a low toxicity  profil e
log(α 2), log(β 2) -2.692, -1.26 1.0, 1.0 0 0.8
Component 2: priors for a more toxicity  sensitive population
log(α 2), log(β 2) -2.3, 0 2, 1 0 0.2
Component 1:
For the intercept parameter log(α 2), the prior mean of -2.692 is derived based on the a-priori
median of an assumed 6.3% DLT rate at the reference dose d2*= 3 mg/kg. By setting the 
standard deviation of log(α 2) =1, the respective upper bound of the 95% a -priori interval of the 
DLT rate at dose 3 mg/kg is 32.5%, lower than 33%, which represents the a-priori assumption 
that 3 mg/kg of PDR001 is a safe dose.
For the log-slope parameter log(β 2), the prior mean of -1.26 and prior standard deviation of 1 
have the following interpretation: when tripling the dose, the odds of having a DLT are 
multiplied by a factor of 3β, i.e., by 1.4 for the median and approximately (1.0, 9.1) for the 95% 
interval. This reflects the a -priori assumption that the dose -DLT curve may  be quite flat for the 
anti-PD1 antibody .
Component 2:
This weakly informative bivariate normal prior allows for a case with higher toxicity .
For the intercept parameter log(α 2), the prior mean of -2.3 is derived based on the a-priori 
median of an assumed 9.1% DLT rate at the reference dose d2*= 3 mg/kg. By setting the 
standard deviation =2, the respective 95% a-priori interval at dose 3 mg/kg is wide (0.2%, 84%), 
which represents weak prior information.
For the log -slope parameter log(β 2), the prior mean of 0 and prior standard deviation of 1 allow 
for very  flat to very  steep slopes. Therefore, it is a weakl y informative prior. The interpretation 
is as follows: when tripling the dose, the odds of having a DLT are multiplied by a factor of 3β, 
i.e., by  3 for the median and (1.2, 2439.2) for the 95% interval.
For both components, the correlation between log(α 2) and log(β 2) is set to 0.

Novartis Confidential Page 166
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Prior for LA G525 parameters (log(α 1), log(β 1)):
Before observing any clinical data, the DLT profile of single -agent LAG525 is expected to be 
similar to that of single -agent PDR001. Therefore, it is reasonable to use the same mixture prior 
defined in Table 14 -7for (log(α 1), log(β 1)).
Table 14-8, Table 14 -9 and Table 14-10summarize the DLT rates of the associated prior 
distribution. The doses not meeting the overdose criteria are bold in the table, i.e. it is not 
eligible at the start of the study  (under the pri or).
Table 14
-8 Summary  of prior distribution of DLT rates –phase I single agent 
LAG525 (derived from the mixture prior in Table 14 -7)
LAG525 dose 
(mg/kg Q2W)Prior probabil ities that Pr(DLT) is in 
interval:
Mean SDQuantiles
[0, 0.16) [0.16,0.33) [0.33, 1] 2.50% 50.00% 97.50%
0.3 0.939 0.047 0.014 0.049 0.076 0 0.024 0.252
1 (starting dose) 0.9 0.075 0.026 0.069 0.095 0.001 0.039 0.334
3 0.805 0.134 0.061 0.11 0.133 0.006 0.066 0.518
10 0.615 0.2 0.185 0.205 0.233 0.012 0.114 0.946
Table 14-9 Summary  of prior distribution of DLT rates –phase I single agent 
LAG525 (derived from the Component 1 prior in Table 14 -7)
LAG525 dose 
(mg/kg Q2W)Prior probabilities that Pr(DLT) is in 
interval:
Mean SDQuantiles
[0, 0.16) [0.16,0.33) [0.33, 1] 2.50% 50.00% 97.50%
0.3 0.948 0.046 0.006 0.048 0.059 0 0.028 0.216
1 (starting dose) 0.918 0.071 0.011 0.064 0.069 0.004 0.041 0.257
3 0.849 0.127 0.024 0.09 0.084 0.009 0.064 0.327
10 0.683 0.211 0.106 0.151 0.154 0.013 0.1 0.603
Table 14-10 Summary  of prior distribution of DLT rates –phase I single agent 
LAG525 (derived from the Component 2 prior in Table 14 -7)
LAG525 dose 
(mg/kg Q2W)Prior probabilities that Pr(DLT) is 
in interval:
Mean SDQuantiles
[0, 0.16) [0.16,0.33) [0.33, 1] 2.50% 50.00% 97.50%
0.3 0.898 0.053 0.048 0.056 0.129 0 0.006 0.496
1 (starting dose) 0.821 0.09 0.089 0.095 0.167 0 0.022 0.653
3 0.624 0.162 0.214 0.193 0.231 0.002 0.092 0.838
10 0.345 0.154 0.501 0.42 0.346 0.006 0.332 0.999
Note: bold values indicate doses not meeting the overdose criterion (less than 25% chance of excessive 
toxicity) with the prior information only.
To check the performance of the model, the document summarizes some hypothetical dose 
escalation scenarios. Details regarding dose recommendation are described in Section 10.4.2 of 
the protocol.

Novartis Confidential Page 167
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.3.1.2 Hypothetical dose escalation scenarios for the single -agent LAG525 
arm
In order to show how the Bayesian model performs, different hypothetical dose escalation 
scenarios were investigated. The design should make reasonable dose-recommendations during 
the clinical trial based on the observed DLTs for hypothetical dose escalation scenarios. During 
the study , the decision to dose escalate after completion of a given cohort and the actual dose 
chosen for the subsequent cohort will depend on the recommendation o f the BLRM per EWOC 
principle, estimated/predicted exposure at each dose level, and medical review of available 
clinical and laboratory  data.
Some hypothetical dose escalation scenarios to illustrate the dose escalation up to the fourth 
dose cohort are listed in Table 14-11. The maximum dose increment allowed in the scenarios 
did 
not exceed 334% as per escalation rules defined in Section 6.2.3. The recommended next 
dose level satisfied the EWOC principle.
Table 14
-11 Hypothetical dose escalation scenarios for on -study  decisions –
phase I single agent LA G525
Scena
rioLAG525 Dose level 
(mg/kg)Np
atNt
oxNext Dose Level 
(NDL)P(Target) 
NDLP(Over) 
NDLMedian DLT rate 
(NDL)
1 1 4 0
3 0.101 0.026 0.054
2 1 4 1
3 0.264 0.108 0.121
3 1 4 2
1 0.365 0.221 0.19
4 1 4 0
3 3 0
10 0.146 0.108 0.079
5 1 4 0
3 3 1
3 0.215 0.055 0.098
6 1 4 0
3 3 2
1 0.21 0.036 0.089
7 1 4 0
3 6 0
10 0.126 0.084 0.068
8 1 4 0
3 6 1
10 0.241 0.193 0.137
9 1 4 0
3 6 2
3 0.338 0.089 0.142

Novartis Confidential Page 168
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Scena
rioLAG525 Dose level 
(mg/kg)Np
atNt
oxNext Dose Level 
(NDL)P(Target) 
NDLP(Over) 
NDLMedian DLT rate 
(NDL)
10 1 4 0
3 3 1
3 3 0
10 0.241 0.193 0.137
11 1 4 0
3 3 1
3 3 1
3 0.338 0.089 0.142
12 1 4 0
3 3 1
3 3 2
1 0.254 0.034 0.103
13 1 4 0
3 3 2
1 3 0
3 0.337 0.248 0.191
14 1 4 0
3 3 2
1 3 1
1 0.367 0.064 0.143
15 1 4 0
3 3 2
1 3 2
1 0.506 0.212 0.222
16 1 4 1
3 3 0
10 0.274 0.118 0.128
17 1 4 1
3 3 1
3 0.38 0.15 0.168
18 1 4 1
3 3 2
1 0.416 0.179 0.192
19 1 4 1
3 3 1
3 5 0
10 0.364 0.137 0.16

Novartis Confidential Page 169
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Scena
rioLAG525 Dose level 
(mg/kg)Np
atNt
oxNext Dose Level 
(NDL)P(Target) 
NDLP(Over) 
NDLMedian DLT rate 
(NDL)
20 1 4 1
3 3 1
3 5 1
3 0.463 0.102 0.175
21 1 4 1
3 3 1
3 5 2
1 0.445 0.082 0.166
22 1 3 0
3 5 2
1 3 1
3 0.479 0.182 0.201
23 1 3 0
3 5 2
1 3 1
1 4 0
3 0.429 0.128 0.173
Overall, the model is showing appropriate behaviors, in agreement with clinical sense and 
decision making process. The dose levels investigated correspond to the provisional dose levels 
specified in 
Section 6.2.2 .
14.3.1.3 Prior specifications for LA G525 + PDR001 combination model 
parameters
The 5-parameter BLRM used to guide the dose escalation for the combination of 
LAG525+PDR001 will use DLT information from both dose escalation arms: patients receiving 
the single-agent LAG525 and patients receiving the LAG525+PDR001 combo. At each dose 
escalation meeting, 
data from the last completed single agent cohort will be incorporated 
directly  into the model, without down -weighting. The available single agent data from 
CPDR001X2101 study  will also be used to check the prior information for the BLRM model.
The prior distributions of model parameters for single -agent LAG525 and single -agent PDR001 
have been derived in Section 14.3.1.1 .
Prior for the interaction parameter η 12:
A normal prior distribution for the interaction parameter η12is to be derived to reflect the current 
uncertaint y about the toxicity  profile of the combination of LAG525 and PDR001. The risk of 
significant positive interaction between LAG525 and PDR001 cannot be totally  excluded. The 
interaction parameter η12was chosen accordingl y but with a degree of uncertainty  in order to 
allow for the possibility  that the interaction may be positive or negative. Therefore the following 
assumption is made for the interaction parameter:

Novartis Confidential Page 170
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
η12is normally  distributed and centered at log (1.5)*(d 1/d1*)*(d 2/d2*), i.e. 50% increase in 
odds of DLT due to interaction compared to independence at the anticipated combination 
reference dose d 1*and d 2*.
97.5thpercentile of η 12is log (5)*(d 1/d1*)*(d 2/d2*), i.e.5 -fold increase in odds of DLT d ue 
to interaction compared to independence at the combination reference dose d 1*and d 2*.
Therefore the prior mean for η 12is 0.405 and the prior standard deviation is 0.614. This allows 
for the potential of both synergism and antagonism between the safety profiles of the two drugs. 
Since the interaction is dose-dependent (see model definition in Section 10.4.2 ), the prior for 
the interaction parameter has a simple interpretation only at the anticipated combination 
reference dose of LAG525 = 3 mg/kg Q2W and PDR001 = 3 mg/kg Q2W.
Table 14-12 summarizes the prior distributions of the model parameters and Table 14-13
summarizes the corresponding prior distribution for the DLT rates at each provisional dose level.
Table 14
-12 Prior distribution of model parameters –phase I L AG525 + PDR001
Parameters Description MeansStandard 
deviations Correlation Weight
log(α 1),log(β 1) LAG525 parameters -2.692, -1.26 1.0, 1.0 0 0.8
-2.3, 0 2, 1 0 0.2
log(α 2),log(β 2) PDR001 parameters -2.692, -1.26 1.0, 1.0 0 0.8
-2.3, 0 2, 1 0 0.2
η12 Interaction LAG525 -
PDR0010.405 0.614
Table 14-13 Summary  of prior distribution of DLT rates –phase I LA G525 + 
PDR001
LAG525 dose 
(mg/kg Q2W)Prior probabilities that Pr(DLT) is 
in interval:
Mean SDQuantiles
[0, 0.16) [0.16,0.33) [0.33, 1] 2.50% 50.00% 97.50%
PDR001 = 0.3 mg/kg Q2W
0.3 0.834 0.129 0.037 0.097 0.105 0.004 0.066 0.386
1 0.778 0.168 0.053 0.117 0.119 0.009 0.082 0.451
3 0.658 0.241 0.102 0.16 0.148 0.019 0.114 0.61
10 0.448 0.292 0.261 0.264 0.238 0.029 0.181 0.96
PDR001 = 1 mg/kg Q2 W
0.3 0.778 0.169 0.053 0.117 0.118 0.009 0.083 0.448
1 0.709 0.216 0.075 0.14 0.13 0.015 0.102 0.509
3 0.556 0.3 0.144 0.191 0.161 0.026 0.143 0.673
10 0.309 0.288 0.403 0.339 0.259 0.033 0.264 0.975
PDR001 = 3 mg/kg Q2 W
0.3 0.655 0.243 0.102 0.16 0.147 0.019 0.116 0.599
1 0.551 0.303 0.146 0.192 0.161 0.026 0.144 0.663
3 0.35 0.329 0.321 0.282 0.208 0.035 0.226 0.831
10 0.211 0.135 0.654 0.534 0.339 0.013 0.556 0.997

Novartis Confidential Page 171
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
LAG525 dose 
(mg/kg Q2W)Prior probabilities that Pr(DLT) is 
in interval:
Mean SDQuantiles
[0, 0.16) [0.16,0.33) [0.33, 1] 2.50% 50.00% 97.50%
PDR001 = 10 mg/kg Q2W
0.3 0.438 0.298 0.263 0.266 0.236 0.029 0.184 0.957
1 0.302 0.287 0.411 0.341 0.258 0.033 0.268 0.972
3 0.208 0.137 0.655 0.535 0.339 0.013 0.561 0.997
10 0.21 0.04 0.75 0.71 0.398 0 0.981 1
Note: bold values indicate doses not meeting the overdose criterion (more than 25% chance of excessive 
toxicity) with the prior information only.
14.3.1.4 Hypothetical dose escalation scenarios for LA G525 + PDR001 
combination arm
Table 14-14 shows on- study  dosing recommendations for some hy pothetical data scenarios.
Note that the next dose combination is selected in concordance with the provisional dose levels 
specified in Section 6.2.2 of the protocol wherever it is allowed, to mimic possible on-study 
escalation steps.
Table 14
-14 Hypothetical dose escalation scenarios for on -study  decisions –
phase I LA G525 + PDR001
ScenarioDose combination 
LAG525 (mg/kg Q2W) / 
PDR001 (mg/kg Q2W) Npat NtoxNext dose 
combination 
(NDC)P(target) 
NDCP(over) 
NDCMedian DLT 
rate (NDC)
1 1/1 4 0
1/3 0.237 0.052 0.108
2 1/1 4 1
1/3 0.408 0.163 0.181
3 1/1 4 2
0.3/1 0.409 0.183 0.187
4* 1/0 (single agent cohort 
1)
1/13
40
2
1/1 0.444 0.183 0.195
5 1/1
1/34
30
0
3/3 0.32 0.129 0.144
6 1/1
1/34
30
1
1/3 0.364 0.082 0.148
7 1/1
1/34
30
2
1/1 0.358 0.064 0.141
8 1/1
1/34
51
0
3/3 0.395 0.191 0.187
9 1/1
1/34
51
1
1/3 0.481 0.104 0.18

Novartis Confidential Page 172
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
ScenarioDose combination 
LAG525 (mg/kg Q2W) / 
PDR001 (mg/kg Q2W) Npat NtoxNext dose 
combination 
(NDC)P(target) 
NDCP(over) 
NDCMedian DLT 
rate (NDC)
10 1/1
1/34
51
2
1/1 0.486 0.113 0.184
11 1/1
0.3/14
32
0
1/1 0.441 0.128 0.177
12 1/1
0.3/14
32
1
0.3/1 0.489 0.223 0.222
13 1/1
0.3/14
32
2 Stop
14* 1/0 (single agent cohort 
1)
1/1
0.3/13
4
30
2
2
0.3/0.3 0.495 0.241 0.231
15* 1/0 (single agent cohort 
1)
3/0 (single agent cohort 
2)
1/1
1/33
3
4
30
0
0
0
3/3 0.293 0.088 0.127
16* 1/0 (single agent cohort 
1)
3/0 (single agent cohort 
2)
1/1
1/33
3
4
30
0
0
1
3/3 0.4 0.235 0.205
17* 1/0 (single agent cohort 
1)
3/0 (single agent cohort 
2)
1/1
1/33
3
4
30
0
0
2
1/1 0.276 0.032 0.117
18* 1/0 (single agent cohort 
1)
3/0 (single agent cohort 
2)
1/1
1/33
3
4
30
1
1
1
1/3 0.526 0.189 0.217
19* 1/0 (single agent cohort 
1)
3/0 (single agent cohort 
2)
1/1
1/33
3
4
30
1
1
2
1/1 0.543 0.173 0.214

Novartis Confidential Page 173
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
ScenarioDose combination 
LAG525 (mg/kg Q2W) / 
PDR001 (mg/kg Q2W) Npat NtoxNext dose 
combination 
(NDC)P(target) 
NDCP(over) 
NDCMedian DLT 
rate (NDC)
20* 1/0 (single agent cohort 
1)
3/0 (single agent cohort 
2)
1/1
1/33
3
4
30
0
1
1
1/3 0.466 0.15 0.188

Novartis Confidential Page 174
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
ScenarioDose combination 
LAG525 (mg/kg Q2W) / 
PDR001 (mg/kg Q2W) Npat NtoxNext dose 
combination 
(NDC)P(target) 
NDCP(over) 
NDCMedian DLT 
rate (NDC)
21* 1/0 (single agent cohort 
1)
3/0 (single agent cohort 
2)
1/1
1/33
3
4
30
0
1
2
1/1 0.47 0.13 0.186
*PDR001 dose of 0 represents a single-agent LAG525 cohort. Data from patients receiving the single -agent 
LAG525 are incorporated directly into the model, without down -weighting
Within Table 14 -14, P(Target) NDC represents the probability that the true DLT rate for the dose lies in the 
target interval (16%, 33%) while P(Over) NDC represents the probability that the true DLT rate for the dose 
exceeds 33%.
Within Table 14-14, it can be seen that the model generally  leads to decisions that are in 
agreement with clinical sense. The dose levels investigated correspond to the provisional dose 
levels specified in Section 6.2.2 .
14.3.1.5 Operating characteristics for LA G525 + PDR001 c ombination arm
Scenarios
In order to show how the design performs, 5 h ypothetical scenarios were investigated:
1.For scenario 1, the odds of DLT are aligned with the prior information, i.e. the DLT rates 
for dose combinations are set to the median values derived from the prior.
2.
For scenario 2, the odds of DLT are assumed to be 33% decrease from scenario 1
3.For scenario 3, the odds of DLT are assumed to be 25% increase from scenario 1
4.For scenario 4, the odds of DLT are assumed to be 2 -folder increase from s cenario 1
5.For Scenario 5, it was assumed all provisional combination doses are safe. The odds of 
DLT remain flat when the doses are escalated beyond 3 mg/kg of LAG525 and 3 mg/kg of 
PDR001.
The true probabilities used in the simulation are presented in the tables for each scenario above.
Scenario 1 –aligned with prior
Table 14-15 True underly ing probabilities of DLT for Scenario 1
LAG525
(mg/kg, Q2W)PDR001 (mg/kg, Q2W)
0.3 1 3 10
0.3 0.066 0.083 0.116 0.184
1 0.082 0.102 0.144 0.268
3 0.114 0.143 0.226 0.561
10 0.181 0.264 0.556 0.981
Bold values indicate dose combinations in the targeted toxicity interval [16%, 33%).

Novartis Confidential Page 175
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Scenario 2 –Scenario 1 + 33% decrease in odds of DLT
Table 14-16 True underly ing probabilities of DLT for Scenario 2
LAG525
(mg/kg, Q2W)PDR001 (mg/kg, Q2W)
0.3 1 3 10
0.3 0.045 0.057 0.080 0.131
1 0.056 0.070 0.101 0.196
3 0.079 0.100 0.163 0.460
10 0.128 0.193 0.455 0.972
Bold values indicate dose combinations in the targeted toxicity interval [16%, 33%).
Scenario 3 –Scenario 1 + 25% increase in odds of DLT
Table 14-17 True underly ing probabilities of DLT for Scenario 3
LAG525
(mg/kg, Q2W)PDR001 (mg/kg, Q2W)
0.3 1 3 10
0.3 0.081 0.102 0.141 0.220
1 0.100 0.124 0.174 0.314
3 0.139 0.173 0.267 0.615
10 0.216 0.310 0.610 0.985
Bold values indicate dose combinations in the targeted toxicity interval [16%, 33%).
Scenario 4 - Scenario 1 + 2 folder increase in odds of DLT
Table 14-18 True underly ing probabilities of DLT for Scenario 4
LAG525
(mg/kg, Q2W)PDR001 (mg/kg, Q2W)
0.3 1 3 10
0.3 0.124 0.153 0.208 0.311
1 0.152 0.185 0.252 0.423
3 0.205 0.250 0.369 0.719
10 0.307 0.418 0.715 0.990
Bold values indicate dose combinations in the targeted toxicity interval [16%, 33%).
Scenario 5 – Misspecification of DLT relationship
Table 14-19represents the hypothetical scenario that all provisional combination doses are safe. 
The odds of DLT are set the same as in scenario 1 for lower dose combinations and remain flat 
when the doses are escalated bey ond 3 mg/kg of LAG525 and 3 mg/kg of PDR001.

Novartis Confidential Page 176
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 14-19 True underly ing probabilities of DLT for Scenario 5
LAG525
(mg/kg, Q2W)PDR001 (mg/kg, Q2W)
0.3 1 3 10
0.3 0.066 0.083 0.116 0.184
1 0.082 0.102 0.144 0.268
3 0.114 0.143 0.226 0.268
10 0.181 0.264 0.264 0.268
Bold values indicate dose combinations in the targeted toxicity interval [16%, 33%).
Simulation parameters:
1000 trials were used to simulate each scenario. The starting dose combination was chosen as 
1 mg/kg for LAG525 and 1 mg/kg for PDR001, and the maximal dose to jump to was orthogonal, 
and follows the protocol specifications ( Section 10.4.2 of the protocol). The number of patients 
to enroll i
n each cohort and stopping rules used to declare MTD were defined as:
Maximum number of patients treated: 60
Minimum cohort size: 3
Minimum number of patients treated at a given dose combination in order to declare 
MTD: 6
Posterior probability  of targeted toxicity  at this combination dose > 50% and is the highest 
among potential doses, or
Minimum number of patients treated in the trial: 15
Metrics
Operating characteristics were reviewed for the simulations to compare the relative 
performance under each true scenario. The metrics reviewed were:
1.Average proportion of patients receiving a target dose combination on study  (I)
2.Average proportion of patients receiving a dose combination with true P(DLT) ≥ 33% on 
study  (II)
3. Average proportion of patients receiving a dose combination with true P(DLT) < 16% on 
study  (III)
4. Proportion of trials that were recommended a target dose combination as the MTD 
(correct final decision) (IV)
5.Proportion of trials that were recommended a dose combinations with true P(DL T) ≥ 33% 
as the MTD (patient risk) (V)
6.Proportion of trials that were recommended a dose combination with true P(DL T) < 16% 
as the MTD (VI)
Results
Table 14-20 below summarizes the simulated operating characteristics of the model for the 5 
different scenarios studied, additionally  showing the percentage of trials stopped before 
declaring MTD when all dose combinations were considered too toxic.

Novartis Confidential Page 177
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 14-20 Results
Scenario Metric
I II III IV V VI Stopped
1 0.418 0.003 0.579 0.573 0 0.420 0.007
2 0.527 0.018 0.454 0.787 0.009 0.203 0.001
3 0.672 0.002 0.326 0.915 0 0.075 0.010
4 0.745 0.201 0.054 0.785 0.162 0.019 0.034
5 0.434 0 0.566 0.602 0 0.392 0.006
The simulated operating characteristics presented show that the combination model performs 
well under the h ypothetical scenarios investigated.
The proportion of patients treated at overl y toxic dose combinations (metric II) is ve ry low for 
all the scenarios. The probability of identifying a dose with P (DLT) > 0.33 as MTD (metric V) 
is low for all scenarios.
In scenarios 2, 3 and 4, the probability  that the identified MTD falls within the target interval 
(metric IV) is more than 78%, showing excellent targeting of MTD.
In scenarios 1, the underly ing P
 (DLT) is low and below 0.33 for most dose combinations except 
3/3, 3/10 and 10/3 for LAG525 in mg/kg / PDR001 in mg/kg; in scenario 5, none of the 
underly ing P (DLT) is above 0.33. This explains why  scenarios 1 and 5 have a relativel y high 
proportion of patients receiving a dose with P (DLT) < 0.16 (metric III) and why the probability 
that the identified MTD falls within the under- dose interval (metric VI) is not very  low.
The percenta ges of trials that were stopped when all dose combinations were considered too 
toxic are low (< 5%) in all scenarios.
In conclusion, the simulations performed illustrate that the model has good operating 
characteristics.
14.3.2 Prior specifications for phase II hierarchical model
As a supporting analysis, for patients in phase II part, the ORR for each of 16groups is estimated 
using a hierarchical model with two exchangeable groups and 
one non-exchangeable group (see 
Section 10.4.4 ) and data from all 1 6groups.
The model is given in Section 10.4.4 and the details of prior specifications are provided here. 
Three results will be used in the below specifications:
a.For a probability  , we construct a weakly -informative prior distribution on the logit -
scale, i.e. for log( /(1-)), as follows: the prior median is set to a plausible value m , and 
the “prior sample size” will be approximately one. For the latter, under a no rmal 
approximation, the resulting variance on the logit -scale is v = 1/m + 1/(1 - m). This 
leads to a weakly -informative normal prior distribution for log( /(1-)) with mean m and 
variance v .
b.For exchangeable group -specific parameters j= log( j/(1-j)), j~ N(, 2), let the prior 
distributions be ~ N(m µ, vµ) and ~ HN(s). Here, HN(s) denotes the half- normal 
distribution with scale parameter s.

Novartis Confidential Page 178
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
c.Assume that the marginal (total) variance V( ) as well as the scale parameter s are known, 
where the first defines the a
-priori uncertainty  for the indication parameters, and the 
second defines the a -priori degree of borrowing across groups. From these specifications, 
the prior variance of follows from the law of total variance
V() = E(V( |,) + V(E( |,)) = E( 2)+V() = s2+ v µ,.
From this, the variance of is vµ= V() s2.Based on these results, we specified the prior 
distributions for parameters in the hierarchical model as follows:
1.The group
-specific normal priors for the non-exchangeable case, defined by m wand v w
were derived from (a) above. The prior median for the response probability was set as 0.2 
(a limited treatment effect), and the corresponding variance was derived as described in 
(a) above. This results in
mw= logit(0.2) = 1.386, v w= 1/0.2 + 1/(1 – 0.2)= 2.52
2.For the exchangeable cases, the specifications were as follows:
2.1Apply ing (b) above, 1and 2were given a half-normal distribution with scale 0.5, 
imply ing a prior 95% -interval for as (0.016, 1.12), which allows f or small to large 
between -indication heterogeneity  (Spiegelhalter 2004 ).
2.21and 2were given normal prior distributions. For 1, the mean of the prior 
distribution was set to logit(0.1) = 2.197 corresponding to no treatment effect. For 
2, the mean was set to logit(0.3) = 0.847 corresponding to a substantial treatment 
effect.
2.3Assume  jbelongs to the first exchangeability  distribution. Apply ing (c) above, the 
total variance worth approximately one subject is 3.332. Since  1~ HN(0.5) the 
variance for the normal prior distribution for 1 becomes 3.2962. The same approach 
was used to derive the variance for the normal prior distribution for 2, yielding a 
variance of 2.1242.
3.Finally , for each group j, the prior mixture weights pjwere chosen as
pj= (0.25, 0.25, 0.50), j=1,…,16.
This means that each group has 25% prior probability  to belong to the first exchangeability 
distribution, 25% probability  to belong to the second exchangeability  distribution, and 50% 
probability  to be non-exchangeable with some (or all) of the other indications.
The prior distributions are summarized in Table 14- 21, which also shows the prior median s and 
95%- intervals for the response rates j.

Novartis Confidential Page 179
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 14-21 Prior distribution of hierarchical model parameters
Parameter Prior distribution 
1 N(-2.197, 3.2962)
2 N(-0.847, 2.1242)
1 HN(scale=0.5)
2 HN(scale=0.5)
mw, vw, 1.386, 2.52
pj= (p j1,pj2,pj3), j=1,…,12 (0.25, 0.25, 0.5)
Median (2.5% , 97.5% )
i 0.2 (0.001, 0.98)

Novartis Confidential Page 180
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.4 Appendix 4: Statistical details of Phase I Bay esian logistic 
regression model (BLRM) in Japanese patients treated with 
single agent of LA G525
This appendix provides details of the statistical model, the derivation of prior distributions from 
historical data of LAG525 from global patients, and the results of the Bayesian analyses and 
respective dosing decisions for some h ypothetical data scenarios.
14.4.1 Statistical model
An adaptive Bayesian logistic regression model (BLRM) guided by the escalation with 
overdose control (EWOC) principle will be used to make dose recommendations and estimate
the maximum tolerated dose (MTD) and/or identify  the recommended dose for expansion 
(RP2D) during the dose escalation part of the study . The use of Bayesian response adaptive 
models for Phase I studies has been advocated by the EMEA guideline on small populations 
(2006) and by Rogatko (2007) and is one of the key elements of the FDA’s Critical Path 
Initiative.
Single agent LAG525 for Japanese patient s: In the single -agent LAG525 dose escalation part, 
the dose -toxicity  (DLT) relationship is described by the following 2- parameter BLRM:
logit((d)) =log(α) +βlog(d /d*), α>0, β>0
Where  , and (d) is the probability  of a DLT at dose d.
Doses are r escaled as d/d* with reference dose d*=3 mg/kg of LAG525. As a consequence α is 
equal to the odds of DLT rate at d*, and β(>0) is the increase in the log-odds of a DLT by a 
unit increase in log -
dose. Note that for a dose equal to zero, the probability of toxicity  is zero.
The Bayesian approach requires the specification of prior distributions for all model parameters. 
This section provides details of the statistical model, the derivation of prior distributions for the 
model parameters, and the properties of the adaptive design (dosing recommendations for 
hypothetical data scenarios and operating characteristics).
14.4.2 Prior specifications
The Bayesian approach requires the specification of prior distributions for all model parameters. 
A meta -analytic-predictive (MAP) approach was used to derive the prior distribution for the 
model parameters.
14.4.2.1 Prior distribution for the logistic parameters
A mixture prior distribution for the single -agent LAG525 model parameters was derived. It 
consists of a mixture of a meta -analytic-predictive (MAP) prior and a weakly  informative prior 
corresponding to high toxicity  to make the prior more robust . To obtain the mixture prior, 50% 
weight was assigned to the MAP prior, and 50% weight was assigned to the weakl y informative 
prior.

Novartis Confidential Page 181
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.4.2.1.1 Description of the MAP approach
The aim of the MAP approach is to derive a prior distribution for the logistic parameters (log( α*), 
log(β*)) of the new trial (eg., Japanese sub -population in the LAG525x2101 study ) using DLT 
data from the ongoing dose- escalation in global patients (L AG525x2101 study ).
Let rdsand ndsbe the number of patients with a DLT, and the total number of patients at dose d
in historical trial s(s=1, … , S). The corresponding probability  of a DLT  is ds. The model 
specifications for the derivation of the MAP prior are as follows:
rds| ds~Bin (ds, nds)
logit(ds) =log(αs) +βslog(d /d*)
(log(αs), log(βs)) | µ, ѱ~BVN ( µ, ψ), s =1, … , S
(log(α*), log(β*)) | µ, ѱ~BVN ( µ, ψ)
Where d*= 3 mg/kg and S= 1 in this study  and refers to Arm A. The parameters µ=(µ1, µ2) 
and ѱare the mean and between -trial covariance matrix for the logistic parameters, the latter 
with standard deviations τ1, τ2, and correlation p. The parameters τ1and τ2quantify  the degree 
of between trial heterogeneity . The main objective is to estimate the predictive distribution
(log(α*), log(β*)) | (rds, nds: s=1, … , S)
based on DLT data from arm A. To do that, it is assumed:
normal priors for 
µ1and µ2,
log-normal priors for τ 1and τ2, and
a uniform prior for p.
Since the predictive distribution is not available analy tically , the Markov Chain Monte Carlo 
(MCMC) method is used to simulate values from this distribution. This is implemented using 
WinBUGS 14.1.3. The sample from this distribution is approximated by  a mixture of bivariate 
normal (BVN) distributions. BVN mixtures with increasing numbers of mixture components 
are fitted to the sample using the expectation -maximization (EM) algorithm ( Dempster 1977 ). 
The optimal number of components of the mixture is then identified using the Akaike 
information criterion (AIC) ( Akaike 1974
).
14.4.2.1.2 Implementation of the MAP approach
For the MAP model, data from global patients treated in Arm A of the global study 
[CLAG525X2101C] was used ( Table 14 -22).
Table 14
-22 Data from global patients in study  CLA G525X2101C
Dose of LAG525 * Dose of LAG525 (mg/kg,Q2w) No of DLTs/No of evaluable patients
1 (mg/kg,Q2w) 1 1/12
3(mg/kg,Q2w) 3 0/11
5(mg/kg,Q2w) 5 2/4
10(mg/kg,Q2w) 10 0/4
3(mg/kg,Q4w) 1.5 0/5
5(mg/kg,Q4w) 2.5 0/3

Novartis Confidential Page 182
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Dose of LAG525 * Dose of LAG525 (mg/kg,Q2w) No of DLTs/No of evaluable patients
10(mg/kg,Q4w) 5 0/4
* Data cut -off date: 22 January, 2016
Weakly  informative priors are assumed for µ1and µ2, with means corresponding to a risk of 
DLT at the reference dose of 10%, and a doubling in dose leading to a doubling in the odds of 
the risk of a DLT, respectively . Priors for τ1and τ2are assigned such that (1) their medians 
correspond to moderate between trial heterogeneity , and (2) their uncertainty  (95% prior 
interval) cover plausible between -trial standard deviations 
(Schmidli 2014). The prior 
distributions for the model used for deriving the MAP priors ar
e specified in Table 14-23.
Table 14-23 Prior di stributions for the parameters of the MA P model used to derive 
the prior
Parameter Prior distribution
µ1 N(mean = logit(0.10), sd = 2)
µ2 N(mean = 0, sd=1)
τ1 log-normal(mean = 0.25, sd = log(2)/1.96)
τ2 log-normal(mean = 0.125, sd = log(2)/1.96)
p uniform(-1,1)
14.4.2.1.3 Derivation of the weakly informative prior
A weakl y informative BVN prior to allow higher toxicity  than MAP prior is derived by 
assuming median probability  of DLT at 3 mg/kg to be 20%, as well as a log -linear relationship 
between dose and the odds of DLT as defined in Section 14.4.1. This results in setting the mean 
of log(α) equal to -1.386. The mean of log(β) is set to 0. Furthermore, setting standard deviation 
of log(α) = 2 and log(β) = 1, and setting the correlation between log(α) and log(β) = 0 to 
complete the determination of this prior. See Table 14 -24.
14.4.2.2 Summary  of prior distributions
The prior distributions of the model parameters are summarized in Table 14 -
24.
Prior summaries for DLT rates are summarized at each provisional dose level in Table 14
-25.
Table 14-24 Prior distribution of model parameters
Parameter Mean Standard deviations Correlation Weight
LAG525 MAP prior, BVN mixture (log( α), log( β)), weight = 50%
BVN mixture 1 (-2.410 , -0.602 ) (0.572 , 0.555) -0.179 0.206
BVN mixture 2 (-2.988 , -1.050 ) (0.719 , 0.747) -0.272 0.180
BVN mixture 3 (-2.758 , 0.025) (0.779 , 0.419) -0.178 0.114
Weakly  informative prior ( log(α ), log(β)), weight = 50%
Weakly informative (-1.386, 0) (2, 1) 0 0.5

Novartis Confidential Page 183
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 14-25 Summary  of prior distribution of DLT rates
PDR001 dose
(mg/kg, Q2W)Prior probabilities that
P(DLT) is in interval:
Mean SDQuantiles
[0, 0.16) [0.16, 0.33) [0.33, 1] 2.5% 50.0% 97.5%
0.3 0.905 0.046 0.050 0.062 0.134 0.000 0.017 0.534
1 (starting 
dose)0.842 0.070 0.088 0.101 0.170 0.000 0.038 0.697
3 0.690 0.126 0.185 0.188 0.230 0.008 0.088 0.870
10 0.412 0.222 0.367 0.349 0.318 0.022 0.207 0.997
SD = standard deviation.
Bold values indicate dose (s)not meeting the EW OC principl e with the prior information only.
14.4.3 BLRM design properties for hy pothetical data scenarios
Table 14-26 shows on-study  dosing recommendations for some hypothetical data scenarios.
Note that the next dose is selected in concordance with the provisional dose levels specified in 
Section 6.2.2 of the protocol wherever it is allowed, to mimic possible on study escalation steps.
Table 14-26 Hypothetical dose escalation scenarios for on -study  decisions –
phase I single agent LA G525
Scena
rioLAG525 Dose level 
(mg/kg)Np
atNt
oxNext Dose Level 
(NDL)P(Target) 
NDLP(Over) 
NDLMedian DLT rate 
(NDL)
1 1 4 0 3 0.106 0.080 0.069
2 1 4 1 1 0.197 0.111 0.089
3 1 4 2 0.3 0.267 0.241 0.164
4 1 4 0
3 3 1 3 0.229 0.136 0.118
5 1 4 0
3 3 2 1 0.168 0.051 0.066
6 1 4 0
3 6 0 10 0.223 0.151 0.118
7 1 4 0
3 6 2 3 0.346 0.191 0.174
8 1 4 0
3 3 1
3 5 0 5 0.219 0.113 0.117
9 1 4 0
3 3 1
3 3 1 3 0.346 0.191 0.174
10 1 4 0
3 3 1
3 3 2 1 0.191 0.041 0.072
11 1 4 0
3 3 2
1 3 1 1 0.352 0.110 0.148

Novartis Confidential Page 184
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Scena
rioLAG525 Dose level 
(mg/kg)Np
atNt
oxNext Dose Level 
(NDL)P(Target) 
NDLP(Over) 
NDLMedian DLT rate 
(NDL)
12 1 4 0
3 3 2
1 3 2 0.3 0.274 0.092 0.113
13 1 4 1
1 5 0 3 0.199 0.134 0.110
14 1 4 1
1 3 2 0.3 0.321 0.194 0.166
15 1 4 1
1 5 0
3 4 0 10 0.315 0.144 0.148
16 1 5 0
3 4 0
10 3 0 10 0.184 0.033 0.090
Within Table 14-26, it can be seen that the model generally  leads to decisions that are in 
agreement with clinical sense: progressive increase of the doses if no DLT is observed, enrolling 
of a new cohort at the same dose level when 1 DLT is reported, and de-escalation when more 
than 1 DLT is reported in a cohort. It is expected that the dose-DLT relationship in Japanese 
patients will be very similar to that observed outside Japan. Scenario 16 is a hypothetical 
scenario where the dose-DLT relationship is consistent between global and Japanese patients. 
In this case, the posterior weight for the prior components based on data from the global study  
[CLAG525X2101C] increases to from 50% to 70%, demonstrating support for the 
exchangeability  of these two populations based on DL T data.
In addition, Table 14 -26shows also some examples for the unlikel y case of dissimilarity in the 
dose-DLT relationship between Japanese and global patients. Scenario 5 is an example 
illustrating such dissimilarity . In this case, the posterior weight for the prior components based 
on data from the global study  [CLAG525X2101C] reduces to 19%. Overall, in the case of 
dissimilarity , the model performs appropriatel y, leading to dose de -escalation.
14.4.3.1 Operating characteristics
In order to show how the proposed design performs under different true dose-DLT profiles, 
various hy pothetical scenarios were investigated.
14.4.3.2
Simulation setup
Table 14-27 shows 4dose-DLT scenarios, taking scenario 1 (true DLT rates equal to mean prior 
DLT rates) as the basis. Scenarios 2, 3 and 4 have increased DLT ra tes compared to scenario 1:
-Scenario 2: the odds of DL Ts are 2 -fold larger than the ones of scenario 1
-Scenario 3: the odds of DL Ts are 3 -fold larger than the ones of scenario 1
-Scenario 4: the odds of DL Ts are 5 -fold larger than the ones of scenario 1
The following table presents the true underl ying probabilities of DLT for each scenario

Novartis Confidential Page 185
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
Table 14-27 dose- DLT scenarios
Test 
scenariosAssigning DLT probabilities to each dose level
Note 0.3 mg/kg 1 mg/kg 3 mg/kg 10 mg/kg
1 0.062 0.101 0.188 0.349 True dose -DLT relationship based on prior 
mean DLT rates
2 0.117 0.183 0.316 0.517 2-fold odds inflation from test scenario 1
3 0.165 0.252 0.410 0.617 3-fold odds inflation from test scenario 1
4 0.248 0.360 0.537 0.728 5-fold odds inflation from test scenario 1
n-fold odds inflation: p1/(1 -p1) = n*[p0/(1 -p0)], p1=n*p0/(1 -p0+n*p0), where p0 is a probability  of test 
scenario 1
For each scenario data for 1000 trials were generated.
Dose levels investigated: 0.3, 1 (starting dose), 3, 10 mg/kg
Cohort size: 3, 4, 5, or 6 patients (randoml yassigned with a uniform rate of 25%)
Stopping rule/MTD selection criteria:
Maximum number of patients per a trial: 30 patients
Minimum number of patients per a trial: 12 patients
Minimum number of patients at MTD: 6 patients
Posterior probability  of targe ted toxicity  at MTD: >50%
Table 14-28 Operating characteristics of BLRM -based dose escalation design
Profile ParameterPDR001 dose level (mg/kg) stopped 
(toxicity ) 
[2]stopped 
(max N) 
[3] 0.3 1 3 10
1 True probability of DLT (%) [1] 6.2 10.1 18.8 34.9
Average # of patients recruited 0.45 6.8 6.84 3.09
Average # of DLTs 0.04 0.69 1.26 1.08
% of MTD selection 1.7 23.8 48.8 23.1 2.3 0.3
2 True probability of DLT (%) [1] 11.7 18.3 31.6 51.7
Average # of patients recruited 1.36 8.48 5.23 0.91
Average # of DLTs 0.16 1.60 1.64 0.47
% of MTD selection 8.5 46.5 31.2 3.1 10.4 0.3
3 True probability of DLT (%) [1] 16.5 25.2 41 61.7
Average # of patients recruited 2.19 8.69 3.66 0.32
Average # of DLTs 0.36 2.13 1.50 0.2
% of MTD selection 15.7 50.2 13.6 0.4 19.8 0.3
4 True probability of DLT (%) [1] 24.8 36.0 53.7 72.8
Average # of patients recruited 3.17 7.76 1.62 0.08
Average # of DLTs 0.77 2.86 0.84 0.06
% of MTD selection 24.5 23.2 2.4 0.0 49.7 0.2
[1] Bolding indicates doses with true probability of DLT within the target toxicity interval [16%, 33%).
[2] Proportion (%) that a trial is stopped since all dose levels are too toxic.
[3] Proportion (%) that a trial is stopped since the maximum number of patients is reached without selecting a 
MTD.

Novartis Confidential Page 186
Amended Protocol Version 10 (Clean) Protocol No. CLAG525X2101C
14.4.3.3 Results
The simulated operating characteristics presented show that the BLRM performs well under the 
hypothetical profiles investigated. Indeed, the simulations performed illustrate that the model 
has reasonable operating characteristics and the number of patients with DLT was limited 
through a trial. In scenario 1, the odds of DLT are aligned with the prior information. In this 
scenario, the simulations show that about 49% and 23% of chance for selecting MTD at 3mg/kg 
and 10mg/kg dose levels, respectivel y. Finall y, in scenario 4, with 5-fold odds inflation from 
test scenario 1, the chance to stop the trial due to high toxicity of all dose levels is very high 
(49.7%) as expected since only  0.3 mg/kg dose has the underl ying P (DLT) that is below 33%. 
The simulations show that there is about 23% of chance for selecting MTD at 1mg/kg dose level 
since the assumed P(DLT) for this dose lies very  close to the upper boundary  of at those doses
the target interval, leading to a tendency  for the model estimate of the probability  of overdose 
to identify  this as a dose not satisfy ing the EWOC criterion.
In conclusion, the simulations performe d illustrate that the model has good operating 
characteristics under the 4 hy pothetical profiles investigated.
References (available upon request)
Akaike H (1974) A new look at the statistical model identification. IEEE Transactions on 
Automatic Control ; 19(6):716-723.
Dempster AP, Laird NM, Rubin DB (1977) Maximum L ikelihood from Incomplete Data via 
the EM Algorithm. Journal of the Roy al Statistical Society ; 39(1):1 -38.
EMEA (2007) Guideline on Clinical Trials in Small Populations. Committee for Medicinal
Products for Human Use (CHMP).
Schmidli H, Gsteiger S, Roy choudhury  S et al (2014) Robust meta -analytic-predictive priors 
in clinical trials with historical control information. Biometrics; 70(4):1023 -1032.
Rogatko A, Schoeneck D, Jonas W, et al (2007) Translation of innovative designs into phase I 
trials. J Clin Oncol; 25:4982-6.
Spiegelhalter DJ, Abrams KR, My les JP (2004) Bay esian Approaches to Clinical Trials and 
Health-Care Evaluation.
